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Abstract
Vitamin E (a-tocopherol) is the major lipid soluble secondary antioxidant in vivo 
and is important for maintaining the integrity of cell membranes. It may also have 
more specific functions in vivo including roles in cell signaling and gene 
expression. Relatively little is known, however, about the details and dynamics of 
vitamin E metabolism, which may be important in fully understanding its role(s) 
in vivo. Vitamin E metabolites detected in urine include a-tocopheronolactone (a- 
TL), with an oxidized chroman ring, and compounds with successively shortened 
phytyl side chains, including the carboxyethyl-hydroxychromans (CEHC) and 
carboxymethylbutyl-hydroxychromans (CMBHC). As a-TL can be produced 
from a-tocopherol by oxidation it may be a potential biomarker of in vivo 
oxidative stress. The CEHCs are the major urinary metabolites but the cellular 
localisation of the side-chain shortening process (mitochondria and/or 
peroxisomes) remains undefined. The aims of my studies were to determine 
whether a-TL could be a useful biomarker of oxidative stress and define the 
cellular localisation of the side-chain shortening process of the tocopherols.
Initially methods were established and validated for the measurement of urinary 
vitamin E metabolites and the F2-isoprostane, 8isoPGF2a (a non-enzymatically 
derived isomers of the prostaglandins, formed in vivo by free radical mediated 
oxidation of arachidonic acid and an accepted biomarker of oxidative stress) by 
gas chromatography-mass spectrometry (GC-MS).
1
To investigate whether a-TL was a potential biomarker of in vivo oxidative stress, 
urinary a-TL and 8-isoprostane were measured in healthy trained and untrained 
males before and after a standardised endurance exercise regimen. A significant 
correlation (p<0.0001) was found between the concentrations of a-TL and 8- 
isoPGF2a. There was, however, no evidence of an increase in oxidative stress 
following exercise in the subjects studied.
Studies to investigate the role of peroxisomes and mitochondria in vitamin E 
metabolism utilized two approaches. The first involved the analysis of urinary 
vitamin E metabolites of patients with peroxisomal (n=5) and mitochondrial (n=3) 
disorders, and those suspected of peroxisomal or mitochondrial disorders (n=5) 
compared to age matched controls (n=19). No consistent and significant 
differences in metabolite profiles were found between the groups. The second 
approach involved tissue culture studies to investigate peroxisomal and 
mitochondrial function. These studies suggested that both organelles played a role 
in tocopherol metabolism.
To conclude, firstly a-TL was not shown conclusively, by this thesis to be a 
biomarker of oxidative stress, but its correlation with the independent biomarker, 
8-isoPGF2«, may suggests that there is still potential in it being a biomarker in 
other states of oxidative stress such as in sepsis or disease. Therefore the 
techniques developed and used here may be used in further investigations to 
answer the question whether a-TL is a biomarker of oxidative. Secondly, the 
localization of y-tocopherol metabolism has been shown to involve the
2
peroxisome and mitochondria, in human liver HepG2 cells, with effects at 
different stages of metabolism showing similarity to the branched chain fatty acid 
metabolism pathway.
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Chapter 1 
General Introduction
Chapter 1 -  General Introduction
1.1 The History of vitamin E
In 1922 Evans and Bishop found that pregnant female rats fed with what they thought 
was a complete diet, did not give birth to offspring as a result of foetal resorption. 
However, upon the addition of lettuce to the diet, the foetal resorption defect was 
corrected and the female rats produced healthy offspring (Evans and Bishop, 1922). It 
was, therefore, hypothesised that the initial diet had a nutrient deficiency that could be 
corrected by supplementing with lettuce leaves. In 1936, Evans named this nutrient 
‘tocopherol’, which is a Greek word, meaning ‘to bear offspring’. The name 
tocopherol is now used to refer to a sub-group of vitamin E compounds.
1.2 Structure and nomenclature of vitamin E
All vitamin E compounds consist of a characteristic chromanol ring and carbon side- 
chain. They comprise two sub-groups; the tocopherols which have a saturated side- 
chain, and the tocotrienols which have an unsaturarted side-chain with three double 
bonds (figure 1.1). Both the tocopherols and tocotrienols have four different forms. 
These forms vary depending on the number and arrangement of the methyl groups on 
the benzene ring, and are designated, a , p, 5 and y, as shown in figure 1.2.
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R
HO
c h 3
tocopherols
HO
tocotrienols
Figure 1.1 Chemical structure of the tocopherols and tocotrienols
GH
HO
CH3
HO
CH3
a -  6-
CH
HO
CH3
HO
HX
P -  Y-
Figure 1.2 The arrangement of methyl groups on the benzene ring of the four 
different forms of tocopherols and tocotrienols
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The structural formula of a-tocopherol (a-TH) was first published in 1938 by 
Fernholz. The tocopherols, due to their saturated phytyl-chain, have three chiral 
centres, at carbon positions 2, 4’ and 8 ’ (figure 1.3). Rotation depends on the order of 
the three different groups about these carbon centres and their relative masses to one 
another, and can occur either as R-rotation or as S-rotation. Naturally occurring 
vitamin E, exhibits R-rotation at all three centres (ftRft-tocopherol), whereas synthetic 
all-rac-tocopherol consists of an equimolar racemic mixture of all 8 possible stereo­
isomers (RRR, RRS, RSR, SRR, RSS, SSR, SRS and SSS- tocopherols) (figure 1.3).
1.3 Sources of vitamin E
In nature vitamin E is synthesised only by plants and other photosynthetic organisms 
(Sattler et al., 2003). The richest dietary source of vitamin E is edible vegetable oils 
with varying proportions of a , p, 6 and y-tocopherols (TH) and tocotrienols. 
Generally, RRR-a-TH is high in wheat germ, safflower and sunflower oils, RRR-y- 
TH and tocotrienols are high in soyabean and com oils, and a/y-tocotrienols are 
abundant in palm oil (Traber and Sies, 1996). The THs are present in oil, seed, leaves 
and other green parts of higher plants. a-TH is mainly present in photosynthetic 
tissues, while P, 6 and y-TH frequently predominate in non-photosynthetic tissues 
(Kamal-Eldin and Appelqvist, 1996; Hofius and Sonnewald, 2003).
22
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CH
HO
8' position
4' position
2 position
(R)
O
(R)o o
Figure 1.3 The rotation of bonds around the three chiral centres of tocopherol. 
[Synthetic vitamin E : RRR, SRR, SSR,SSS, RSR, RSS,
RRS, SRS (all possible forms), Natural vitamin E :RRR]
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The tocotrienols are not found in the green parts of plants but rather in the bran and 
germ fractions of certain seeds and cereals.
The principal forms of vitamin E in human and mammalian diets vary around the 
world and depend mainly on the type of plant oils used. In a typical North American 
diet, due to a widespread use of com and soya oil, RRR-y-TH is the most abundant 
and approximately two to four times in excess of RRR-a-TH (Vatassery et al., 1983; 
Behrens and Madere, 1986). Less y-TH is consumed in European and in South East 
Asian diets, and tocotrienols are in much higher abundance due to the use of palm oil. 
Despite these dietary differences generally 90% of vitamin E in human plasma and 
tissues is in the RRR-a-TH form (Traber et al., 1993).
1.4 Vitamin E absorption and transport
Vitamin E compounds are lipid soluble and as a result their absorption follows a 
similar process to that of dietary lipids such as triglycerides and cholesterol. The 
absorption process of dietary lipids comprises 1) emulsification 2) solubilisation 
within mixed bile salt micelles, 3) uptake by small intestinal cells (enterocytes), 4) 
packaging within lipoprotein particles (chylomicrons), and 5) secretion into the 
circulation via the lymphatic system (figure 1.4). Emulsification begins in the 
stomach to form chyme and is achieved by predominantly mechanical forces. In the 
small intestine, chyme mixes with pancreatic and biliary secretions. Pancreatic lipase
24
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Figure 1.4; Vitamin E absorption and its transport through the body
[VitE= vitamin E; LL= lipoprotein lipase ; VLDL= very low density lipoprotein; FA= fatty acid]
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hydrolyses triglycerides in the small intestine to monoglycerides and fatty acids. The 
products of lipolysis form molecular aggregates with bile salts called micelles, which 
are able to solubilise more hydrophobic molecules such as tocopherol. When these 
mixed micelles come into contact with the brush-border membrane of the enterocytes, 
tocopherol is absorbed by the cells by passive diffusion. This has been confirmed by 
both in vitro studies using small intestinal bowel sacs incubated in a micellar medium 
(Hollander et al., 1975) and in vivo studies with rats (Muralidhara and Hollander, 
1977). Once in the enterocyte, vitamin E along with other lipids, is packaged into 
chylomicrons, which are large lipoproteins, consisting of a lipid-rich centre and 
phospholipids and proteins on the surface. These are secreted into the plasma 
circulation via the lymphatic system. Chylomicrons in the circulation are then 
metabolised by an enzyme known as lipoprotein lipase, which is anchored in the 
endothelial lining of the capillary walls. Lipoprotein lipase hydrolyses the 
triglycerides located inside the chylomicrons, releasing fatty acids and converting the 
chylomicrons to smaller particles or remnants. The remnants are taken up by the liver. 
In the liver, fatty acids are converted back to triglycerides and loaded onto nascent 
very low density lipoproteins (VLDL) for secretion back into the blood stream. It is at 
this stage that different forms of vitamin E are discriminated (see section 1.5), 
resulting in preferential loading of the natural, RRR-a-TH. form onto VLDL.
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1.5 Regulation of vitamin E uptake and tissular 
distribution
1.5.1 Introduction
Studies in man have shown that upon ingestion of equal doses of deuterium labeled 
RRR and SRR-a-TH, similar amounts of both isomers appear in the chylomicrons, 
suggesting comparable intestinal absorption (Traber et al., 1990). However, many 
studies have demonstrated that the natural RRR-a-TH form is preferentially enriched 
in VLDL, with subsequent enrichment of all circulating lipoproteins with this form 
(Traber et al, 1990; Traber, 1994). Similar experiments using deuterated labeled 
compounds have investigated the uptake of the synthetic SRR-a-TH isomer, and 
natural RRR-a-TH isomer in the plasma and different tissues of male Sprague-Dawley 
rats (Ingold et al., 1987). The synthetic a-TH, SRR-isomer, was found to accumulate 
in the liver. In all other tissues and the plasma, however, there was an excess of the 
natural, RRR-form. These findings were later confirmed by Traber et al (1998) where 
human volunteers were given a supplement of 150mg of deuterated d6-all-rac-a- 
tocopheryl acetate and d3-i?/?/?-a-tocopheryl acetate over a twenty four hour period. 
Natural RRR-a-TH was taken up twice as efficiently as synthetic SRR-a-TH into the 
plasma. It was later confirmed by radio-labeling experiments carried out by Kaneko et 
al (2000) that the 2R configuration was preferentially secreted back into the plasma 
circulation via VLDL. Similar experiments were carried out to compare a-TH with y-
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TH, where it was found that upon supplementation with labeled a-TH, the newly 
absorbed a-TH replaced unlabeled plasma a-TH and y-TH. Another study showed 
that despite y-TH intake exceeding that of a-TH in a typical American diet, plasma 
levels of y-TH in fasting subjects were usually <20% of a-TH (Swanson et al., 1999). 
Although a- and y-TH exhibit similar absorption efficiencies, the overall retention of 
y-TH and secretion back into the plasma circulation after reaching the liver is 
considerably less than that for a-TH. It therefore appears that there is a mechanism 
that specifically selects 2R forms of a-TH for secretion back into the plasma 
circulation.
Due to thermodynamic barriers imposed on the diffusion of hydrophobic molecules 
through an aqueous environment, there exist specific binding proteins that facilitate 
lipid transport. These binding proteins recognize a specific lipid with high affinity and 
then release the ligand to an acceptor membrane. There are several lipid binding 
protein families. One of these families consists of proteins with a conserved lipid- 
binding domain, a CRAL-TRIO motif (also known as Secl4 domain). This family 
includes cellular retinaldehyde binding protein (CRALBP), yeast phosphatidylinositol 
transfer protein SEC14p, supernatant protein factor (SPF, also known as tocopherol 
associated protein (TAP)) and a-tocopherol transfer protein (a-TTP).
Three tocopherol regulatory proteins (TRPs) have been identified to date, that 
specifically bind to THs and all belong to the same family of cytosolic lipid binding 
and transfer proteins. These proteins include the a-tocopherol transfer protein (a- 
TTP), tocopherol associated proteins (TAPs) and tocopherol binding proteins (TBPs).
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The regulation of TRPs is not yet understood. Because vitamin E deficiency is almost 
always found during protein calorie malnutrition, it may be that either vitamin E 
and/or protein deficiency is responsible for the regulation of TRP levels and/or 
activity. Upon inadequate protein intake, hepatic a-TTP levels are less well 
maintained compared to other proteins (Tamai et al., 2000). Oxidative stress may also 
modulate a-TTP. It has been shown that in diabetic rats and in humans, hepatic a- 
TTP and its mRNA are increased along with plasma a-TH levels (Tamai et al., 2000).
1.5.2 a-Tocopherol transfer protein (a-TTP)
Catignani (1980) identified a 30-35 kDa liver protein in human and rat as a-TTP. 
Since then, this protein has been reported to be present in rat brain, spleen, lung and 
kidney (Hosomi et al., 1997) and in human brain (Copp et al., 1999). The relative 
affinities of purified a-TTP for different THs, have been determined by competition 
between vitamin E analogues for transfer between liposomes and membranes in vitro 
and has been reported as follows ; 100% for RRR-a-TH, 38% for |3-TH, 9% for y-TH, 
2% for 6-TH, 12% for a-tocotrienol and 11% for SRR-a-TH (Hosomi et al, 1997). 
Initially it was postulated that a-TTP actively incorporated a-TH with the 2R 
configuration into VLDL. However, subsequent experiments using brefeldin A, which 
inhibits VLDL secretion from the Golgi apparatus indicated no affect on the secretion 
of a-TH by hepatocytes in culture (Arita et al., 1997). This would suggest that a-TH 
is not transferred to nascent VLDL during its assembly but possibly at a later stage.
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Blatt et al (2001), proposed that a-TH efflux from hepatocytes depended on the 
ability of a-TTP to transfer a-TH to the plasma membrane.
a-TTP is a cytosolic protein which specifically binds a-TH (Panagabko et al., 2002). 
Recently, Meier and coworkers elucidated the crystal structure of a-TTP, and 
reported two different conformational states of the molecule (Meier et al., 2003), 
representing either an open or a closed conformation involved in the TH transfer 
mechanism. The difference between the open and closed conformations is the 
positioning of extracellular fluid exposed residues that can be thought of as a “lid”, 
that affects the access of ligands to the lipid binding site (CRAL-TRIO motif) located 
inside a hydrophobic pocket. In the closed conformation the large hydrophobic area of 
the lid is in direct contact with the RRR-a-TH  side chain, whereas on lid opening the 
hydrophobic residues of the lid shift towards the exterior and inserts into the 
membrane lipid bilayer. As a result the open lid conformation at the surface of the 
protein mediates ligand exchange between the hydrophobic cavity of the protein and 
the acyl-chain environment of the membrane bilayer, with the bound TH ligand being 
released into the membrane. Conversely, TH is moved into the empty or water-filled 
binding pocket by lid closure. Upon closure, the lid exposes a more polar face to the 
extracellular fluid and membrane and the charged carrier ligand complex can leave 
the membrane
Mutations in the gene encoding a-TTP have been shown to result in a rare inherited 
disorder termed ataxia with isolated vitamin E deficiency or AVED (Ben Hamida et
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al., 1993). AVED patients exhibit normal intestinal a-TH absorption and transport in 
the chylomicrons but fail to produce VLDL enriched with a-TH, resulting in low 
RRR-a-TH in plasma and tissues. Untreated patients have a characteristic progressive 
peripheral neuropathy resulting in ataxia. The biochemical characterisation of six 
misense mutations in a-TTP that are found in AVED patients was achieved by 
expression studies in E.coli. These studies suggested that AVED may not arise from 
an inability of a-TTP to bind or to transfer a-TH, due to the TTP mutations impact in 
vitro on TTP activity being quite benign, but rather from defects in other biochemical 
activities of the protein, yet to be described (Morley et al., 2004). Three of the 
mutations studied, R59W, E141K and R221W, were associated with severe and early 
onset of AVED, that in vivo demonstrated profound effects and in vitro only a 2-3 
fold reduction in a-TTP transfer kinetics. The other mutations were associated with 
milder forms of AVED, which demonstrated perturbations of TH homeostasis in vivo, 
but in vitro showed similar activity to wild-type a-TTP.
1.5.3 Tocopherol-associated protein (TAP) and tocopherol- 
binding protein (TBP)
In addition to a-TTP, there may be other proteins that are responsible for the 
distribution of a-TH to intracellular compartments and which regulate signal 
transduction and gene expression by a-TH. The functions of both TAP and TBP 
remain undefined. These two proteins contain a lipid binding domain, CRAL-TRIO
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motif, and are suggested to have a role in the modulation of intracellular rather than 
tissue distribution of a-TH.
The first discovery of TAPs was that of a 46kDa protein found in bovine liver cytosol 
(also known as supernatant protein factor (SPF))(Stocker et al., 1999). The human 
homologue of bovine TAP was later described by Zimmer et al (2000) and termed 
hTAP. These TAP proteins were shown to stimulate microsomal squalene epoxidase 
(Shibata et al., 2001) in addition to their ability to bind a-TH (Stocker et al., 1999; 
Zimmer et al., 2000; Yamauchi et al., 2001). Although no specific function has been 
demonstrated for this protein, it shows significant homology to a-TTP. hTAP has a 
carboxy terminus domain, however, which is not present in a-TTP, which suggests 
these proteins have different functional roles. Additionally TAPs exhibit a GTP 
binding motive and GTPase activity (Zimmer et al., 2000) which may be important to 
confer hTAP regulatory properties and modulation of phospholipid/tocopherol 
secretion and/or phospholipid/tocopherol signalling (reviewed by Azzi et al., 2002). 
Immunoprecipitation and purification of three recombinant hTAPs (hTAP 1, 2 and 3) 
indicated that they share high sequence homology suggesting they perform similar 
functions. These hTAPs also demonstrated binding capabilities not only to THs but 
also to phosphatidylinositol, phosphatidylcholine and phosphatidylglycerol (Kempna 
et al., 2003). It has been shown that TAPs bind THs with an equal affinity to 
phosphatidylinositol (Kempna et al., 2003) which suggests that TAP is non-selective 
toward THs (Panagabko et al., 2002; Manor and Atkinson, 2003).
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TBP, a 14.2kDa cytosolic protein was first identified by Dutta-Roy et al (1993). 
Purified TBP from rabbit heart cytosol has been found to bind selectively to a-TH, 
and is capable of increasing in vitro transfer of RRR-a-TH from liposomes to 
mitochondria by 8 to 10 fold. Dutta-Roy (1994) also described a plasma membrane 
TBP (TBPpm) in human erythrocytes and liver, that may be responsible for the 
regulation of a-TH in these cells. a-TH binding sites have also been shown to be 
present in membranes of different cell types, such as aortic endothelial cells and rat 
adrenal cells (Kitabchi et al., 1980). The binding affinity of TBPpm in human 
erythrocytes was similar for a-, p-, 6- and y-TH (Bellizzi et al., 1997). This may 
enable the erythrocytes to use all the TH homologues to prevent oxidative damage.
1.6 Vitamin E metabolism in the human body
1.6.1 General metabolism of lipids and xenobiotics
The human body is exposed to a range of different xenobiotics and lipophilic 
compounds from a variety of pharmaceutical and food components throughout the 
course of a lifetime. Many of these molecules remain un-ionized or partially ionized 
at physiological pH in the body. They are often bound to plasma proteins and are not 
readily excreted in the bile or urine or efficiently reabsorbed. The body has developed 
specialised mechanisms capable of handling these compounds by either increasing 
their rate of excretion or by detoxification enzymes (reviewed by Liska, 1998).
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Although the underlying metabolic processes are often considered to be detoxification 
processes, this is not always the case. In many cases the resultant metabolites are 
either more active and/or toxic than the parent compound. The “detoxifying” 
mechanisms show great variability depending on environmental responses, lifestyle 
and genetic background among different individuals. The compound must be rendered 
water-soluble in order to facilitate excretion as waste products. These metabolic 
reactions are carried out mainly in two organs, namely the liver and kidney. In the 
liver the end products are excreted via the bile into the feces and in the case of the 
kidney excretion occurs in the urine. The first analytical attempts of scientists to 
understand how the body manages various lipophilic and xenobiotic compounds 
began by the collection and analysis of urine almost two and a half centuries ago. In 
1773 hippuric acid was identified in human urine, but it was not until 1842 that 
Keller, after ingesting benzoic acid, reported that it was the amount of ingested bezoic 
acid that was related to hippuric acid excretion. It is now known that hippuric acid 
comprises benzoic acid conjugated to glycine (Keller, 1842). It was later observed 
that adminstration of other acids also resulted in the excretion of hippuric acid, which 
led to the postulation of oxidation of these acids to benzoic acid as an intermediate 
step.
Lipophilic and xenobiotic compounds initially undergo side-chain shortening by a, 
a) and p-oxidation pathways located in the ER, mitochondria and peroxisomes. These 
side-chain shortened products then undergo biotransformation to water-soluble 
compounds (Williams, 1947). The biotransformation mechanism commonly consists 
of two steps. Firstly a polar group is introduced to the compound, for example, a
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hydroxyl or carboxyl group by reduction/oxidation mechanisms. This principally 
occurs in the endoplasmic reticulum (ER) and is catalysed by cytochrome P450 and 
cytochrome P450 reductase supergene family of enzymes with the use of NADPH as 
a cofactor. The resulting molecules are able to cause damage to proteins, RNA and 
DNA and, therefore, need to undergo further modification. In the second step, these 
reactive molecules are conjugated to water-soluble groups, such as glucuronic acid, 
sulphate, glycine, glutamine, taurine, ornithine and glutathione. Glucuronyl 
transferase enzymes in the ER, for example, catalyse the binding of glucuronic acid to 
hydroxyl groups of these reactive molecules. Sulphate conjugation occurs in the 
cytosol and binds to phenol groups. These polar conjugates may then be readily 
excreted either in the bile directly from the liver or reabsorbed into plasma and 
transported to the kidney where they are filtered into the urine.
Additionally, the intestine appears to play an important role in metabolism. It contains 
metabolising enzymes, such as the cytochrome P450 enzyme, CYP3A, at high 
concentrations. The gut microflora also produce compounds that are able to induce or 
inhibit these enzyme activities, and are also able to remove some conjugated moieties 
and convert the compounds to their original form, subsequently allowing re-entry into 
the circulation.
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1.6.2 Vitamin E metabolism
1.6.2.1 Products of vitamin E metabolism
The structure of vitamin E compounds, both tocopherols and tocotrienols, consist of a 
side-chain and a chromanol ring, which are capable of producing two distinct groups 
of metabolites. One group of metabolites result from the reaction of the chromanol 
ring with oxidants, and the other group is produced by shortening of the side chain.
Simon et al (1956) carried out vitamin E supplementation studies in both rabbits and 
humans. They discovered two urinary metabolites, known as 2-(3-hydroxy-3-methyl-
5-carboxypentyl)-3,5,6-trimethyl-l,4-benzoquinone (a-tocopheronic acid, a-TA) and 
its y-lactone derivative, a-tocopheronolactone (a-TL), now referred to as the ‘Simon 
metabolites’ (figure 1.5). The detection of these metabolites appeared to show 
evidence of oxidative ring opening of the a-TH. It was postulated that the metabolic 
pathway of TH proceeded by the following steps (see figure 1.6); 1-chroman ring is 
opened, leading to a-tocopheryl quinone (a-TQ); 2- reduction of the a-TQ to a- 
tocopheryl hydroquinone (a-TQH2); 3- side chain shortening by (3-oxidation to give 
a-TA and side-chain rearrangement to form a-TL; 4- conjugation of metabolites with 
glucuronic acid, and then 5- excretion in the urine. Following oral administration of 
a-TQ in humans, Schmandke (1965) showed that a-TA was excreted in the urine. 
The amount of metabolite, however, was only 0.3% of the original dose, which was 
most likely the result of poor absorption of a-TQ by the intestine.
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Figure 1.5; The ‘Simon urinary vitamin E metabolites’, a-tocopheronic acid 
(a-TA) and a-tocopheronolactone (a-TL).
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Following injection of rats with radiolabeled 6-TH, a new urinary metabolite was 
discovered by Chiku et al (1984). The metabolite was identified as 6-carboxy-ethyl- 
hydroxychroman (6-CEHC), consisting of an intact chroman ring. It was proposed 
that this metabolite was formed by the shortening of the phytyl side-chain by 13- 
oxidation. The a-TH homologue of 6-CEHC was later identified in human urine 
(Schultz et al., 1995 ) and this metabolite i.e. 2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-
6-hydroxychroman (a-CEHC), was demonstrated to be the principal urinary 
metabolite following supplementation with doses of 50-150mg/day of RRR-a-TH. 
This finding further supported the proposal of side-chain metabolism of a-TH without 
previous oxidative ring opening (see figure 1.6). Enzymatic studies revealed that a- 
CEHC was excreted in the urine predominantly as sulphate conjugates (Schultz et al., 
1995). Although a-TL was also detected in this study, it appeared to result from the 
artefactual oxidation of a-CEHC. It was therefore considered that the metabolites 
detected by Simon and his group were produced by artefactual oxidation during 
sample processing, as this group used drastic acid hydrolytic deconjugation at an 
elevated temperature as opposed to the more gentle enzymatic deconjugation (Schultz 
et al., 1995). However, whether some of the detected a-TL is produced in vivo, is still 
uncertain.
If a-TL is produced in vivo, concentrations should be raised in the presence of 
oxidative stress and may be a potential in vivo biomarker. This hypothesis was tested 
in the present investigation (see chapter 4) by exercise-induced oxidative stress, where 
human subjects undergoing exercise were studied. In this study urinary concentrations
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of a-TL were compared to urinary concentrations of 8-isoprostane, a well recognised 
biomarker of oxidative stress (see chapter 3).
In 1996, a new endogenous natriuretic factor (a factor controlling the body’s pool of 
extracellular fluid by facilitating urinary excretion of sodium) was isolated and 
characterised as unconjugated y-CEHC (Y-carboxyethyl-hydroxychroman), also 
referred to as LLU-a (Wechter et al., 1996). They proposed that this compound was a 
metabolite of y-TH. As mentioned previously, Swanson et al found that although there 
was a higher intake of y-TH in a typical north American diet, plasma levels were only 
20% that of a-TH, due to preferential secretion of a-TH back into the plasma 
circulation (Swanson et al., 1999). Urinary analysis, on the other-hand, showed 
greater concentrations of y-CEHC than a-CEHC. These results confirmed the 
preferential release of a-TH from the liver into the circulation and the preferential 
metabolism of y-TH and excretion of its products.
In confirmation of a sequential side-chain shortening pathway involved in the 
metabolism of vitamin E, Parker and Swanson (2000), described the precursor of y- 
CEHC, y-carboxymethylbutyl-hydroxychroman (y-CMBHC) in human urine and also 
in HepG2 cell cultures grown on medium supplemented with y-TH. Pope et al (2002) 
later unequivocally confirmed the presence of a-CMBHC in human urine by the 
synthesis of a-CMBHC standard. A precursor of CMBHC with two extra carbons, y- 
carboxymethylhexyl-hydroxychroman (y-CMHHC), was subsequently described by 
Birringer and coworkers in 2002 in studies with HepG2 cell cultures (figure 1.6) 
(Birringer et al., 2002).
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1.6.2.2 Proposed pathway for the metabolism of vitamin E
Vitamin E metabolism results in the formation of water-soluble metabolites with 
successive side-chain shortened structures, including CEHC, CMBHC and CMHHC, 
which are conjugated with glucuronide or sulphate groups and excreted in the urine. 
This provides evidence of vitamin E undergoing metabolism by a similar mechanism 
to that involved in the general metabolism of lipids and xenobiotics. The saturated 
phytyl side-chain of the tocopherols is identical to the structure of a well studied fatty 
acid (FA), phytanic acid. The metabolism of tocopherol, therefore, might be expected 
to follow the same chain-shortening ^-oxidation pathway as phytanic acid without 
prior oxidative ring opening (see chapter 5 section 5.1.4 for more detail) (figure 1.6). 
It is not known whether this takes place in mitochondria and/or peroxisomes. This 
question will be addressed in studies in patients with mitochondrial and peroxisomal 
disorders (chapter 5). Additionally the ‘Simon metabolite’ a-TL may be formed upon 
oxidative ring opening followed by p-oxidation (forming a-TA) and finally side-chain 
rearrangement to form a lactone group.
p-Oxidation
As discussed above, analysis of rat and human urinary vitamin E metabolites and 
studies in tissue culture using HepG2 cells have shown the secretion of successive 
side-chain shortened metabolites, CMBHC and CEHC (figure 1.6). The detection of 
these metabolites confirms that TH undergoes systematic side-chain shortening which 
may involve p-oxidation.
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o-Oxidation
Prior to p-oxidation, THs undergo oxidation of the terminal co-methyl group. A 
number of studies have provided evidence that this oxidation is achieved by 
microsomal co-oxidation, whereby a carboxylic group is added to the co-site. 
Microsomal co-oxidation is catalysed by cytochrome P450 enzymes (CYPs). 
Cytochrome P450 is a family of enzymes that exist with extensive sequence 
similarities. These proteins are conveniently arranged into CYP gene families and 
subfamilies within which enzymes are grouped according to their percentage 
sequence homology (Nebert and Gonzalez, 1987). Eighteen of these families have 
been recorded in mammals. One of these families of CYP enzymes, CYP 3A is 
responsible for a large proportion of cytochrome P450-mediated metabolism of 
therapeutic drugs. Different CYP proteins have been shown to regulate the 
degradation of y and a-TH to different extents, whereby the activity toward a-TH is 
consistently lower than y-TH. Rifampicin an inducer of CYP 3A4 activity enhanced 
a-TH metabolism, but had no effect on y-TH in HepG2 cells (Birringer et al., 2001). 
Additionally, Sontag and Parker (2002), using microsomes isolated from insect cells 
transfected with a series of CYPs, showed that CYP 4F2 was associated with the 
hydroxylation of y-TH but had poor activity toward a-TH. Parker et al (2000), found 
that ketoconozole which is an effective inhibitor of CYP 3A, resulted in the inhibition 
of y- and a-TH metabolism in rat hepatocytes in cell culture, and y- and 6-TH in 
HepG2/C3A cells. To support this, Ikeda et al (2002), found y-CEHC excretion 
decreased after feeding rats sesame seeds, which contain sesamin, an inhibitor of CYP 
3A.
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The intracellular site of vitamin E side-chain shortening, however, remains 
unresolved. Chapter 5 describes two studies that were carried out to investigate the 
intracellular site of vitamin E side-chain oxidation. The first of these studies involved 
urinary vitamin E metabolite analysis in patients with mitochondrial and peroxisomal 
disorders (section 5.2). The second study involved in vitro tissue culture methods 
using skin fibroblasts and HepG2 cells with and without modulators of peroxisomal 
and mitochondrial function.
1.7 Functions of vitamin E
1.7.1 Antioxidant properties of vitamin E
1.7.1.1 Introduction to oxidative stress and antioxidant defences
Oxygen and nitrogen are major constituents of the environment in which aerobes 
exist, and are potentially poisonous molecules. Both oxygen and nitrogen readily react 
to form highly reactive oxygen and nitrogen species (ROS and RNS) in biological 
systems. Reactive oxygen species (ROS) include hydrogen peroxide (H2O2), and
oxygen derived free radicals such as superoxide (02* ) and the hydroxyl radical (OH*)
(Halliwell and Gutteridge, 1999). Reactive nitrogen species include nitrous acid
(HNO2), peroxynitrite (ONOO ), nitric oxide (NO*) and nitrogen dioxide (NO2 ). Free
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radicals are molecular entities, which contain one or more unpaired electrons in the 
outer orbit, which make them highly reactive. They can react by either donating or 
removing an electron from other molecules, which subsequently become radicals 
themselves, thus propagating a chain-reaction.
Reactive oxygen and nitrogen species are formed during normal cell metabolism and 
other biological processes, such as a by-product of molecular oxygen flux through the 
mitochondria, the respiratory burst of macrophages against invading pathogens, and 
exposure to a range of external influences, such as pollutants, heavy metals and 
ionising radiation. These reactive species attack all biomolecules of the cell, including 
lipids, DNA, carbohydrates and proteins. Living organisms have evolved antioxidant 
defence mechanisms to protect against ROS (Halliwell and Dizdaroglu, 1992). These 
antioxidant defences include 1)- the catalytic removal of ROS, by enzymes such as 
superoxide dismutase, catalase and glutathione peroxidase. 2)- minimising the 
availability of pro-oxidants, such as iron and copper ions by action of proteins e.g. 
ferritin (iron), transferrin (iron) and ceruloplasmin (copper). 3)- the protection of 
biomolecules against damage by action of proteins, such as heat shock proteins. 4)- 
scavenging of ROS by low-molecular-mass species, such as glutathione, ascorbate, 
uric acid which are water soluble, and a-TH which is lipid soluble. The level of 
activity of these different antioxidant defence mechanisms varies between different 
organs, tissue types, cell types and extracellular fluid. In healthy organisms there is a 
balance between the production of ROS and the antioxidant defence systems. When 
antioxidant levels, however, are outweighed by ROS and RNS the system is said to be 
in a state of oxidative stress. Oxidative stress is associated with many disease
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pathologies (see chapter 3) and can lead to adaptation by up-regulation of the 
antioxidant defences, and/or cell injury.
1.7.1.2 Lipid oxidation, vitamin E and redox cycling
The oxidation of lipids, also referred to as lipid peroxidation, by oxygen in the 
atmosphere is the reason fats become rancid. Lipid peroxidation (figure 1.7) occurs 
via a chain of reactions that comprise three distinct stages; initiation, propagation and 
termination (Halliwell and Gutteridge, 1985). Lipid peroxidation is initiated when
FAs are attacked by free radical species such as hydroxyl radicals ( OH), that are
capable of abstracting a hydrogen atom from a methylene group (-CH2-) adjacent to a 
carbon-carbon double bond. This results in the formation of a carbon centred free
radical (L‘) which undergoes molecular rearrangement and can react with molecular
oxygen to produce lipid peroxyl free radicals (LOO*). Peroxyl free radicals are
sufficiently reactive to abstract further hydrogen atoms from adjacent polyunsaturated
acyl chains, resulting in the formation of another lipid peroxyl free radical (LOO ) and
a stable lipid hydroperoxide (LOOH). This is referred to as the propagation stage, as 
this secondary radical can lead to further peroxidation. Termination occurs when 
either two radicals react to form stable products or a compound donates a hydrogen 
atom to the lipid peroxyl radical, again producing a non-radical product and therefore 
preventing further peroxidation.
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TH is able to interfere with the free radical propagation steps by scavenging FA 
peroxyl free radicals (L-OO*) and thereby terminating the chain reaction of lipid
peroxidation. It donates the labile hydrogen atom of its phenol group to the lipid 
peroxyl radical, thereby forming a lipid hydroperoxide and a tocopheroxyl radical (T-
0 ‘) (Boguth and Niemann, 1971; Mukai et al., 1982). The reaction with TH is
favoured, as the rate of reaction of TH with peroxyl radicals is greater than the
reaction with LH. This may be due to the tocopheroxyl radical (T-0‘) being more
stable because of resonance stabilisation, and the possibility of the tocopheroxyl 
radical being recycled back to TH by vitamin C, which has been shown to occur in 
vitro (Packer et al., 1979; Niki et al., 1982). The tocopheroxyl radical is stable due to 
resonance stabilisation of the chroman ring by electron delocalisation (Burton et al., 
1985), and is therefore less likely to propagate the radical chain reaction (Boguth and 
Niemann, 1971; Mukai et al, 1982).
For TH to be an effective in vivo antioxidant, redox cycling must occur to prevent the
potential prooxidant activity of the tocopheroxyl radical (T-0‘). Two different
mechanisms have been proposed for TH redox cycling. The ‘one electron redox
cycle’ involves T-O* being reduced back to TH by co-antioxidants in vivo, such as
vitamin C, ubiquinol and NAD(P)H dependent enzymes (Packer et al., 1979;
Halliwell et al., 1992). T-O* radicals which do not undergo this reduction are proposed
to take part in a ‘two electron redox cycle’. This involves reaction with further 
peroxyl radicals in two different reaction pathways yielding two groups of “non-
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radical” adducts. Such non-radical adducts include 8a-substituted tocopherones 
(Winterle et al., 1984; Yamauchi and Matsushita, 1979; Durckheimer and Cohen, 
1964; Liebler and Burr, 1992) and epoxytocopherones. To maintain the redox cycle, 
8a-substituted tocopherones may be reduced back to TH by enzymatic catalysis 
(Liebler et al., 1989) or alternatively, a-TQ has also been shown to undergo a 
reduction reaction to form a-tocopherol hydroquinone (a-TQ H 2)(Bindoli et al., 1985; 
Kohar et al., 1995). C1-TQH2 has been shown to provide potent antioxidant protection 
(Liebler and Burr, 2000).
1.7.1.3 Antioxidant ability of vitamin E
The heterocyclic chromanol ring of the tocopherols and the tocotrienols is responsible 
for the antioxidant ability of these compounds. As described above (1.7.1.2), the 
oxidation of the chromanol ring occurs by the donation of a phenolic hydrogen to a 
lipid peroxyl radical, forming a resonance stabilised chromanoxyl radical. It would be 
expected that a-TH would be a more potent hydrogen donor due to its two ortho­
methyl groups, compared to |3, y, 6-THs (refer to figure 1.2). Some studies, however, 
have shown a-TH to be a less potent antioxidant then y-TH in vitro (Gottstein and 
Gosch, 1990).
The tocotrienols have been shown by electron spin resonance (ESR) studies to 
generate tocotrienoxyl radicals (Goh et al., 1990). The three double bonds in the side
48
Chapter 1 -  General Introduction
chain, however, seem to render the tocotrienols less efficient as in vivo antioxidants in 
comparison to the tocopherols.
When considering the relative antioxidant activities of the different vitamin E species 
in vivo, it is not only important to consider their chemical reactivity but also their 
relative bioavailabilities and biokinetics i.e. association with proteins such as a-TTP.
1.7.1.4 Vitamin E as an antioxidant supplement
Oxidative stress can result from a number of physiological conditions and 
pathological states including exhaustive exercise (Banerjee et al., 2003), 
atherosclerosis (Holvoet and Collen, 1994), diabetes (Baynes, 1991) Alzheimer’s 
disease (Pratico et al., 2000a), Parkinson’s disease (Ebadi et al., 1996; Betarbet et al., 
2000), Down’s syndrome (Kedziora and Bartosz, 1988) and environmental factors, 
such as smoking and inhalation of fumes (Petruzzelli et al., 2000). Vitamin E 
supplementation studies in individuals undergoing intense exercise or patients with 
diseases associated with oxidative stress have provided mixed results. Some studies 
show a beneficial effect of vitamin E supplementation, which is reflected in improved 
outcome measures or levels of oxidative stress biomarkers. This has been documented 
in studies in Alzheimer’s disease (Sano et al., 1997; Engelhart et al., 2002 ), type 1 
and type 2 diabetes (Skyrme-Jones et al., 2000), hypercholesteroleamia (Neunteufl et 
al., 1998), coronary heart disease and atherosclerosis (Stephens et al., 1996; Boaz et 
al., 2000). Hartmann et al (1995) reported that supplementation with vitamin E
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inhibited exercise induced DNA strand breakage. Some other studies have however 
shown that vitamin E supplementation has no beneficial effect, for example in 
patients with diabetes (Gazis et al., 1999), hypercholesterolaemia (Gilligan et al., 
1994) and atherosclerosis (Marchioli, 1999; Yusuf et al., 2000). The lack of 
consistency in clinical trials with the same condition may be a result of a number of 
other factors including the effect of combination therapy, stage of advancement of the 
disease and the dose and duration of vitamin E administered.
1.7.2 Non-antioxidant functions of vitamin E
With the exception of a-TH, the tocopherols and tocotrienols are not retained in 
humans. a-TH is uniquely recognised and appears to have a number of functions in 
vivo that are distinct from its antioxidant or radical scavenging abilities. A number of 
biomolecules that exhibit antioxidant properties also have additional properties that 
are often responsible for their principal functions i.e. retinol (Tesoriere et al., 1993; 
Tesoriere et al., 1996) and melatonin (Reiter et al., 1994; Reiter, 1995; Konturek et 
al., 1997).
Reported functions of a-TH that are not related to its antioxidant activity include 
effects on the regulation of phosphorylation/dephosphorylation of proteins and cell 
signalling, gene transcription, anti-inflammatory properties, regulation of cell 
adhesion processes and regulation of drug metabolism pathways.
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a-TH, but not the other tocopherols, has been shown to regulate protein kinase C 
(PKC) in different cell types, including monocytes (Devaraj et al., 1996; Rattan et al., 
1997), macrophages (Freedman et al., 1996), neutrophils (Kanno et al., 1995; Kanno 
et al., 1996), fibroblasts (Hehenberger and Hansson, 1997) and mesangial cells 
(Studer et al., 1997; Tada et al., 1997). The mechanism by which PKC activity is 
inhibited by a-TH is associated with its dephosphorylation via the activation of 
protein phosphatase type 2A (PP2A)(Hansra et al., 1996). PKC consists of a family of 
at least 12 isoforms, which are involved in transmitting signals from the extracellular 
medium to the nucleus mainly via its ability to activate the transcription factor API 
(Angel et al., 1987; Schonthal et al., 1988). The age dependent increase of PKC-a is 
paralleled by increased expression of enzymes that are under the control of PKC via 
API such as collagenase, which is responsible for the degradation of collagen 
(Ricciarelli et al., 1999). It has, therefore, been proposed that a-TH may protect skin 
from age-related collagen breakdown.
a-TH reduces the increased expression by oxidised LDL (oxLDL) of the class A 
scavenger receptor, SR-A, and the class B scavenger receptor, CD36 (Teupser et al., 
1999; Devaraj et al., 2001b). Scavenger receptors (SRs) are responsible for the 
mediation of cellular uptake of modified lipoproteins such as oxLDL, which are 
assumed to be involved in foam cell formation in atherosclerosis. The inhibitory 
mechanism of a-TH is non-antioxidant dependent as other antioxidants, including f3 
and y-TH failed to decrease CD36 expression. Inhibition is also PKC independent as 
demonstrated by the lack of effect of PKC inhibitors. Hence, a-TH reduces the uptake
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of oxidised lipoproteins with consequent reduction in foam cell formation in 
atherosclerotic lesions (Ricciarelli et al., 2000).
a-TH also exhibits a role as an anti-inflammatory agent, whereby it inhibits the 
secretion by macrophages of pro-inflammatory, proatherogenic cytokines such as 
interleukin 1(3 (IL-1(3) (Akeson et al., 1991; Devaraj and Jialal, 1999) and tumour 
necrosis factor (TNF-a) (Devaraj and Jialal, 2000; van Tits et al., 2000). The 
inhibition of the release of cytokine IL-1(3 has been demonstrated to occur via the 
inhibition of 5-lipooxygenase (5-LO) activity, by impairment of 5-LO translocation 
from the cytosol to the membrane by a-TH (Chan et al., 1989; Reddanna et al., 1985).
a-TH has been shown to play a role in the inhibition of monocyte endothelial cell 
adhesion (Devaraj et al., 1996) by inhibition of counter-receptors on monocytes and 
inhibition of the transcription factor NF-kB (Islam et al., 1998). NF-kB is responsible 
for the induction of a variety of genes in atherosclerotic lesions, such as those 
encoding tumour necrosis factor (TNF-a) and interleukin 1(3 (IL-1|3).
All forms of vitamin E have demonstrated an ability to activate a nuclear receptor, 
pregnane X receptor (PXR) mediated gene expression in HepG2 cells (Landes et al., 
2003) and have therefore been suggested to interfere with drug metabolism via the 
nuclear receptor, PXR. PXR regulates a variety of drug metabolising enzymes, 
including cytochrome P450 3A (CYP3A) type enzymes, and is involved in the drug 
hydroxylation and elimination pathways. As discussed previously, vitamin E appears 
to be metabplised similarly to xenobiotics in that they undergo co-oxidation by CYPs
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followed by (3-oxidation (Birringer et al., 2001; Sontag and Parker, 2002) before 
being conjugated and excreted in urine or bile. This may suggest that vitamin E forms 
are able to impose some regulation on their own metabolism.
1.8 Vitamin E-deficiency syndromes
A number of vitamin E deficiency syndromes have been described in human and 
animal species. Features include foetal resorption, ataxia, growth retardation, 
encephalomalacia, haematological abnormalities, liver necrosis and myopathy 
(Goettsch and Pappenheimer, 1931; Wasserman and Taylor, 1972). In man vitamin E 
deficiency is rare because of the widespread availability of the different forms of 
vitamin E in the human diet. Typically, vitamin E deficiency results from generalised 
fat malabsorption but in rare cases it results from a vitamin E specific mechanism as a 
result of a defective tocopherol transfer protein (a-TTP).
Patients exhibiting severe and chronic vitamin E deficiency as a result of severe fat 
malabsorption caused by the condition, abetalipoproteinaemia were first described in 
detail by Muller et al (1977). Abetalipoproteinaemia is an inborn error of lipoprotein 
metabolism, where infants show undetectable vitamin E concentrations from birth 
(Muller et al., 1974) and later develop a characteristic neurological syndrome during 
their second decade of life (Muller et al., 1983) which leads to crippling and 
blindness. Vitamin E cannot be absorbed or transported in these patients due to a lack
53
Chapter 1 -  General Introduction
of all lipoproteins except high density lipoproteins (HDL). Severe vitamin E 
deficiency has also been associated with severe fat malabsorption caused by other 
factors including obstructive jaundice (cholestatic liver disease) whereby patients lack 
the necessary bile salts in the intestinal lumen for solubilisation of dietary fats 
(Harries and Muller, 1971; Elias et al., 1981) and occasionally patients with cystic 
fibrosis (Elias et al., 1981).
Ataxia with vitamin E deficiency (AVED) is a rare condition resulting from a lack of 
functional hepatic a-TTP (Ouahchi et al., 1995). As mentioned in section 1.5.2, a- 
TTP is necessary for the transfer of a-TH to very low density lipoprotein (VLDL) and 
secretion back into the circulation. In AVED patients, there is an impaired 
incorporation of RRR-a-TH onto nascent VLDL and impaired secretion of vitamin E 
back into the circulation and resulting in very low plasma and tissue vitamin E levels. 
Vitamin E deficiency in AVED patients in the absence of generalised fat 
malabsorption provided a human condition with a specific deficiency of this vitamin 
(Sokol et al., 1988). These patients exhibit the same characteristic neurological 
syndrome as those with generalised fat malabsorption.
In conditions of severe vitamin E deficiency neuropathy is progressive unless treated. 
Early treatment with a-TH prevents the appearance of neurological signs and 
symptoms. In cases where symptoms of vitamin E deficiency are already present, 
treatment halts the progression and in some cases can produce improvement (Muller 
et al., 1977; Muller et al., 1983). Supplementation of appropriate doses of vitamin E, 
to patients with vitamin E deficiency or to those at risk of vitamin E deficiency is
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recognised as an important preventive measure against the devastating peripheral 
neuropathy resulting from the deficiency of vitamin E.
The characteristic neuropathy resulting from vitamin E deficiency may be due to the 
particular susceptibility of the nervous system to oxidative stress. The brain contains 
high concentrations of polyunsaturated fatty acids (PUFAs) that are susceptible to 
lipid peroxidation, in addition the brain utilises a large percentage of the body’s 
oxygen and is relatively deficient in antioxidant defense systems. Other functions 
unrelated to oxidative stress may also be involved.
In the following chapters methods for the estimation of urinary vitamin E metabolites 
and isoprostanes will be described. Their use in monitoring oxidative stress and the 
cellular localisation of vitamin E metabolism will be discussed.
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2.1 Measurement of urinary vitamin E metabolites
2.1.1 Introduction
This chapter describes the modification and use of a method initially developed by 
Pope et al (2000) in our laboratory for the quantitative measurement of urinary 
vitamin E metabolites using gas chromatography-mass spectrometry (GC-MS). 
The method was modified in order to reduce artefactual oxidation and shorten the 
sample preparation time by reducing the incubation period for the enzymatic 
hydrolysis of the conjugated metabolites. Secondly, the stability of metabolites in 
urine samples stored under different conditions was tested for both short and long 
term storage periods.
2.2 Experimental protocol
2.2.1 Introduction to methodology
The protocol used to extract and measure urinary metabolites was based on the 
methodology developed in our laboratory by Pope et al (2000). The analytical 
procedure consisted of essentially six steps which included: pre-treatment of urine 
samples, extraction of metabolites, deconjugation, extraction of deconjugated 
metabolites, derivatization, and analysis by GC-MS (figure 2.1).
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1 ml URINE
I
Add internal standard 
d9-a-CEHC
#
Acidify to  pH 2.5 
#
Solid Phase Extraction; C4 cartridge
I
DECONJUGATION; p-glucuronidase and aryl sulphatase
f
Solid Phase Extraction; C4 cartridge
I
DERIVATISATION; BSTFA/Acetonitrile
I
ANALYSIS by GC-MS
Figure 2.1; Preparation and extraction protocol for urinary analysis of vitamin 
E metabolites
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Pre-treatment involved the addition of standards to the urine samples in order to 
quantify endogenous urinary metabolites, and to estimate artefactual oxidation 
occurring during sample preparation. The samples were then acidified to pH 2.5 
using HC1 to protonate the metabolites and to increase their affinity for the C4 
sorbent.
Extraction of metabolites was achieved by solid phase extraction (SPE). The 
properties of the solid phase could be chosen according to the separation 
requirements. The advantage of SPE compared to other extraction methods such 
as solvent extraction, was that SPE required small solvent volumes, and was ideal 
for batch processing in a cartridge format. The basic protocol for SPE entailed 
priming of the cartridge using an organic solvent such as methanol and washing 
with water prior to loading of sample. The cartridge was again washed following 
loading of the sample, then the metabolites were eluted using an organic solvent, 
usually the same solvent as used for the priming stage.
Deconjugation of metabolites was performed using p-glucurodinase and aryl 
sulphatase to liberate the unconjugated forms of the metabolites from the 
extracted metabolites.
Extraction of deconjugated metabolites was carried out using SPE cartridges to 
separate the unconjugated metabolites from the enzyme reaction mixture. 
Derivatisation for GC-MS analysis was performed by converting the 
metabolites to their trimethyl silyl (TMS) derivatives which are more volatile, 
enabling them to be analysed in the gaseous phase by gas chromatography (GC). 
Analysis by GC-MS was performed after injecting samples onto the GC column. 
The GC-MS instrument was programmed to run the sample through a 
preprogrammed method.
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2.2.2 Materials
Trolox was purchased from Sigma-Aldrich Company Ltd and d9-a-CEHC was a 
gift from Dr G Burton (Steacie Institute of Molecular Sciences, National Research 
Council, Ottawa, Canada). Isolute C4 solid phase extraction cartridges (500mg 
sorbent mass, 6ml reservoir volume) were supplied by Jones Chromatography. (3- 
glucuronidase (with sulphatase activity) was purchased from Sigma-Aldrich 
Company Ltd (G-7017, activity of 100,000 (3-glucuronidase units/ml and 7,500 
sulphatase units /ml from Helix pomatia type HP-2). The TMS derivatising agent, 
N,0-bis(trimethylsilyl)trifluoroacetamide (BSTFA) was purchased from Pierce 
Chemicals Ltd). All other chemicals were purchased from Sigma-Aldrich 
Company Ltd unless otherwise stated.
2.2.3 Sample preparation and analytical method
Aliquots of 1ml of urine samples were used for the extraction of metabolites. The 
urine samples were centrifuged to remove solid material, followed by the addition 
of d9-a-CEHC (lOnmoles) and trolox (5nmoles) standards dissolved in lOpl of 
methanol. The samples were acidified to pH2.5 with 3M HC1 and loaded on to C4 
SPE cartridges that had been primed using 4ml of methanol, followed by 4ml 
deionized water acidified to pH2.5. Following the elution of the urine samples, 
cartridges were washed with 4ml deionized water (pH2.5), to remove any 
unbound compounds. Elution of the vitamin E metabolites was achieved using 
4ml methanol. The cartridges were eluted under gravity, with a constant flow rate
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of approximately 0.5 ml/min throughout. The eluates were evaporated to dryness 
under a stream of N2, dissolved in 1ml deconjugation solution, which consisted of 
500pl deionised water, 475 pi 5M sodium acetate (pH 4.5) and 25pi suspension of 
(3-glucurodinase with sulphatase activity (activity of 100,000 (3-glucuronidase 
units/ml and 7,500 sulphatase units/ml from Helix pomatia type HP-2) and 
incubated at 37°C for 18 hours. At the end of the incubation, samples were again 
acidified to pH2.5, and extracted using new C4 SPE cartridges. The eluates were 
evaporated to dryness under a gentle stream of N2. The unconjugated metabolites 
were then derivatised to form their TMS derivatives, by redissolving in a 
derivatising solution consisting of 200pl acetonitrile/BSTFA (1:1), and incubated 
at 60°C for 60 minutes.
The derivatised samples were analysed by GC-MS. lp l of derivatised sample was 
injected by splitless mode onto a HP-1 methyl siloxane column (30m, 0.25mm ID, 
0.25 pm film thickness) supplied by Jones Chromatography Ltd, in a Hewlett- 
Packard 6890 series GC system. The GC was linked to a Hewlett-Packard 5973 
mass-selective detector (MSD) and Chem station data system. The oven was 
maintained at 120°C for 2 min at the start of the run. It was then ramped to 200°C, 
at a rate of 20°C/min, then to 240°C, at 2°C/min. The final ramp was to 300°C at 
50°C/min, which was held at 300°C for 5mins. The total run time per injection 
was 32.2min. The ionization energy was 70 eV, and the MSD was run in SCAN 
mode to enable detection of the full spectrum of ions.
61
Chapter 2 - Measurement of urinary vitamin E metabolites
2.2.4 GC-MS data analysis and metabolite measurement
The internal standards and the metabolites were visualised by extracting 
chromatograms for the following mass/charge (m/z) ions;
Internal standards- (figure 2.2 and 2.3)
Trolox parent fragment m/z 394, daughter fragments m/z 236/237; d9-aCEHC 
parent fragment m/z 431, daughter fragments m/z 245/6 and d9-a-TL (oxidised 
form of d9-a-CEHC standard) parent fragment m/z 431, daughter fragments m/z 
318, 245/6.
Metabolites- (figure 2.4 and 2.5)
dO-a-CEHC parent fragment m/z 422, daughter fragments m/z 237; dO-a- TL 
parent fragments m/z 422, daughter fragments m/z 309, 237 ; dO-a-CMBHC 
parent fragment m/z 464, daughter fragment m/z 237 and oxidised a-CMBHC 
parent fragment m/z 626, daughter fragments m/z 536, 309 
dO-p-CEHC parent fragment m/z 408, daughter fragment m/z 222/223 ; p- 
CMBHC parent fragment m/z 450, daughter fragment m/z 2222/23 ; d0-6-CEHC 
parent fragment m/z 394, daughter fragment m/z 208/209 ; 8-CMBHC parent 
fragment m/z 436, daughter fragment m/z 208/209 ; dO-y-CEHC parent fragment 
m/z 408, daughter fragment m/z 222/223 ; y-CMBHC parent fragment m/z 450, 
daughter fragment m/z 222/223. Chromatographic peaks were identified by the 
mass spectra, characteristic for each metabolite (figures 2. 2- 2.5). TMS- 
esters/ethers of a-TL and a-CEHC are isobaric compounds, both showing a large
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Figure 2 .2; Mass spectrum of trolox.
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Figure 2.3; Mass spectra of the internal standard d9-a-CEHC and its 
oxidation product d9-a-TL.
64
Chapter 2 -  Measurement of urinary vitamin E metabolites
m/z 236/237
TMSO a-CEHC;
M+422
,Q TMS
m/z 73
422
237
m /x ,— »-
m/z 309
V b undanc i 
1 B O O C
m/z 236/237
TMSO
TMS
m/z 99
m/z 73
73
237
99
309
a-TL; 
M+ 422
422
3 ’i b  " "  'V i b
Figure 2.4 a); Mass spectra of a-CEHC and a-TL
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Figure 2.5; Fragment patterns of P, 8, and y-tocopherol derived metabolites, 
CEHC and CMHBCs.
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molecular ion of m/z of 422 for the undeuterated metabolite and m/z 431 for the 
d9-deuterated internal standard. All TMS ethers/esters show characteristic 
fragments of 73 m/z representing a TMS group that breaks between an oxygen 
and silicon atom. The major fragment ions are generated by the cleavage of weak 
bonds, such as those separated by a single bond from double bonds of the 
unsaturated ring (allylic bonds). TMS ethers/esters of both a-TL and a-CEHC 
also show cleavage of two allylic bonds shown in figure 2.4, resulting in a m/z 
236/237 fragment. In addition, the a-TL also shows a peak at 309 m/z 
representing cleavage of a single allylic bond.
Standards were not available for all metabolites, therefore, concentrations of the 
metabolites were expressed as d9-a-CEHC equivalents per mmole creatinine.
2.2.5 The use of d9-a-CEHC as an internal standard
The internal standard, d9-a-CEHC, was added to the urine before sample 
processing to provide a measure of artefactual oxidation during the procedure. 
Any d9-a-TL detected must be derived artefactually from d9-a-CEHC (figure 
2.6). This was used to estimate and correct for the amount of artefactual oxidation 
of the endogenous dO-a-CEHC occurring in the individual samples, from the point 
of spiking to analysis on GC-MS. This presumes that both deuterated (d9) and 
undeuterated a-CEHC are affected to the same extent by artefactual oxidation.
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Internal standard
% ARTEFACTUAL 
OXIDATION 
d9-a-CEHC --------------------- ► d9-a-TL
Metabolite
% ARTEFACTUAL 
OXIDATION
dO-a-CEHC  ► dO-a-TL
+
REAL a-T L  
METABOLITE
Figure 2.6; The artefactual oxidation of a-CEHC.
The percentage total a-TL detected is almost always greater than that calculated as being 
due to artefactual conversion from the internal standard. It may therefore be postulated 
that the difference represents the presence of ‘REAL’ a-TL in the urine.
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The internal standard percentage conversion of d9-a-CEHC to d9-a-TL was 
almost always less than the endogenous percentage of dO-a-TL in relation to dO-a- 
CEHC plus dO-a-TL (see figure 2.6). This difference, therefore, may represent real 
a-TL present in the urine which was not formed as a result of the artefactual 
oxidation that occurred upon sample preparation. The concentrations of the 
metabolites were expressed as d9-a-CEHC equivalents. This was achieved by 
comparing peak correlated areas of the metabolites of interest (molecular ion) to 
the peak correlated area of a known amount of d9-a-CEHC (M+ 431), including 
both d9-a-CEHC plus d9-a-TL. These d9-a-CEHC equivalent values measured in 
moles were then expressed per mmol of creatinine.
2.2.6 Urinary creatinine
Urinary concentrations of creatinine were measured using a test kit (ABX 
Diagnostics, CREATININE 80) on a COBAS analyser. The test involved the 
kinetic determination of creatinine, without deproteinisation, by the complex 
formed by creatinine and picric acid in an alkaline medium (Vasiliades, 1976).
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2.3 Modifications of the method
2.3.1 Incubation time for enzymatic hydrolysis of 
glucuronide and sulphate conjugated vitamin E metabolites
The original protocol for deconjugation of the metabolites from the urine involved 
enzymatic hydrolysis with (3-glucuronidase (with sulphatase activity) at 37°C for 
18 hours. As a result, the preparation and analysis of samples took approximately 
two days, and resulted in the artefactual oxidation of approximately 10-15 % 69- 
a-CEHC to d9-a-TL. The aim of these experiments was to examine whether a 
shorter incubation period would reduce the level of artefactual oxidation without 
compromising the extent of metabolite deconjugation. Samples were prepared as 
described in the original method, except the incubation time for enzymatic 
hydrolysis was varied between 1 and 25 hours. SPE of the unconjugated 
metabolites was immediately carried out and the eluates evaporated to dryness and 
stored at 4°C. Once all samples had been extracted they were derivatised and 
analysed at the same time.
Results and Discussion
The effect of time of incubation on the concentration of vitamin E metabolites and 
the percentage conversion of d9-a-CEHC to a-TL is shown in figures 2.7, 2.8 and 
2.9. Figure 2.7 shows the actual concentrations of a-CEHC and a-TL after 
correcting for
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Figure 2.7; Actual concentrations of urinary a-CEHC and a-TL with increasing 
incubation time of enzymatic hydrolysis
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Figure 2.8; Concentration of urinary a-CMBHC and y-CEHC with increasing 
incubation time of enzymatic hydrolysis
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Figure 2.9; Percentage artefactual oxidation of d9-a-CEHC to d9-a-TL and the 
corrected percentage dO-a-TL relative to dO-a-CEHC with increasing incubation 
time of enzymatic hydrolysis.
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correcting for any artefactual conversion estimated by the deuterated internal 
standard. It can be seen that there was little change in a-CEHC concentration over 
the first 3 hours of incubation, with a slight increase of approximately 6-7% 
between 3 and 16 hours of incubation with no consistent change thereafter. a-TL 
concentrations showed an increase each hour in the first 3 hours, whereas there 
was no further consistent increase up to 24 hours incubation. Figure 2.8 shows the 
concentrations of a-CMBHC and y-CEHC over this time period. Both these 
metabolites show only a slight increase in concentration from 3 to 24 hours of 
approximately 6-10%. These results suggest that effective hydrolysis of 
conjugated metabolites can be achieved within the first few hours of incubation 
and only a slight increase is seen with more prolonged incubation. The level of 
artefactual oxidation illustrated by percentage conversion of d9-a-CEHC to d9-a- 
TL L  shown in figure 2.9. A trend of increasing artefactual formation of d9-a-TL 
with time is evident. Percentage conversion was constant within the first 3 hours 
of incubation at approximately 4%. This increased to 8% at 16 hours and 10-11% 
at 25 hours. The corrected “real” percentage of a-TL (compared to a-CEHC) was 
relatively consistent with time at approximately 12.5%. The reason for the high 
artefactual oxidation of the sample at 19 hours is unknown.
From these results it was decided to shorten the incubation period to 3 hours. This 
would reduce the level of artefactual oxidation with only a very slight effect on 
the deconjugation of the metabolites. An added advantage was the reduction in 
analysis time that enabled analysis to be carried out within a day. In all subsequent 
experiments, a 3 hour incubation period for the enzymatic hydrolysis was used.
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2.3.2 Effect of storage conditions on urinary vitamin E 
metabolites
There was little information available on the effect of storage conditions on the 
stability and artefactual oxidation of urinary vitamin E metabolites. As the 
samples analysed in the present study (see chapters 4 and 5) were collected and 
stored for different periods and under different conditions at other laboratories, it 
was necessary to investigate the effect of sample storage conditions. The three 
parameters chosen were;
1) effect of the presence of ascorbate (vitamin C) as an antioxidant to prevent 
possible artefactual oxidation during storage
2) effect of storage temperature
3) effect of storage time
To investigate the effect of the above parameters on metabolite recoveries, a 
morning void of fresh urine collected from a 26 year old female colleague (no 
vitamin supplements consumed for at least 2 years, non-smoker, teetotal), was 
spiked with internal standards, d9-a-CEHC (10 pM) and Trolox (5pM). The 
mixture was divided into two batches, and ascorbate (5mg/ml) was added to one 
batch according to our laboratory’s standard protocol. From both batches 1ml 
aliquots were stored at varying temperatures (-80°C to room temperature (21°C)) 
and analysed at different time points (0-6 months), as indicated in table 2.1. Note 
that aliquots at time point ‘0’ represent the baseline and are prepared, extracted 
and analysed within 6 hrs of collection (fresh urine).
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STORAGE
TIME
STORAGE
TEMPERATURE
0 hrs RT
24 hrs RT, 4 UC
48 hrs RT, 4 UC
1 wk RT, 4 UC, -20 uC,-80 UC
2 wks -20 UC, -80 UC
6 wks -20 °C, -80 UC
6 ninths -20 °C, -80 UC
[RT= room temperature]
Table 2.1; Plan for the investigation of the stability of metabolites stored at different 
temperatures for varying lengths of time.
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Results and Discussion
The concentrations of a-CEHC and a-TL, for each sample are shown in figure 
2.10 and for a-CMBHC and y-CEHC in figure 2.11. The data show that ascorbate 
had no consistent significant beneficial effect on the stability or oxidation of any 
of the urinary metabolites, under any of the conditions tested, except for the 
marked increase observed for a-TL at room temperature after 1 week in the 
absence of ascorbate, which may be a rogue result. When stored at room 
temperature, a-CEHC concentrations tended to decrease with time both in the 
presence and absence of ascorbate. The largest decrease occurred in the absence of 
ascorbate by up to approximately 40% after 1 week.
The concentration of a-CMBHC and y-CEHC showed no consistent and 
significant change when stored at room temperature either in the presence or 
absence of ascorbate for up 48 hours, suggesting these metabolites are highly 
stable. However, after 1 week in the absence of ascorbate a-CMBHC, y-CEHC 
and a-TL concentrations were increased.
The concentrations of all the metabolites with the exception of a-CMBHC 
remained relatively constant over time from 1 week to 6 months, if the samples 
were stored at -20°C or -80°C. Some variability was, however, observed at the 
longer storage times for a-CMBHC. This may be explained by the longer 
retention time of a-CMBHC and relatively low concentrations, resulting in a 
lower accuracy of measurement.
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It was concluded that the addition of ascorbate was not necessary and that the 
urinary vitamin E metabolite, a-CEHC, tended to decrease if kept for over 24 
hours at room temperature (21°C). Urinary vitamin E metabolites can, however, 
be stored safely at 4°C for up to a week and at -20°C or -80°C for at least 6 
months.
2.3.3 Reproducibility of the modified method
The reproducibility of the modified method was investigated by the repeated 
preparation and analysis of a quality control (QC) on different days. The QC 
consisted of a pool of normal healthy human urine stored at -80°C in the absence 
of ascorbate. The sample preparation of the QC samples was carried out using the 
modified method with enzymatic deconjugation at 37°C for 3 hours. Figure 2.12 
shows the recovered concentrations of the endogenous metabolites a-CEHC and 
a-TL over 12 days (a-CEHC mean concentration of 7.49 pM and a coefficient of 
variation (CV) of 3.87%; a-TL mean concentration of 1.52pM and CV of 
27.11%). The intra-assay variation of these species confirmed the reproducibility 
of the method.
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Figure 2.12; The reproducibility of the analysis of endogenous dO-a-CEHC and d0-a- 
TL over time. Each point for each day represents a single preparation and analysis.
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3.1 Independent marker of oxidative stress
3.1.1 The need for an independent biomarker of oxidative 
stress
a-Tocopheronolactone (a-TL) derived from a-tocopherol has been proposed as a 
potential biomarker of in vivo oxidative stress (Pope et al 2000). To test this 
hypothesis, it was necessary to assess an independent and well recognised 
biomarker of oxidative stress for comparative purposes.
3.1.1.1 Biomarkers of oxidative stress
Oxidative stress is induced by the propagation of free radicals (see chapter 1 
section 1.7.1). Free radicals are extremely reactive and short-lived and it is 
difficult to measure these species and, therefore, oxidative stress directly. Electron 
spin resonance (ESR) can theoretically be used to detect free radicals. However, in 
practice it has been found to be necessary to use indirect spin trap methods to 
detect radical adducts (Poyer et al., 1980). This method is not feasible for 
application to sample batches in clinical trials. Most methodologies, therefore, 
measure putative products of oxidative stress. Products of oxidative stress are 
variable and numerous, as free radicals attack all cell components resulting in
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peroxidation of lipids, oxidation of protein and carbohydrates, and oxidative 
damage to DNA.
Oxidative DNA damage appears to occur continuously in vivo, where reactive 
oxygen species (ROS) cause lesions to the bases. Damaged DNA is repaired by 
DNA repair enzymes, which remove modified bases from the DNA. Guanine is 
the DNA base most prone to oxidative damage resulting in the most predominant 
lesion, 8-hydroxydeoxyguanosine (8-OHdG). 8-OHdG has been studied widely in 
both cellular DNA analyses (Kasai et al., 1989) and in non-invasive urinary 
analysis (Fraga et al., 1990). 8-OHdG and other modified DNA base products 
need elaborate separation techniques and sensitive detection systems as these 
products exist in complex matrices in biological samples. In samples such as 
urine, they are present in the low nano-molar range. Another problem is that these 
modified DNA base products are difficult to measure due to the complexity of the 
preparation procedure which results in their artefactual formation and/or 
modification (Halliwell, 2000; Douki et al., 1996).
Other frequently used markers of oxidative stress are products of lipid 
peroxidation. A direct approach would involve the measurement of primary 
products of peroxidation, the hydroperoxides. However, hydroperoxides are 
unstable, so indirect measures are frequently used which employ determination of 
secondary or end products derived from further oxidation of the hydroperoxides. 
The most frequently quoted index of lipid peroxidation is the aldehyde, 
malondialdehyde (MDA). MDA is a three carbon, low-molecular weight aldehyde 
that can be produced from free radical attack on polyunsaturated fatty acids. 
Documented methods to measure MDA either involve the measurement of free
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MDA or a MDA derivative. The most common and simple method employs 
measurement of an MDA derivative, where MDA reacts with thiobarbituric acid 
(TBA) at low pH and elevated temperature to produce fluorescent and pigmented 
adducts, referred to as thiobarbituric acid reactive substances (TBARS). This 
method is however non-specific, when analysing extracts from biological fluids as 
other low molecular weight aldehydes are also able to react with TBA. Asakawa 
and Matsushita (1980) demonstrated that MDA levels detected by this method are 
increased by artefactual lipid peroxidation during sample processing. Direct 
measurement of free MDA have involved HPLC techniques with 
spectrophotometric detection (Esterbauer et al., 1984; Tsaknis et al., 1998; 
Hultqvist et al., 1997). These methods offer higher specificity and sensitivity than 
the TBARS assays.
Other urinary aldehydes, such as non-polar aldehydes and carbonyl compounds 
have been used as indicators of in vivo lipid peroxidation. These include butanal, 
butan-2-one, hexa-2-enal and hexanal. Aldehyde excretion, however, has also 
proved to be unreliable as their levels are influenced by many factors including 
energy status, physical activity, environmental temperature and the intake of 
peroxides in the diet (Draper et al., 2000).
A hydrocarbon breath test measures exhalation of a group of volatile 
hydrocarbons, the alkanes, formed by in vivo lipid peroxidation of 
polyunsaturated fatty acids (PUFAs). The alkanes most frequently measured 
include ethane and pentane. Kivits et al (1981) demonstrated that an increased 
recovery of exhaled ethane resulted from increased oxidation of (o-3-PUFA, and
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oxidation of a>6-PUFAs was responsible for increased pentane recovery. Practical 
limitations of this non-invasive approach include the lack of standardised methods 
of collecting, processing and analysing expired air and the fact that in ambient air 
the levels of ethane and pentane are greater than in expired air and can easily 
contaminate the breath samples.
Many studies have measured a group of compounds called the F2-isoprostanes, a 
family of eicosanoid like biomolecules, as a sensitive marker of in vivo oxidative 
stress. The F2-isoprostanes are lipids that are non-enzymatically derived isomers 
of the prostaglandins, formed in vivo by free radical mediated oxidation of 
arachidonic acid. Pratico et al (1998b) have reported the stability of these species 
in biological specimens. Auto-oxidation can be minimised in lipid containing 
samples, such as plasma, if immediately snap frozen. Urinary concentrations of 
isoprostanes did not appear to be affected by auto-oxidation when stored at room 
temperature for up to seven days.
3.1.1.2 Selecting a biomarker of in vivo oxidative stress
To select a recognised biomarker of in vivo oxidative stress for comparative 
studies with vitamin E metabolites, it was important to consider its specificity and 
stability. Isoprostanes (iPs) are chemically very stable compared to other lipid 
oxidation products which have been used as indices of oxidative stress, such as 
thiobarbituric acid reactive substances (TBARS) and exhaled alkanes (pentane 
and ethane). The urinary F2-isoprostanes provide a sensitive, specific and non-
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invasive index of lipid peroxidation. Sensitive and specific analytical techniques 
described in the literature for the measurement of F2-isoprostanes, include gas 
chromatography-mass spectrometry (GC-MS) (Roberts et al., 1996; Lawson et al., 
1998; Proudfoot et al., 1999; Bessard et al., 2001) and enzyme immuno-assays 
(EIA) (Proudfoot et al., 1999; Bessard et al., 2001).
3.1.2 Isoprostanes as indices of oxidative stress
3.1.2.1 History and chemistry of the isoprostanes
The isoprostanes were first documented as in vitro auto-oxidation products of 
polyunsaturated fatty acids in 1976 (Pryor et al., 1976). It was not, however, until 
1990 that studies by Morrow and coworkers, showed that the isoprostanes were 
produced in vivo in humans (Morrow et al., 1990). The F2-isoprostanes consist of 
4 regioisomers (class III, IV, V, VI) (figure 3.1), which can exist in eight racemic 
diastereomeric forms (figure 3.2). The most studied of these are the isoprostanes 
isomeric to PGF2a, especially the class III F2-isoprostane (iPF2a-HI) species, 8-iso 
PGF2a (figure 3.2). Studies have shown that this isomer is also produced as a 
minor product of platelet COX-1 activity in response to stimuli such as collagen, 
thrombin and arachidonic acid. However, Pratico et al (1998a) found that in 
practice COX-1 activity did not contribute significantly to the total urinary 8- 
isoPGFza concentration. This was shown by the failure of COX-1 inhibition to
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suppress elevated levels of 8-isoPGF2a in urine of individuals under oxidative 
stress. A number of studies have shown that the F2-isoprostanes are reliable 
indicators of lipid peroxidation and oxidative stress (Pratico et al., 1998a;Roberts 
and Morrow, 2000). Elevated levels have been detected for example in patients 
with cardiovascular disease (Reilly et al., 1997), Alzheimer’s disease (Pratico et 
al., 1998b; Montine et al., 1999), Down’s syndrome (Pratico et al., 2000b) asthma 
(Dworski et al., 2001; Wood et al., 2000) and both type-1 and type-2 diabetes 
(Davi et al., 1999; Devaraj et al., 2001a). It was found that the elevated levels of 
F2-isoprostanes in type-2 diabetic patients could be significantly reduced by 
supplementation with a-TH (Devaraj et al., 2001). This finding suggested a 
possible use of the isoprostanes for monitoring antioxidant therapies.
3.1.2.2 Methods for analysis and measurement of isoprostanes
The two most commonly used methods for measuring urinary F2-isoprostanes are 
by GC-MS and enzyme immuno-assay (EIA).
The GC-MS and EIA methods have been compared by two research groups. 
Proudfoot et al (1999) found that GC-MS gave higher results for 8-isoPGF2a 
concentration than EIA, which they explained by GC-MS failing to discriminate 
between a number of different F2-isoprostane isomers, whereas EIA was specific 
for a particular isomer. In contrast, Bessard et al. (2001) reported lower
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concentrations of 8-isoPGF2a using GC-MS than EIA, and concluded that EIA 
was less specific.
The fundamental differences between the GC-MS and enzyme-immuno assay 
(EIA) techniques is that EIA measures F2-isoprostanes that bind to an antibody 
raised against 8-isoPGF2a, whereas GC-MS measures isomers with common 
retention times to an internal standard d4-8-isoPGF2a- 8-isoPGF2a isomers that 
may not be present in the GC-MS peak may, therefore, have a high cross­
reactivity with the antibody, and isomers that co-elute may not react with the 
antibody of the EIA.
The F2-isoprostanes are widely considered to be a ‘gold standard’ for the 
measurement of in vivo lipid peroxidation as a result of oxidative stress (Pratico, 
1999). Urinary measurements of these chemical species provide a non-invasive, 
and direct approach to measure in vivo oxidative stress, with no in vitro 
artefactual oxidation. 8-isoPGF2a is the only isomer for which a deuterated 
standard is commercially available, which is important for quantitation of 
endogenous levels present in the samples.
The method published by Pratico et al to measure 8-isoPGF2a using GC-MS was 
refined as described and validated below.
91
Chapter 3 -  Measurement of an independent biomarker of oxidative stress
3.2 Method development for the measurement of 
urinary isoprostanes
3.2.1 Gas chromatographic-mass spectrometric analysis of 
8-iso-PGF2a standards
It was considered necessary to first establish a method that would measure 
efficiently both deuterated and undeuterated forms of 8-iso-PGF2a standards. The 
deuterated standard d4-8-iso-PGF2a , contains four hydrogen atoms replaced by 
deuterium atoms (figure 3.3). Hence d4-8-iso-PGF2a is characteristically heavier 
than its undeuterated form by four mass units enabling the two species to be 
distinguished using gas chromatography-mass spectrometry (GC-MS). d4-8-iso- 
PGF2a is therefore a potential internal standard for the quantitation of endogenous 
8-iso-PGF2a levels during the analysis of extracted urine samples.
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Figure 3.3 Principal fragments of trimethyl silyl (TMS) derivatives of undeuterated and 
deuterated 8-isoPGF2a
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3.2.1.1 Detection and analysis of deuterated and undeuterated 8-iso- 
PGF2a standards by GC-MS
Materials
8-isoprostane standards 8-isoprostaglandin F2a (CAY-16350) and 8- 
isoprostaglandin F2«-d4 (CAY-316350) were supplied by Cayman Chemicals. 
These standards were made up into stock solutions of 20ng/ml in methanol and 
stored at -20°C. In this state they are reported by the manufacturer to be stable for 
up to six months. The trimethyl-silyl derivatising agents used included N,0- 
bis(trimethylsilyl)trifluoroacetamide (BSTFA) and BSTFA with 1% trimethyl- 
chlorosilane (TMCS), and were purchased from Pierce Chemicals Ltd. All other 
chemicals were purchased from Sigma-Aldrich unless otherwise mentioned.
Preparation and analysis of standards
Analysis of these standards by GC-MS, was initially carried out by modifying the 
method of Bessard et al (2001). The standards were derivatised to their trimethyl- 
silyl derivatives using 60 pi BSTFA (+1%TMCS). Bessard’s method involved no 
incubation for the derivatisation, suggesting immediate derivatisation. 
Derivatisation conditions were adapted in the present study and incubated at 45°C 
for 20 minutes to ensure derivatisation reached completion. GC-MS analysis of 
the derivatised standards was performed in electron impact (El) mode at 70
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electron volts, using a Hewlett Packard GC-MS system (HP-5973 mass selective 
detector, HP-6890 series GC instrument with an automatic auto sampler, and HP- 
Chem station for data acquisition). The initial oven temperature of 130°C was 
maintained for 1 minute, then increased to 300°C at 18°C/min, which was then 
held for 2 minutes. The oven temperature was then increased to 310°C at 4°C/min 
and maintained at this temperature for 5 minutes to purge the column. The total 
run time was 19.94 minutes. The injector system was run in splitless mode. The 
helium carrier gas was kept at a constant flow rate of lml/min. GC-MS 
temperatures were set as follows; injector at 250°C, interface at 300°C, source at 
220°C and the quadrupole at 100°C.
The mass spectrometer (MS) was programmed to run the above method in both 
complete scan mode and in selected ion-monitoring (SIM) mode. For the selected 
ion-monitoring mode the principal fragments were selected for identification and 
are shown in figure 3.4. The fragments of dO-8-isoPGF2a include 571m/z ion (loss 
of C5H11) and 481m/z (loss of C5H11 and trimethyl-silyl (TMSO)). The equivalent 
corresponding fragments of d4-8-isoPGF2a were 575m/z and 485m/z. 
Quantification was achieved by measuring the peak heights of the highest 
abundance mass ions for both undeuterated and deuterated 8-isoPGF2«, which 
were the ions 481m/z and 485m/z respectively in SIM mode.
The chromatographic peaks for both undeuterated and deuterated 8- 
isoPGF2a standards were successfully identified according to their characteristic 
fragmentation demonstrated by the corresponding mass spectra for the peaks 
(figure 3.4 and 3.5). When, however, standards were analysed at a concentration
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equivalent to that which might be expected in human urine i.e. 88-442pg/mg of 
creatinine (Wang et al., 1995), the peaks were either undetectable or of poor 
shape. In an attempt to improve the sensitivity of detection of the isoprostane 
species, the derivatisation step was modified.
Modification of the conditions for the derivatisation of 8-isoPGF2a
Initially the derivatising solution, BSTFA (+1%TMCS), described by Bessard et 
al (2001) was used. In contrast to Bessard, however, derivatisation in this 
experiment was achieved by incubation at 45°C for 20 minutes. Different 
derivatising agent mixes were compared over a time course of incubation. 
Deuterated 8-isoPGF2a standard, at a concentration equivalent to 600pg/ml if 
spiked in 4ml of urine, was derivatised using BSTFA (+1% TMCS), BSTFA alone 
and BSTFA/acetonitrile (1:1). Samples were incubated at 45°C at 10 minute 
intervals from 20 to 100 minutes (figure 3.6).
BSTFA (+1% TMCS) yielded no defined chromatographic peaks at the level of 
standard derivatised. It was found that BSTFA/acetonitrile gave the best recovery 
of the silylated standard, showing approximately a five fold greater recovery than 
that of BSTFA alone (figure 3.6). There was no consistent change in recovery 
after 20 minutes and it was decided that in all further studies, derivatisation should 
be carried out using BSTFA/acetonitrile (1:1), at 45°C for 80 minutes to ensure 
derivatisation went to completion.
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Range and proportionality of detection of 8-isoPGF2a
A series of d4-8-isoPGF2a concentrations were prepared (equivalent to the 
concentrations expected in urine samples) in order to estimate the concentration 
range within which effective and reliable detection is obtained using the 
derivatising conditions and GC-MS program set out in the protocol. Figure 3.7 
shows a standard curve of d4-8-isoPGF2a , in the range of 50-5,000pg/ml and 
demonstrates linearity up to 2,500pg/ml. It was, therefore, concluded that the 
derivatisation and detection methods used would be sufficiently sensitive for 
quantitation of extracted endogenous urinary 8-isoPGF2a using d4-8-isoPGF2a as 
an internal standard.
3.2.2 Method development for the extraction of 8-isoPGF2a 
from urine
3.2.2.1 Polarity dependent solid phase extraction
Bessard’s (2001) method of extraction is relatively simple, involving two solid 
phase extraction (SPE) steps and relies on the characteristic polarity of the 
isoprostanes for their extraction.
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Figure 3.7; Standard curve of d4-8-iso-PGF2a in range 50-5,000pg/ml.
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Materials
C18 10ml cartridges (lOOmg sorbent mass) and NH2 10ml cartridges (lOOmg 
sorbent mass) were supplied by Isolute.
Extraction protocol using solid phase extraction cartridges
The method involved using 4ml of urine (a morning void of fresh urine collected 
from a 26 year old female colleague (no vitamin supplements consumed for at 
least 2 years, non-smoker, teetotal)) spiked with deuterated (d4-) and undeuterated 
(d0-) 8-isoPGF2a standards at concentrations equivalent to 2,000pg/ml and in the 
range of 100-3,200pg/ml respectively. The first SPE step was carried out using a 
C l8 cartridge, with a solvent program as follows;
1) cartridges primed with 2ml methanol and 2ml dP^O (pH2.5)
2) sample loaded onto cartridge
3) washed with 6ml dH20 (pH2.5), and 6ml acetonitrile/water (15:85)
4) eluted using 4ml hexane/ethyl-acetate/propan-2-ol (30:65:5).
The eluate was then further extracted using an NH2 cartridge. The solvent program 
for the NH2 cartridge was as follows;
1) cartridges primed with 5ml hexane
2) sample loaded onto cartridge
3) washed with 5ml hexane/ethylacetate (30:70), and 5ml acetonitrile
4) eluted using ethylacetate/methanol/acetic acid (10:85:5).
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The extract was evaporated to dryness under a gentle stream of N2 and then 
derivatised as described in the modified method in section 3.2.1.1, using 
BSTFA/acetonitrile at 45°C for 80 minutes. The derivatised extract was analysed 
by GC-MS in both scan and SIM modes as detailed for standards in section 
3.2.1.1.
Results
The chromatograms of the extracted samples showed evidence of peaks for do- 
and d4-8-isoPGF2a at their characteristic retention times identified for the 
standards in section 3.2.1.1. Figure 3.8 shows the extracted ion chromatogram for 
dO-8-isoPGF2a (481m/z) and d4-8-isoPGF2a (485m/z), and the respective mass 
spectra for the two species. Although the peaks for the two isoprostane forms can 
be identified, the signal to noise ratio is low, and the respective mass spectra for 
the 8-isoprostane peaks contained many other fragment ions that could not be 
explained by these specific isoprostane species alone. This suggested that other 
species may be co-eluting with the isoprostane species of interest. It was 
subsequently concluded that this extraction procedure was not sufficiently specific 
to clean the sample adequately, and allow clear detection of the 8-isoPGF2tt 
species.
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Figure 3 .8; Extracted ion chromatogram of ions 485m/z and 481 m/z for extracted 
urine spiked with 2000pg/ml d4 standard and 2000pg/ml dO standard (A), and 
mass spectra for peaks representing d4 (B) and dO-8-isoPGF2«(C).
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3.2.2.2 Extraction of 8-isoPGF2a from urine using affinity chromatography
A more specific method for the extraction of 8-isoPGF2a would be to use affinity 
chromatography. Cayman Chemicals have developed an affinity sorbent for the 
purification of 8-isoPGF2a from urine and plasma, which consists of mouse anti-8- 
isoprostane antibody covalently bound to Sepharose 4B. They report the 
specificity to be 100% for 8-Isoprostane (8-isoPGF2a), 7.6% for 8- 
isoprostaglandin F3a, 2.85% for prostaglandin F la , 0.88% for prostaglandin F2a, 
with other prostaglandins and related species below 0.5%.
The affinity sorbent is supplied in both column format or as sorbent alone. It was 
decided to use the 8-isoprostane affinity column, consisting of 1ml sorbent in a 
column with a 20ml sample volume capacity. The binding capacity per millilitre 
of sorbent was lOng. In order to extract a sufficient level of endogenous 8- 
isoPGFza together with a deuterated internal standard for detection by GC-MS, 
while not exceeding the sorbent binding capacity, 4ml of urine sample was used.
Materials
8-Isoprostane affinity columns with a sorbent mass of 1ml, and a cartridge volume 
for samples of 20ml were supplied by Cayman Chemicals. The reagents for use in 
the extraction protocol were made up using “ultrapure” filtered deionised water.
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All chemicals were purchased from Sigma-Aldrich Chemicals unless otherwise 
stated. The reagents include;
i) eicosanoid affinity column buffer ; 0.1M phosphate buffer: 13.3g K2HPO4, 
3.22g KH2PO4, 0.5g NaN3 and 29.2g NaCl made to llitre with “ultrapure” 
water, pH7.4
ii) eicosanoid affinity column elution solution ; 95% ethanol in 5% 
“ultrapure” water
iii) “ultrapure” water
Derivatisation materials were as used in section 3.2.1
Extraction protocol and analysis method using affinity columns
The extraction procedure was carried out as follows;
1- urine samples were centrifuged at 3,000g for 5 minutes to remove particulate 
matter
2- 4 ml urine was spiked with undeuterated 8-isoPGF2a standard (to give a final 
concentration of 500pg/ml), and mixed by inverting
3- affinity column extraction
i) storage column buffer was allowed to drain out
ii) urine sample loaded
iii) column washed with 10ml column buffer, followed by 10ml 
“ultrapure” water
iv) water allowed to completely drain from the column
v) bound isoprostane eluted using 5ml elution solution, and collected
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vi) columns recycled by washing with 10ml “ultrapure” water, followed 
by 5ml column buffer and allowed to drain before storing at 4°C in 5ml 
column buffer
4- eluate evaporated to dryness under gentle stream of N2
5- derivatised using 60pi BSTFA/acetonitrile (1:1) at 45°C for 80 minutes
6- analysed on GC-MS, using method described in section 3.2.1.1.
Results
The extraction of urine samples using the affinity column resulted in 
chromatograms with significantly lower baseline noise and a larger sharper peak 
for the 8-iso-PGF2« (figure 3.9) compared with the solid phase extraction method 
described in section 3.2.2.1 (figure 3.8). The mass spectra for the peaks of interest 
contain the fragments relevant to the 8-isoPGF2a species with few other 
fragments. The differences observed following the two extraction methods 
suggested that the affinity column method was much more efficient at cleaning the 
samples resulting in easier detection and therefore more reliable quantification of 
the species of interest.
The 8-isoPGF2a peak, with a retention time of 10.5 minutes, was identified using 
the scan acquisition mode and the selected ion-monitoring (SIM) mode in an 
unspiked urine sample and a sample spiked with 500pg/ml dO-8- 
isoPGFza standard. This showed that endogenous levels were detectable using this
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Figure 3.9; Extracted ion chromatogram (A) and mass spectrum (B) for dO-8 - 
isoPGF2« extracted from urine, spiked with 500pg/ml dO-8 -isoPGF2« using 
affinity chromatography columns and SCAN analysis
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extraction and analysis method. Endogenous levels, however, were not always 
detectable in the scan mode, possibly due to variation between sample 
preparations and the low levels present in urine. For effective detection and 
quantitation of endogenous 8-isoPGF2a the use of SIM acquisition mode was more 
sensitive.
The main problem with this method was inconsistency of the packing of the 
sorbent material into the column of approximately one in every four columns 
supplied. This resulted in poor results for the samples prepared using these 
“faulty” columns, due to ineffective retention of 8-isoPGF2a by the sorbent. It was 
therefore decided to use the sorbent supplied by the manufacturer in its free 
unpacked form, as opposed to packed into columns.
3.2.2.3 Extraction of 8-isoPGF2a from urine using unpacked affinity sorbent 
Materials
8-Isoprostane affinity sorbent was supplied by Cayman Chemicals in 1ml aliqouts. 
Reagents used were the same as described for the affinity column technique.
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Extraction protocol using the sorbent “batch” procedure
The batch procedure for the extraction of 8-isoPGF2« from urine described by the 
manufacturer was initially used and involved a series of centrifugation steps as 
follows;
1) 1ml sorbent added to 1ml urine, gently rotated for 30-60mins
2) centrifuged at l,500g for 5 mins, then supernatant pippetted off
3) sorbent washed with 1ml column buffer, centrifuged, then supernatant 
removed
4) sorbent pellet resuspended in 0.5ml elution solution (95% EtOH), 
centrifuged, supernatant collected
5) step 4 was repeated, the two extractions pooled together and 
evaporated to dryness.
It was necessary, however, to modify the original protocol to obtain cleaner
chromatograms. It was found that the washing sequence had to be more thorough
prior to elution, to remove all the phosphate remaining from the 0.1M phosphate 
buffer which hindered the derivatisation step. Also, if the supernatants were 
removed from too close to the sedimented sorbent layer, some sepharose beads 
were removed and this caused contamination of the eluate. It was, therefore, 
necessary to leave a small volume of supernatant above the sorbent mass layer. 
The final procedure which included the above mentioned adjustments was as 
follows;
1- Preparation of urine samples
i) urine was centrifuged to remove particulate matter
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ii) 4ml urine was aliquoted into 15ml plastic Falcon conical base 
centrifuge tubes
iii) urine aliquots were spiked with lOpl of 200pg/ml 8-iso- 
PGF2a standard stock and then vortexed for 30secs
2- Preparation of affinity sorbent
i) sorbent was resuspended in 2ml column buffer, by gently pipetting 
and expelling to make homogenous, and then aliquoted into the 
urine sample
ii) mixed by inverting, and then mixed by rotating for 90mins
3- Extraction of 8-isoprostane from urine sample
i) sorbent-urine mixture was centrifuged at 2,000g for 5mins, to 
sediment the sorbent
ii) supernatant was removed (supernatant devoid of 8-isoPGF2a )
iii) sorbent was washed with 5ml column buffer (0.1M phosphate 
buffer) and vortexed for 30secs
iv) centrifuged at 2,000g for 5mins to sediment sorbent
v) supernatant removed, and steps iii) to v) were repeated (supernatant 
devoid of 8-isoPGF2a)
vi) sorbent washed with 5ml ultrapure dF^O and vortexed for 30secs
vii) centrifuged at 2,000g to sediment sorbent
viii) supernatant removed, and steps vi) to viii) were repeated twice 
(supernatant devoid of 8-isoPGF2a )
ix) sorbent pellet resuspended in 2.5ml of elution solution (95% EtOH) 
and vortexed for 30secs
x) centrifuged at 2,000g for 5mins, to sediment sorbent
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xi) EtOH phase removed carefully (so as not to disturb sorbent) and 
collected into 10ml glass tube
xii) steps ix) to xii) were repeated twice
4- Derivatisation of eluate
i) EtOH phase was evaporated to dryness (when approximately 1ml 
remained this was transferred to a 2ml derivatising vial before 
completing evaporation)
ii) derivatising agent added (60 pi Acentonitrile/BSTFA (1:1)) and 
incubated at 45°C for 80 mins
5- Run sequence on GC-MS, as described in 3.2.1.1 in both scan and SIM 
acquisition modes
6- Regeneration of sorbent
i) sorbent washed with 5ml “ultrapure” dH20, this was repeated twice 
and the washes were discarded
ii) washed with 5ml column buffer (0.1M phosphate buffer), wash 
discarded
iii) 2.5ml column buffer (0.1M phosphate buffer) added
iv) centrifuged at 2,000g for 5mins, and supernatant removed until a 
total volume including sorbent mass of 2ml remained
v) sorbents were stored at 4°C
The manufacturer of the sorbent recommended a maximum of five regeneration 
cycles per sorbent, as each regeneration cycle decreases the resin binding capacity. 
It was found, however, in the present study that sorbents were reliable after only 
one regeneration cycle. After the second use of the sorbents a general decrease in 
extraction efficiency was evident (figure 3.10).
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Figure 3.10; Percentage recovery of spiked 8 -isoPGF2a from urine after 
repeated use of the sorbents, compared to an external standard.
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Results
In order to test the effectiveness of the method, peak heights of 8-isoPGF2a were 
compared from triplicate samples of urine and water both spiked with a final 
concentration of 500pg/ml of d4-8-isoPGF2a, unspiked urine and duplicate 
standards of 500pg/ml 8-isoPGF2a • The urine and spiked water samples were 
extracted and derivatised whereas the standards were only derivatised. The peak 
heights of the duplicate standard (external standard) were compared to the 
recovery of the standard from the spiked urine and water samples to test the 
extraction efficiency of the method.
The duplicate standards gave peak heights of 16 and 18 arbitrary units (au)(figure 
3.11) and the mean was taken as 100% recovery. The peak heights of the extracted 
standard from water were in the range of 17-20. The peak heights of the extracted 
standard from spiked urine samples gave >100% recovery, with peak heights of 
20-26. This discrepancy which was consistent may be due to the lower signal to 
noise ratio in extracted urine samples. The peak heights of the endogenous dO-8- 
isoPGF2a in the unspiked urine samples gave a mean concentration of 270 pg/ml.
114
Pe
ak
 
he
ig
ht
 
(a
rb
itr
ar
y 
un
its
)
Chapter 3 — Measurement of an independent biomarker of oxidative stress
20-
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water d4; 
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Figure 3.11; The mean peak heights for the d4-8-isoPGF2a standard, the recovered 
d4-8-isoPGF2« standard from spiked water and urine, and endogenous dO-8 - 
isoPGF2« from urine. NOTE: n=2 for d4 standards and for each remaining column 
n=3, and error bars represent standard deviation.
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3.2.2A Reproducibility of the method
The reproducibility of the batch method was investigated by the repeated 
preparation and analysis of a quality control (QC) on different days. The QC 
consisted of a pool of normal healthy human urine stored at -80°C. It was 
assumed that 8-isoPGF2a is stable in these storage conditions. Figure 3.12 shows 
the concentrations of endogenous dO-8-isoPGF2« in pg/mg creatinine over a five 
day period which were in the range of 111.6 to 127.2 pg/mg creatinine with a 
mean of 116.5 pg/mg creatinine and CV of 5.54%. These concentrations were 
near the range for healthy human urine quoted by Cayman Chemicals of 180- 
200pg/mg creatinine, and within the range quoted by Wang et al (1995) of 88-442 
pg/mg creatinine.
The method was considered sufficiently reproducible to be used to measure 
urinary 8-isoPGF2a as an independent biomarker of in vivo oxidative stress in 
samples collected from subjects undergoing an exercise regimen (chapter 4).
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Figure 3  .1 2 ; The reproducibility of the analysis for endogenous dO-8 -isoPGF2a in 
normal human urine. Each point for each day represents a single preparation and 
analysis.
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4.1 In vivo oxidative stress
4.1.1 Investigation of a-tocopheronolactone as a potential 
biomarker of oxidative stress
As mentioned in chapter 2, a-tocopheronolactone (a-TL) can be detected in urine but 
it is not entirely clear whether the levels detected are due to artefactual oxidation 
during sample preparation or whether a proportion is also produced in vivo as a result 
of natural biological oxidation of a-tocopherol (a-TH). If a-TL is a real metabolite of 
a-TH and a product of the antioxidant activity of a-TH, its production might be 
expected to be elevated in states of oxidative stress and excreted in the urine.
This chapter describes a study carried out in collaboration with Dr Mark Goss- 
Sampson and Ms Kim Hastings, The Centre for Sport and Exercise Science, The 
University of Greenwich, to examine the effect of endurance exercise on the urinary 
excretion of a-TL. The project was carried out in accordance with the University of 
Greenwich Ethics Committee guidelines following both verbal and written consent 
from each subject involved in the study. Firstly the importance of oxidative stress in 
medicine and in biological processes of living organisms will be discussed.
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4.1.2 Oxidative stress and antioxidant defence
Oxidative stress results from an imbalance of prooxidant and antioxidant activities, 
where the former outweighs the antioxidant defences (for more detail see chapter 1, 
section 1.7.1.1).
4.1.2.1 Human diseases and conditions associated with oxidative stress
Oxidative stress has been implicated in the pathogenesis of many disease states and 
conditions, including atherosclerosis (Ross, 1999), cystic fibrosis (Winklhofer-Roob, 
1994; Benabdeslam et al., 1999), diabetes (Dandona et al., 1996; Davi et al., 1999), 
Parkinson’s disease (Beal, 1998), Alzheimer’s disease (Mattson, 1995), Down’s 
syndrome (Pastor et al., 1998; Jovanovic et al., 1998), and is also associated with viral 
infections such as human immuno-deficiency virus (HIV) (Droge et al., 1994), some 
cancers (Boyd and McGuire, 1991), with aging (Harman, 1993), cigarette smoking 
(Obata et al., 2000) and exercise which is discussed in more detail below. Oxidative 
stress may be the cause or a consequence of these conditions (Halliwell and 
Gutteridge, 1999).
4.1.2.2 Exercise and oxidative stress
The principal factor considered to be responsible for oxidative stress damage during 
exercise is an increased demand for oxygen supply and consumption to cope with the 
body’s needs for energy. Upon exercising from a state of rest, oxygen uptake by the
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human body increases by approximately 10 to 15 fold, and uptake of oxygen by active 
skeletal muscle can increase by up to 100 fold. Oxidative stress induced by exercise 
has been postulated to occur through a number of mechanisms.
An increased oxygen flux through the muscle cell mitochondria would increase the 
release of reactive oxygen species (ROS) resulting in an increase in oxidative stress. 
The electron transport chain of the mitochondrial inner membrane is well known to be
a major source of superoxide (’O2 ) production, resulting in hydrogen peroxide (H2O2)
and hydroxyl radical (*OH ) formation. The electron carriers, NADH-ubiquinone 
reductase (complex 1) and ubiquinone-cytochrome-c reductase (complex 3) of the 
electron transport chain are known sites of ‘O2 and H2O2 generation via side-reactions 
with molecular oxygen (Chance et al., 1979).
ROS generation could occur as a result of inflammation and muscle damage, and by 
the recruitment of macrophages to repair damaged tissues. It was first demonstrated 
by Davies et al (1982) that muscle damage resulted from severe forced exercise in 
rats, illustrated by decreased control of mitochondrial respiration and loss of structural 
integrity of the sarcoplasmic reticulum. Exercise had also been shown to be 
asssociated with increased inflammatory and anti-inflammatory responses. Studies by 
Sacheck and Blumberg (2001) showed that following prolonged exercise the number 
of circulating neutrophils increased, coupled with some features of an acute-phase 
inflammatory response such as an increase in pro-inflammatory cytokines, 
interleukin-ip (IL-lp), tumour necrosis factor (TNF-a) and interleukin-6 (IL-6) 
concentrations in plasma. Another study involving untrained subjects undertaking a 
45min bicycle exercise and reaching 70% VO2 max had also shown a significant
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increase in the plasma levels of cytokines IL-1(3, TNF-a and IL-6 (Vassilakopoulos et 
al., 2003). The supplementation with a mixture of antioxidants (vitamin E, A, C, 
allupurinol and N-acetylcysteine) reduced the production of IL-ip and IL-6 lower 
than the baseline. The pro-inflammatory cytokines IL-lp, TNF-a and IL-6 facilitate 
the influx of lymphocytes, neutrophils and monocytes into tissue after injury. Exercise 
is thought to activate phagocytotic processes to generate an oxidative burst of ROS
such as superoxide (*02 ) which may aid in proteolysis of the injured cells/tissue.
Oxidative stress may also be caused by ischaemia-repurfusion. During exercise blood 
is shunted away from several organs to cover an increase in blood supply in active 
skeletal muscle leading to transient general tissue ischaemia (O2 depletion) or hypoxia 
(O2 concentration lower than normal) in these organs. In addition, exercise intensity 
exceeding VO2 max leads to muscle fibre hypoxia as the oxygen supply fails to match 
the energy requirements (Koyama et al., 1999). This results in a fall in ATP levels, 
and degradation of AMP resulting in an accumulation of hypoxanthine (figure 4.1). 
As a result of the depletion of ATP the cell can no longer maintain a proper ion 
gradient across the membrane and the tissues are in a state of disruption. This results 
in a cytosolic build up of Ca2+ ions that activate Ca2+-stimulated proteases. These 
proteases catalyse the proteolysis of xanthine dehydrogenase (XDH) to xanthine 
oxidase (XOD) (Roy and McCord, 1983). After exercise, reperfusion (reoxygenation) 
of the hypoxic tissues results in ROS generation, primarily in the form of superoxide 
( O2 ). The major source of superoxide appears to result from the action of XOD and 
its oxidation of hypoxanthine to uric acid (McCord and Fridovich, 1968; Roy and 
McCord, 1983). XOD in contrast to XDH, transfers electrons to molecular oxygen
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rapidly generating superoxide (‘(V) and hydrogen peroxide (H2O2) (McCord et al., 
1985; Halliwell and Gutteridge, 1999).
The role of XOD in exercise-induced oxidative stress has been supported by an 
effective reduction in markers of oxidative stress upon supplementation of an XOD 
inhibitor, allupurinol (Vina et al., 2000).
4.2 The effect of exercise induced oxidative stress on 
urinary a-tocopheronolactone and 8-isoprostane 
concentrations
4.2.1 Experimental protocol
It was proposed that subjecting healthy individuals to a regime of vigorous exercise 
would result in in vivo oxidative stress. To establish whether urinary a- 
tocopheronolactone (a-TL) and 8-isoprostane concentrations were increased in 
response to exercise-induced oxidative stress, two groups of healthy men where 
recruited to undertake an endurance exercise regime. One group consisted of four 
semi-professional triathletes (mean age 27.8 years), and the other group consisted of 
ten untrained sports science students (mean age 24.9 years).
Both the triathlete and untrained groups took part in a five-day regime (figure 4.2), in 
which samples of the first morning void urine were collected each day. The subjects
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Figure 4.2; Study protocol for triathletes and untrained healthy men. Samples of 
the first morning void urine were collected including the exercise day and any 
subsequent urine spot samples on that day following exercise
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did not train for the first two days (day -2 and -1) of the study. At about mid-day on 
the third day (day 0), they underwent an endurance exercise regime. Any subsequent 
spot urine samples on the exercise day were collected. The first moring void urine 
samples were collected into universal containers containing 0.05g ascorbic acid and 
stored at 4°C until they reached the exercise laboratory the next day, where they were 
stored at -80°C prior to analysis. The analysis of the urinary tocopherol metabolites 
was carried out as described in chapter 2, and urinary 8-isoprostane levels were 
measured as described in chapter 3.
The endurance exercise regime undertaken on the third day was organised and 
monitored by Dr Mark Goss-Sampson and Ms Kim Hastings, and was as follows. 
Trained and untrained subjects participated in a 1km run on a ‘Woodway’ treadmill 
(llm ph max) at a pace that was reported as slightly uncomfortable. This was followed 
by a steady state sub-maximal test on a ‘King’ Cycle ergometer. Power output was 
increased incrementally for 4 minutes before maintaining a steady level for another 5 
minutes. After this point, the resistance was ramped up sharply for one further minute 
before maintaining a steady level for the last 5 minutes. Heart rate was recorded after 
nine minutes and at the termination of the exercise. Gases were analysed using 
VacuMed Mini Vista and VO2 values were calculated. Following the sub-maximal 
test, a ramped max-test was administered. This involved the subjects cycling at 
increasing intensities until volitional exhaustion using rating of perceived exertion 
(RPE) scores according to the Borg scale (Borg, 1998), which determines physical 
activity intensity by the total ‘feeling’ of the exercise by the subject. The Borg scale 
starts at 6 for no perceived exertion by the exerciser and increases to 20 for maximum 
exertion.
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The measurements carried out in the laboratory to monitor activity intensities, showed 
that all the triathletes and untrained participants reached 90-100% maximum age- 
related heart rate and VC^max, with RPE scores in the range of 15-20 on the Borg 
scale upon reaching exhaustion and termination of the exercise.
4.2.2 Results
4.2.2.1 Urinary 8-isoprostane and a-TL concentrations
The concentrations of urinary a-tocopheronolactone (a-TL) were measured as 
described in chapter 2, and the “actual” concentrations of a-TL were calculated by 
deducting the estimated artefactual concentration. The concentrations of a-TL 
(nmol/mmol creatinine) in the urine of the participants over the five day regime, were 
compared to the concentrations of urinary 8-isoprostane (pmol/mmmol creatinine) 
and concentrations of urinary creatinine (mmol/1).
Firstly the results from the group of triathletes will be discussed. Figure 4.3 shows the 
levels of a-TL and 8-isoprostane in the urine of each subject over the five day regime. 
a-TL concentrations for subjects 1-4 were in the range of 13-117 nmol/mmol 
creatinine, and 8-isoprostane concentrations were in the range 160-625 pmol/mmol 
creatinine. Only subject 3 showed an increase in both a-TL and 8-isoprostane
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concentrations following exercise, which peaked on the same day as the exercise 
regime (Opm 2) and then decreased. The results from the untrained subjects (7-10) are 
shown in figure 4.4. a-TL concentrations were in the range of 0.4-31 nmol/mmol 
creatinine, and 8-isoprostane concentrations were in the range 50-1537 pmol/mmol 
creatinine. Urinary creatinine concentrations are independent of exercise in both the 
triathlete and untrained subject groups.
A further six untrained individuals (subjects 1-6) also took part in the study. The a- 
TL concentrations in these subjects can be compared to the other subjects but there 
were problems with quantitation of the 8-isoprostane concentrations. This was 
because the deuterated internal standard (d4-8-isoPGF2a) used for the quantitation of 
endogenous urinary 8-isoprostane, was incorrectly designated by the manufacturer 
and the correct concentration of the internal standard was unknown. It was not 
possible to repeat these analyses owing to insufficient volumes of urine. However, the 
relative concentrations are an indicator of any changes in endogenous urinary 8- 
isoprostane in urine samples over the five day regime.
The results of the urine analyses of subjects 1-6 are shown in figure 4.5. a-TL 
concentrations were in the range of 5-77 nmol/mmol creatinine. Urinary a-TL and 8- 
isoprostane concentrations over the five day regime show no evidence of increased a- 
TL and 8-isoprostane concentrations following exercise.
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Figure 4.4; Urinary a-tocopheronolactone, 8-isoprostane and creatinine concentrations 
over the five-day study regime for the untrained subjects (7-10).
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Figure 4.5; Urinary a-tocopheronolactone concentrations, 8-isoprostane levels
and creatinine concentrations over the five day study regime for untrained
subjects 1-6.
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4.2.2.2 Overall trends in urinary levels of a-TL and 8-isoprostane in trained 
and untrained subjects
Urinary a-TL concentrations for the triathletes were in the range of 13-117 
nmol/mmol creatinine compared to 0.4-77 nmol/mmol creatinine for the ten untrained 
subjects. There is a significantly lower mean for the untrained subjects compared to 
the mean of the triathletes with a CV of 48.07%. The urinary 8-isoprostane 
concentrations were in the range of 160-625 pmol/mmol creatinine for the triathletes 
and 50-1537 pmol/mmol creatinine for the untrained group. Only one subject in the 
untrained group had concentrations >500 pmol/mmol creatinine. Most of the subjects 
from both groups had comparable 8-isoprostane concentrations.
4.2.2.3 The correlation between urinary concentrations of 8-isoprostane, and 
a-TL
The correlation between concentrations of 8-isoprostane and a-TL concentrations was 
significant for both the triathletes and the untrained subject group (figure 4.6). The 
triathlete group (number of subjects=4; number of samples=23) Spearman’s r=0.5635, 
and the untrained group (number of subjects=4; number of samples=26) Spearman’s 
r= 0.6367.
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Figure 4.6a); The correlation of a-TL with 8-isoprostane for all urine samples 
analysed (n=26) from the four triathlete subjects. [Spearman’s r=0.5635]
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Figure 4.6b); The correlation of a-TL with 8-isoprostane for all urine samples 
analysed (n=28) from untrained subjects (7-10). [Spearman’s r=0.6367]
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4.2.2.4 The urinary concentrations of a-CEHC, y-CEHC and y-TL over the five 
day regime
The levels of the side-chain oxidised metabolite a-CEHC showed a similar pattern of 
variation to that of a-TL for both trained subjects 1-4 (figure 4.7) and untrained 
subjects 7-10 (figure 4.8) over the five day regime. a-CEHC concentrations were 
generally higher than the concentration of the calculated “real” a-TL by at least two­
fold.
Figure 4.9a shows the correlation of a-CEHC and a-TL concentrations, which was 
not significant for the triathletes (number of subjects=4; number of samples=26, 
Spearman’s r=0.1904). Figure 4.9b shows that the correlation of a-CEHC and a-TL 
concentrations was, however, significant for the untrained subject group (number of 
subjects=10; number of samples=69) Spearman’s r=0.7187. When the results of the 
triathletes and the untrained subject group were combined there was a significant 
correlation between the a-CEHC and a-TL concentrations, with Spearman’s 
r=0.4138.
Urinary concentrations of y-CEHC and y-TL fluctuated over the five-day regime and 
appeared to be independent of the exercise protocol. This is illustrated for untrained 
subjects 7-10 in figure 4.10.
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Figure 4.9a); The correlation of a-CEHC with a-TL for urine samples 
analysed (n=26) from the four triathlete subjects. [Spearman’s r value 
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It was not possible to accurately quantitate the concentrations of a-CMBHC and 
oxidised a-CMBHC as concentrations were consistently very low with a retention 
time towards the end of the chromatographic run resulting in broad peaks.
4.2.3 Discussion and conclusions
The biomarker of lipid peroxidation, 8-isoprostane showed no consistent response to 
exercise in either the trained or untrained subject groups in this study. Additionally, 
urinary concentrations of 8-isoprostane for both the triathlete and untrained groups 
were within similar ranges, suggesting that levels of 8-isoprostane were independent 
of the level of training between the individuals. Thus, as detected by 8-isoPGF2a, 
there was no evidence of increased oxidative stress, in these subjects.
Studies of oxidative stress following exercise in the literature have produced differing 
results. A number of studies have failed to demonstrate signs of exercise-induced 
oxidative stress. Margaritis et al (1997) found no evidence for increased oxidative 
stress in 12 triathletes taking part in a long distance triathlon, by measuring plasma 
glutathione concentrations (GSH), despite an inflammatory response detected by 
increased plasma leukocyte counts and neopterin concentrations. This led them to 
conclude that the level of training of this group of individuals made them less 
susceptible to oxidative stress. Witt et al (1992) showed that the urinary output of the 
oxidatively damaged RNA base 8-hydroxydeoxyguanosine (8-OHdG) was unaffected
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by several sub-maximal exercise bouts. Lovlin et al (1987) found that where 
individuals underwent three different levels of exercise, which included V02max 
(high intensity running to exhaustion), 70%VO2max (moderate intensity running) and 
40%VO2max (low intensity running), only at VC^max was there a large enough 
increase in free radical production to overwhelm the antioxidant defences resulting in 
an increase in plasma MDA. At 70%VO2max no affect was detected and at 
40%VO2max, MDA levels decreased to below baseline. Studies by Mastaloudis et al 
(2001) showed that eleven athletes undergoing a 50 km ultramarathon, had elevated 
plasma 8-isoPGF2a which returned to baseline 24 hours post race.
The effect of exercise on oxidative stress appears to depend on the intensity and 
duration of the exercise regime (Shern-Brewer et al., 1998; Chevion et al., 2003; Liu 
et al., 2000), and appears to affect muscle and heart to a different extent than other 
organs such as the brain and liver (Liu et al., 2000). The general effect of short-term 
intense exercise (acute) is an elevation of oxidative stress biomarkers and an overload 
of the antioxidant defence system (Shern-Brewer et al., 1998). Long term regular 
exercise (chronic) tends, however, to induce an adaptive response, with a decrease in 
biomarkers of oxidative stress as a result of an increase in antioxidant defences and 
the upregulation of repair systems (Shern-Brewer et al., 1998). The adaptive response 
in humans (Asami et al., 1998) and rats (Radak et al., 2002) depends on the level of 
training of the individual taking part in an exercise regime. It has been proposed that 
training-induced adaptation was able to induce accelerated oxygen uptake and 
enhanced ATP/AMP stability which is critical for cellular energy supply and demand 
and thus cell homeostasis (Korzeniewski and Zoladz, 2003). Exercise has been shown 
to induce an increase in antioxidant enzyme activity, including superoxide dismutase 
and catalase activities (Wozniak et al., 2001; Tauler et al., 1999; Jenkins, 1988).
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Svensson et al (2002) reported that the redox balance of reduced glutathione (GSH), 
and its oxidised form (GSSG) in skeletal muscle showed a rapid adaptive response to 
repeated bouts of strenuous exercise with a reduced level of GSSG.
Because only one measure of oxidative stress, urinary concentrations of 8-isoprostane, 
was used and there were no consistent changes following exercise it was not possible 
to determine whether a-TL could be used as a biomarker of in vivo oxidative stress. 
The fact that there was a significant correlation between urinary a-TL and 8- 
isoprostane concentrations suggests that a-TL could potentially be an effective lipid 
peroxidation biomarker, but further data is necessary.
When combining all the data a-CEHC and a-TL concentrations showed a significant 
correlation and it is possible that a-TL concentrations merely reflect the 
concentrations of a-CEHC.
In summary, despite the present study being designed to take into account parameters 
such as exercise intensity, level of training of the individuals and the fact that some 
oxidation products are elevated hours or even days following exercise, no consistent 
response was detected in the urinary lipid peroxidation marker, 8-isoprostane. 
Although urine samples were collected up to two days following the day of exercise, 
it may be that this marker was only elevated after this period, as Sacheck et al (2003) 
reported that plasma total F2-isoprostane (four different isomers including PGF2p, 8- 
isoPGFza, PGF2a and trans-PGF2a) concentrations only showed an increase 72 hours 
post exercise.
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In retrospect, exercise is a complex situation involving a wide range of physiological 
and biochemical responses, including biochemical adaptation (Radak et al., 2002), 
and may have been an inappropriate group to study. Further work carried out by the 
vitamin E research group at the Institute of Child Health, London, has suggested that 
children with sepsis might have been a better group to study.
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5.1 Cellular localisation and mechanism of p-oxidation 
of fatty acids
The saturated phytyl side-chain of the tocopherols is identical to that of the fatty acid 
phytanic acid (see section 5.1.4), it is plausible that tocopherols may follow the same 
metabolic pathway. Fatty acids are normally metabolised in the mitochondria and 
peroxisomes and this will now be briefly discussed.
5.1.1 The metabolism of fatty acids
Fatty acids (FAs) are mainly oxidised by (3-oxidation, a series of reactions that are 
carried out in mitochondria and peroxisomes. The two intracellular organelles play 
distinct roles in the metabolism of FAs in the cell, as the substrate specificities differ 
between the two organelles (figure 5.1). The substrates for mitochondrial (3-oxidation 
are the acyl-CoAs of short, medium and long-straight chain FAs. These FAs comprise 
the bulk of FAs derived from the diet. The substrates for peroxisomal (3-oxidation are 
the acyl-CoAs of the less common FAs comprising a) the branched chain FAs, long- 
chain fatty acids (LCFA), very-long-chain fatty acids (VLCFAs) and 2-methyl- 
branched FAs like pristanic acid, b) bile acid intermediates, dihydroxycholestanoic 
acid (DHCA) and trihydroxycholestanoic acid (THCA) and c) some eicosanoids such 
as the leukotrienes and prostaglandins.
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Figure 5.1; Substrates of mitochondrial and peroxisomal oxidation
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Mitochondrial and peroxisomal (3-oxidation of FAs involves four basic reactions: 
dehydrogenation, hydration, dehydrogenation, and finally thiolytic cleavage. In 
general the enzymes involved in these steps differ between the two organelles and are 
encoded by distinct genes. There are, however, a few exceptions where the enzymes 
in both compartments are products of the same genes. The mitochondria are 
responsible for the complete (3-oxidation of FAs to acetyl-CoA units, which then enter 
the tricarboxylic acid (TCA) cycle. This results in the production of NADH and 
FADH2 which are energy rich molecules that can be used to produce ATP during the 
process of oxidative phosphorylation.
The peroxisomes tend to be involved in chain-shortening of substrates, after which the 
products are exported to the mitochondria for further p-oxidation. Although the 
peroxisomes also contain flavoproteins, electrons are donated to molecular oxygen 
(O2), with the formation of hydrogen peroxide (H2O2). Hydrogen peroxide is 
converted to molecular oxygen and water by a peroxisomal catalase. The peroxisomal 
pathway is only half as efficient in the production of energy in the form of ATP 
compared to the mitochondrial oxidation of FAs.
5.1.2 Role of mitochondria in fatty acid oxidation
FAs have to be converted to coenzyme A (CoA) esters at the outer mitochondrial 
membrane and transported across the inner mitochondrial membrane as carnitine 
esters prior to p-oxidation. The three enzymes involved in the carnitine dependent
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transport system include; camitine-palmitoyl transferase I (CPT-I), camitineiacyl 
carnitine translocase (CACT) and camitine-palmitoyl transferase II (CPT-II). The 
fatty acid acyl-CoAs are converted to acyl-camitines by CPT-I, located in the outer 
mitochondrial membrane (Hoppel et al., 1998). These acyl-carnitines are then 
translocated from the inner membrane space to the mitochondrial matrix by an 
exchange reaction catalyzed by CACT, which is an inner mitochondrial membrane 
protein. Upon entry into the mitochondrial matrix the acyl-camitines are reconverted 
to their respective acyl-CoAs by CPT-II, located in the inner-leaflet of the 
mitochondrial inner-membrane. CPT-I was demonstrated to be the ‘rate-limiting’ step 
of fatty acid p-oxidation flux by inhibition studies of CPT-I with malonyl-CoA 
(McGarry and Foster, 1980).
Once acyl-CoA is regenerated in the mitochondrial matrix, it enters into the P- 
oxidation reaction pathway. The pathway of p-oxidation is shown in figure 5.2. The 
first step involves the formation of 2-enoyl-CoA from its corresponding saturated 
ester by acyl-CoA dehydrogenase which is dependent on electron transfer 
flavoprotein (ETF), a matrix FAD-linked protein. Four different acyl-CoA 
dehydrogenases have been reported with different but overlapping substrate chain- 
length specificities; short-chain acyl-CoA dehydrogenase (SCAD) (C4-C6), medium- 
chain acyl-CoA dehydrogenase (MCAD) (C4-C20), long-chain acyl-CoA 
dehydrogenase (LCAD) (C8-C20), and very long-chain acyl-CoA dehydrogenase 
(VLCAD) (C12-C24). The resulting 2-enoyl-CoAs are then hydrated to 3- 
hydroxyacyl-CoA by 2-enoyl-CoA hydratases. The three enzymes present in the 
mitochondria responsible for these catalytic reactions are short, medium and long- 
chain 2-enoyl-CoA hydratases. The dehydrogenation of 3-hydroxyacyl-CoA, the third
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step, is carried out by two enzymes (3-hydroxyacyl-CoA dehydrogenases) with over­
lapping chain length specificities to form the 3-ketoacyl-CoA intermediate. Finally, 3- 
ketoacyl-CoA undergoes thiolytic cleavage to yield acetyl-CoA and a chain-shortened 
acyl-CoA intermediate. This involves three enzymes of the 3-ketoacyl-CoA thiolase 
family with different substrate specificities. Long chain 2-enoyl-CoAs are handled by 
a multifunctional protein (MFP) to result in a chain shortened acyl-CoA and a unit of 
acetyl-CoA. The mitochondrial trifunctional protein (MTP) also referred to as 
mutifunctional protein (MFP) and trifunctional protein (TFP) is a heterocomplex of 
four a-subunits comprising long-chain enoyl-CoA hydratase and 3-hydroxyacyl-CoA 
dehydrogenase activities and four (3-subunits that possess long-chain 3-ketoacyl-CoA 
thiolase activity.
All the enzymes involved in the P-oxidation pathway have been shown to display 
substrate specificity in the S-configuration on the second carbon in the side chain (see 
figure 5.4). However, natural substrates exist as a mixture of (2R) and (2S)-isomers, 
and in order to overcome this barrier, a-methylacyl-CoA racemase (AMACR) is 
invoked in the racemization of (2R)-isomers to the (2S)-form. AMACR is present in 
both the mitochondrion and the peroxisome and is encoded by the same gene and its 
bimodal distribution is a result of differential targeting of the same gene product.
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5.1.3 Role of peroxisomes in fatty acid oxidation
Although the mitochondria are the principal intracellular organelles for FA p- 
oxidation, Cooper and Beevers (1969) reported that peroxisomes can carry out p- 
oxidation of FAs in a similar way. However, the FAs have to be transported across the 
peroxisomal membrane. Although it was initially suggested that fatty acyl-CoAs 
could diffuse freely across the peroxisomal membrane, subsequent immunological 
studies showed that carnitine:acylcamitine translocase (CACT), first characterised in 
the mitochondria, is also present in the peroxisomal membrane (Ramsay, 2000). 
Additionally, human carnitine octanoyl transferase (COT) has been reported to be 
localised in the peroxisome and shown to be responsible for the conversion of the 
end-product of pristanic acid P-oxidation, 4,8-dimethylnonanoyl-CoA, for its 
transport into the mitochondria (Ferdinandusse et al., 1999).
The first step in peroxisomal P-oxidation involves dehydrogenation of acyl-CoA to 2- 
trans-enoyl-CoA (figure 5.3), which is the “rate-limiting” reaction and is catalyzed by 
FAD-dependent acyl-CoA oxidases (ACO) that reduces molecular oxygen (O2) to 
hydrogen peroxide (H2O2), which is subsequently decomposed by catalase. Two 
forms of ACO are present in humans with different substrate specificities; 1) 
palmitoyl-CoA oxidase (also known as straight-chain acyl-CoA oxidase (SCOX)), 
which acts on both straight and branched-chain saturated fatty acyl-CoAs in rat 
peroxisomes but only on straight-chain acyl-CoAs in human peroxisomes and 2) 
branched-chain acyl-CoA oxidase (BCOX), which acts on
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Figure 5.3; Steps involved in the oxidation of straight-chain very long chain 
fatty acids (VLCFAs) and branched chain fatty acids (e.g.pristanic acid).
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substrates such as di-hydroxycoprostanoyl-CoA and tri-hydroxycoprostanoyl-CoA 
(DHCA and THCA respectively) and is responsible for the conversion of pristanoyl- 
CoA to 2,3-pristenoyl-CoA in human peroxisomes.
The next steps of p-oxidation involve mutifunctional proteins, which exhibit the 
following activities 1) 2-enoyl-CoA hydratase; 2) 3-hydroxyacyl-CoAdehydrogenase; 
3) isomerase. There are two peroxisomal multifunctional proteins (MFP), MFP-I and 
MFP-II also referred to as L-bifunctional protein (L-BP) and D-bifunctional protein 
(D-BP) respectively. These proteins are responsible for at least two steps of the p- 
oxidation pathway and have been described in rat and human peroxisomes. D-BP 
appears to be essential for the P-oxidation of both branched (bile acid intermediates 
and pristanoyl-CoA) and straight-chain FAs. This was shown by FA accumulation in 
D-BP deficient patients (Van Grunsven et al., 1998; Van Grunsven et al., 1999a; Van 
Grunsven et al., 1999b; Suzuki et al., 1997) and later confirmed by studies in D-BP 
knock-out mice by Baes et al (2000). Due to the L-configuration not existing in 
nature, the role of L-BP remains unknown.
The final step of p-oxidation involves the thiolytic cleavage of 3-ketoacyl-CoAs to 
their chain shortened acyl-CoAs and to acetyl-CoA. Two peroxisomal thiolases have 
been reported; 3-ketoacyl-CoA thiolase (Miyazawa et al., 1981) and sterol carrier 
protein (SCPx) (Seedorf et al., 1994; Wanders et al., 1997). Ferdinandusse et al., 
2000b) showed that 3-ketoacyl-CoA thiolase and SCPx are both active on straight- 
chain substrates but SCPx alone is responsible for the final cleavage step in 
P-oxidation of branched-chain substrates including pristanic acid and the bile acid 
intermediates DHCA and THCA (Ferdinandusse et al., 2001).
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5.1.4 The cellular metabolism of phytanic and pristanic acids 
and the possible relation to tocopherols
Phytanic acid is derived from the phytyl side-chain of chlorophyll. The absorption of 
chlorophyll by the human digestive tract, however, is minimal. The sources of 
phytanic acid in humans are from dairy products and ruminant fats. Phytanic acid is a 
branched chain fatty acid consisting of 3 asymmetric centres at carbon 3, 7 and 11 and 
is comparable to the structure of the tocopherols (figure 5.4). The carbon 7 and 11 
atoms exist in the R-configuration (D-configuration). However, the carbon 3 atom has 
been demonstrated to be present in both R- and S-configurations (L-configuration) 
with varying relative proportions.
5.1.4.1 Phytanic acid metabolism
Phytanic acid cannot enter the p-oxidation spiral directly due to a P-methyl group, and 
it must therefore undergo prior a-oxidation, followed by decarboxylation to remove a 
one carbon moiety (Verhoeven et al., 1997a). Prior to a-oxidation, phytanic acid is 
first activated to phytanoyl-CoA by phytanoyl-CoA ligase (Pahan and Singh, 1995) 
(figure 5.5). Phytanoyl-CoA then enters the peroxisome by an undefined mechanism, 
which appears to involve active transport (Poulos et al., 1985; Singh et al., 1993; 
Jansen et al., 1997 and Jansen et al., 1996), where it undergoes a-oxidation (Avigan et 
al., 1966; Eldjam et al., 1966). The first step of a-oxidation is its conversion to 2- 
hydroxyphytanoyl-CoA, by phytanoyl-CoA hydroxylase (PhyH). 2-
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Phytanic acid
HO
R/SR/SR/S
a-Tocopherol
Figure 5.4; The structure of Phytanic acid and its asymetric centres 
compared to a-tocopherol.
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Figure 5.5; The a-oxidation pathway of phytanic acid, prior to p-oxidation
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hydroxyphytanoyl-CoA then undergoes decarboxylation by 2-hydroxyphytanoyl- 
lyase (HPL), to form pristanal, releasing a one carbon compound, formate (Poulos et 
al., 1993; Croes et al., 1996; Verhoeven et al., 1997a). Conversion of pristanal to 
pristanic acid, however, appears to occur by microsomal fatty aldehyde 
dehydrogenase (FALDH) (Verhoeven et al., 1998; Verhoeven et al., 1997b). This 
would imply that pristanal is exported from the peroxisomes to the endoplasmic 
reticulum (ER), where it is converted to pristanic acid. Pristanic acid is then activated 
to pristanoyl-CoA by long-chain acyl-CoA synthase (LCAS) and imported back into 
the peroxisome in a carnitine independent manner.
The first step of p-oxidation involves an acyl-CoA oxidase (ACO). It is known that 
the enzyme reacts exclusively with isomers of the 2S-configuration. Phytanic acid and 
its resulting a-oxidation product, pristanoyl-CoA, exist in vivo as a mixture of 2R and 
2S-isomers. Thus before P-oxidation is able to proceed, substrates with a 2R 
configuration are converted to their 2S-isomers by AMACR located in the 
peroxisome (see section 5.1.2).
Following racemisation to (2S)-pristanoyl-CoA, p-oxidation can proceed. The steps 
and enzymes involved in peroxisomal FA oxidation are described in general in section 
5.1.3. The pathway involved in the p-oxidation of pristanic acid is illustrated in figure 
5.6. Firstly, branched-chain acyl-CoA oxidase (BCOX) converts pristanoyl-CoA to 
2,3-pristenoyl-CoA utilising flavin adeninenucleotide (FAD). The next two steps 
involve D-BP (MFP-II), responsible for the conversion of 2,3-pristenoyl-CoA to 3- 
ketopristanoyl-CoA via 3-hydroxypristanoyl-CoA. These two steps involve firstly 
hydration by 2-enoyl-CoA hydratase activity, followed by dehydrogenation by 3-
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Figure 5.6; The peroxisomal p-oxidation of Pristanoyl-CoA
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hydroxyacyl-CoA dehydrogenase activity. The final step of (3-oxidation involves 
thiolytic cleavage of 3-ketopristanoyl-CoA by (SCPx) to form 4,8,12- 
trimethyltridecanoyl-CoA (Wanders et al., 1997).
Thus the product of one cycle of p-oxidation of pristanoyl-CoA is 4,8,12- 
trimethyltridecanoyl-CoA, which can re-enter the P-oxidation spiral for further chain 
shortening. The product of the second cycle of p-oxidation is in the 2R-configuration, 
and is therefore converted to its 2S-isomer by AMACR, to enable complete 
degradation (Ferdinandusse et al., 2000a). Pristanic acid undergoes three cycles of p- 
oxidation in the peroxisome. The end product, 4,8-dimethylnonanoyl-CoA is unable 
to be further degraded by peroxisomal P-oxidation and is a suitable substrate for 
mitochondrial p-oxidation. Following conversion to a carnitine ester, thought to be 
regulated by COT (Ferdinandusse et al., 1999), it is then exported to the 
mitochondria. The carnitine ester of 4,8-dimethylnonanoyl crosses the outer 
mitochondrial membrane by the action of CPT-I and the inner-membrane of the 
mitochondria by the action of CACT. Upon entry into the mitochondria matrix the 
carnitine ester is converted back to its acyl-CoA derivative by CPT-II. One cycle of 
mitochondrial p-oxidation results in the formation of 2(R),6-dimethylheptanoyl-CoA. 
This product is converted to its 2S-isomer by AMACR present in the mitochondria, 
enabling p-oxidation to proceed to completion forming acetyl-CoA.
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5.1.4.2 Disorders of mitochondria function
There are five principal inborn errors of mitochondrial metabolism that have been 
reported to affect FA oxidation.
1- CPT deficiency- As described in section 5.1.2 the entry of LCFAs into the 
mitochondria and into P-oxidation is facilitated by three carnitine dependent proteins 
CPT-I, CPT-II and CACT. Deficiency of any of these proteins, therefore, results in 
reduced or blocked mitochondrial P-oxidation of LCFAs.
CPT-I deficiency is rare. There are two isoforms of CPT-I, which include a hepatic 
and a muscle form. Patients reported with CPT-I deficiency to date have only 
demonstrated a lack in the activity of the hepatic form (Olpin et al., 2001).
CPT-II deficiency is the most common cause of abnormal lipid metabolism in skeletal 
muscle and/or hepatic tissue (OMIM; 600650). There are two forms of CPT-II 
deficiency, the milder more common myopathic adult form and the severe neonatal 
hepatic form. The difference between the two forms has been studied at a molecular 
genetic level. The infant form has been found to demonstrate 10% residual CPT-II 
activity and impaired LCFA oxidation, whereas the adult form demonstrates a 20% 
residual CPT-II activity with no consequence on LCFA oxidation (Bonnefont et al., 
1996).
CACT deficiency (OMIM: 212138) is caused by insertions (Huizing et al., 1997), 
deletions (Huizing et al., 1998; Ogawa et al., 2000) and mutations (Ogawa et al.,
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2000) in the CACT gene. Seizures and episodes of coma may be provoked by fasting 
as CACT protein is responsible for the transfer of fatty acyl carnitines into the 
mitochondria, whereby mitochondrial oxidation of FAs provides the chief source of 
energy during prolonged fasting.
2- Acyl-CoA dehydrogenase deficiency -  As discussed previously there are four 
enzymes that are responsible for the catalysis of the first step of each cycle of 13- 
oxidation depending of the chain length of the FA. These are long, medium and short 
chain acyl-CoA dehydrogenase (LCAD, MCAD and SCAD) respectively. Clinical 
features include for both MCAD and LCAD are similar and include hypoglycemia 
and cardiomyopathy (Hale et al 1985). SCAD shows essentially two phenotypes, the 
neonatal form were patients show muscle weakness (Roe and Ding, 2001) and the 
middle-aged form where patients develop chronic myopathy (Turnbull et al., 1984).
3- 3-hydroxyacyl-CoA dehydrogenase deficiency- A  deficiency of long-chain 3- 
hydroxyacyl-CoA dehydrogenase (LCHAD) leads to a build up of long-chain 3- 
hydroxy fatty acids, which are potentially toxic, whereby patients develop neuropathy 
and degenerative retinopathy (Tyni and Pihko, 1999).
4- Complete MTP deficiency - All three enzyme activities of this protein are 
deficient due to multiple mutations in either the a- or (3-subunits. This disorder 
includes LCHAD deficiency and exhibits similar clinical features to LCHAD 
deficiency. However, complete MTP deficiency is generally a more severe disorder 
with earlier presentation and severe cardiac involvement (OMIM: 600890).
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5- Disorders o f mitochondrial respiratory chain enzymes- These disorders are 
caused by the loss or delelion of pieces of mitochondrial DNA (mtDNA), where 
different proportions of deleted mtDNA result in defects in subunits of respiratory 
enzyme complexes in various tissues. Pearson et al in 1979, described multiorgan 
disorders that were later found to be several diverse over-lapping syndromes caused 
by mutations of mtDNA (OMIM; 557000). Biochemical characteristics associated 
with this group of disorders referred to as Pearson’s syndrome include mild lactic 
acidosis and reduced respiratory chain function in white cells and muscle biopsies.
5.1.4.3 Peroxisomal disorders
Three main categories of peroxisomal defects have been described to date.
Category A: The Zellweger syndrome (ZS) phenotype is caused by mutations in any 
of several different genes involved in peroxisomal biogenesis. The first description of 
a human disorder being linked to a loss of peroxisomal function was reported by 
Goldfischer et al (1973) who showed that peroxisomal matrix proteins were not 
properly compartmentalised in a group of patients diagnosed with Zellweger 
syndrome (OMIM: 214100).
Category B: Rhizomelic chondrodysplasia punctata (RCDP) was described later 
(Heymans et al., 1985), and was immediately linked to the peroxisome. Unlike the 
Zellweger spectrum of peroxisomal biogenesis disorders (PBDs) (category A), RCDP 
is genetically homogenous and only a small subset of peroxisomal enzymes are
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mislocalised. Because of mutations in the gene encoding the PTS2 receptor located on 
the amino-terminus (N-terminus) of many peroxisomal enzymes and involved in 
peroxisomal import (Motley et al., 1994) the proteins are mislocalised to the cytosol. 
This form is referred to as type 1 RCDP (OMIM: 215100). Two other forms of RCDP 
have also been characterised, and are genetically distinct resulting from mutations in 
the genes for the peroxisomal enzymes, dihydroxyacetonephosphate-acyl transferase 
(DHAP-AT) (type 2 RCDP) (OMIM: 222765) and alkyl-dihydroxy acetonephosphate 
synthase (alkyl-DHAP synthase) (type 3 RCDP) (OMIM: 600121) which are involved 
in ether phospholipid synthesis.
Category C: The third category of peroxisomal disorders, result from single enzyme 
defects caused by specific mutation or loss of a single gene. These disorders are 
protein specific and include, X-linked adrenoleukodystrophy (XALD), short-chain 
acyl-CoA oxidase deficiency (SCOX-deficiency), D-bifunctional protein deficiency 
(D-PP deficiency), and a-methylacyl-CoA racemase deficiency (AMACR 
deficiency).
XALD (OMIM: 300100) is the most commonly diagnosed peroxisomal disorder. The 
condition is caused by a defect in an 80kDa peroxisomal membrane protein, 
adrenoleukodystrophy protein (ALDP). This protein belongs to the ATP binding 
cassettte (ABC) transporter family and is involved in the transport of VLCFAs and 
C26:0- CoA esters, across the peroxisomal membrane into the peroxisomal matrix 
(Mosser et al., 1994).
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The deficiency of the SCOX enzyme (OMIM: 264470) causes VLCFA accumulation, 
whilst concentrations of pristanic acid and the bile acid intermediates, DHCA and 
THCA are normal.
D-BP deficiency (OMIM: 261515) was first discovered by Watkins et al., 1989). Two 
types of this disorder exist which include complete D-BP deficiency (Watkins et al., 
1989; Van Grunsven et al., 1999b) and an isolated deficiency with a mutation in either 
of the two functional sites of the protein (D-3-hydroxyacyl-CoA dehydrogenase)(Van 
Grunsven et al., 1998) or D-BP enoyl-CoA hydratase (Van Grunsven et al., 1999a). 
Biochemically, VLCFA levels are abnormally high, and pristanic and phytanic acid 
concentrations are also elevated in all types of D-BP deficiency.
AMACR deficiency (OMIM: 604489) is associated with neurological disease in adult 
life caused by mutations in the gene encoding peroxisomal AMACR. Symptoms are 
relatively mild. Biochemically there is an accumulation of exclusively (R)-isomers of 
pristanic acid and the C27-bile acid intermediates DHCA and THCA in plasma of 
patients (Ferdinandusse et al., 2001).
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5.2 Urinary vitamin E metabolites of patients with 
peroxisomal and mitochondrial disorders
5.2.1 Introduction
The side-chain shortened products of the tocopherols are recognised urinary 
metabolites, and include the a , p, 6 and y-homologues of carboxyethylhydroxy 
chromans (CEHCs) and carboxymethylbutylhydroxy chromans (CMBHCs) (chapter 1 
section 1.6.2, figure 1.7). If the peroxisomes and/or the mitochondria are involved in 
the p-oxidation of the tocopherols, alterations in the concentration of these urinary 
metabolites might be expected in urine of patients with peroxisomal and/or 
mitochondrial disorders compared to those of healthy controls.
This section describes the investigation of urinary vitamin E metabolites of patients 
with peroxisomal disorders (n=5), mitochondrial disorders (n=4) and suspected 
peroxisomal or mitochondrial defects (n=5) compared to age and sex matched 
controls (n=17).
5.2.2 Experimental protocol
The collection of urine was conducted at either Great Ormond Street Hospital from 
patients with diagnosed or suspected peroxisomal or mitochondrial disorders, under
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the care of Professor P Clayton and Dr S Rahman, or from King’s College Hospital. 
Prior to analysis the urine samples were stored at -80°C within 12 hours of collection. 
The age and sex matched control urine samples were collected from subjects from 
Great Ormond Street Hospital, admitted to the hospital for non-metabolically related 
surgical procedures. This study was carried out with ethical approvel from the 
national standard NHS research ethics committee.
As it was not practical to collect 24 hour urine samples from each patient, spot urine 
samples were obtained and the metabolite concentrations were expressed per urine 
creatinine concentration.
The age and sex of the controls are shown in table 5.1, and brief details of the patients 
are shown in table 5.2. The age range of the patients is from 0.7 to 470 weeks and for 
the controls from 10 to 489 weeks. Age match controls less than 10 weeks of age 
could not be recruited. Unless otherwise stated only one sample was collected from 
each patient.
5.2.3 Analysis of results
The urinary vitamin E metabolite concentrations for the control subjects and patients 
with peroxisomal and mitochondrial disorders were analysed. The metabolites 
measured include a, P, 6 and y-homologues of CEHC and CMBHC and 
concentrations are expressed in nmoles per mmol creatinine.
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CONTROL SEX AGE
(weeks)
Cl m 10
C2 m 12
C3 m 14
C4 f 22
C5 f 24
C6 m 32
C7 f 32
C8 f 52
C9 m 56
CIO f 121
C ll m 128
C12 f 180
C13 m 301
C14 f 328
C15 m 423
C16 m 459
C17 f 489
Table 5.1; The age and sex of the control subjects
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PATIENT SEX AGE
(weeks)
DIAGNOSIS
Peroxisomal
disorder
PI m 0.7 Peroxisomal biogenesis defect; 
Zellweger syndrome
P2 m 5.4 Peroxisomal biogenesis defect; 
Zellweger syndrome
P3 m 470 Peroxisomal biogenesis defect; 
mild, mosaic
P4 m 52 Peroxisome D-BP deficiency; 
3-hydroxyacyl-CoA 
dehydrogenase defective
P5 f 328 Peroxisome D-BP deficiency; 
mild, uncharacterised
Mitochondrial
disorder
M l f 382 Pearson’s syndrome 
(mitochondrial respiratory 
chain defect)
M2a) m 12 Pearson’s-like syndrome
M2b) m 14 (follow-up sample from patient 
M2a))
M3 m 86 LCHAD deficiency
Suspected
peroxisomal!
mitochondrial
disorders
SI f 136 mitochondrial defect
S2 m 5 peroxisomal/mitochondrial
defect?
S3 m 253 mitochondrial -  not respiratory 
chain defect
S4 f 33 mitochondrial defect
S5 f 25 mitochondrial defect
Abbreviations:
D-BP = D-bifunctional protein
LCHAD = Long-chain hydroxy acyl-CoA dehydrogenase
Table 5.2; Details of patients with peroxisomal and mitochondrial disorders
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5.2.3.1 Control subjects
The individual concentrations and means of the urinary metabolites in the 17 control 
subjects are given in table 5.3 and the concentrations plotted against age are shown in 
figures 5.7 and 5.8. It can be seen that the urinary concentrations of a - and y-CEHC 
(figure 5.7) and a  and y-CMBHC (figure 5.8) showed no consistent correlation with 
age. a-CEHC was present in the urine of all control subjects with concentrations 
between the range of 118 to 9,450 nmol/mmol creatinine. The concentrations of a- 
CMBHC were within the range of undetectable to 148nmole/mmole creatinine, where 
five of the seventeen subjects exhibit no detectable a-CMBHC. (3-CEHC was present 
in all the subjects ranging from 10 to 1,639 nmol/mmol creatinine, whilst the 
concentrations of (3-CMBHC were within the range of undetectable to 
126nmole/mmole creatinine, with none detected in six subjects. 6-CEHC was present 
in all subjects with concentrations ranging from 6 to 892nmol/mmol creatinine. 6- 
CMBHC was absent in five subjects, with a range from undetectable to 
114nmole/mmole creatinine. y-CEHC was present in the urine of all the control 
subjects, with concentrations within the range of 60 to 4,351nmol/mmol creatinine. 
The concentrations of y-CMBHC were within the range of undetectable to 
178nmol/mmol creatinine, with six of the seventeen subjects showed undetectable 
levels. It is evident that the longer chain-shortened metabolites, the CMBHCs, are 
often undetectable in the urine of the control subjects. This tends to occur in an 
individual subject for more than one homologue of CMBHC, for example, the control 
subjects C7 and C ll  showed the absence of a , p, 6 and y-CMBHC, C9 showed the
Control subject
METABOLITE C l C2 C3 C4 C5 C6 C7 C8 C9 CIO C ll C12 C13 C14 C15 C16 C17 mean
(range)
a-CEHC 1568 194 520 3408 2929 570 118 344 126 9450 150 2390 172 145 278 484 6739 1740.3
(118-9450)
a-CMBHC 100 18 60 131 76 148 0 44 0 20 0 0 0 48 16 53 16 42.9
(0-148)
P-CEHC 10 30 10 154 71 122 188 411 55 123 100 1639 184 23 80 269 72 208.3
(10-1639)
p-CMBHC 20 9 20 0 0 126 0 6 0 22 0 85 0 46 33 26 24 24.5
(0-126)
6-CEHC 265 36 400 892 735 187 6 67 116 53 713 766 55 13 115 122 63 239.1
(6-892)
6-CMBHC 35 3 30 62 71 104 0 0 12 3 0 114 0 17 29 0 23 29.6
(0-114)
Y-CEHC 225 570 1800 3492 3271 1891 60 500 618 775 1123 4351 514 214 1181 1347 509 1320.1
(60-4351)
y-CMBHC 25 3 0 0 0 178 0 17 0 12 0 84 48 92 102 93 36 40.6
(0-178)
Table 5.3; Concentrations of vitamin E metabolites in nmol/mmol creatinine for control subjects
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plotted against their age in weeks
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absexice of a , p, and y-CMBHC and subject C13 showed the absence of a , P and b- 
CMBHC.
5.2.3.2 Patients with peroxisomal and mitochondrial disorders
The concentrations of the a , p, b and y-homologues of CEHC and CMBHC of the 
patients with peroxisomal disorders, mitochondrial disorders and unconfirmed 
peroxisomal and mitochondrial disorders are shown in table 5.4 and compared to the 
metabolite concentrations found in the control group.
Patients with peroxisomal disorders
The concentrations of the urinary metabolites of vitamin E of peroxisomal patients 
demonstrated no consistent trends. P3 and P4 displayed concentrations of urinary 
vitamin E metabolites within the control ranges. For PI, only p- and 6-CEHC was 
detected. P2 had a urinary metabolite profile similar to that of C7 and C ll, 
demonstrating a lack of CMBHCs and the concentration of a-CEHC (15nmol/mmol 
creatinine) was lower than the lower limit of the control range (llOnmol/mmol 
creatinine). For P5, the concentration of a-CMBHC (515nmol/mmol creatinine) was 
higher than the maximum of the control range (148nmol/mmol creatinine).
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Patients
METABOLITE
PI P2 P3 P4 P5 Ml M2
a)
M2
b)
M3 SI S2 S3 S4 S5 Control
mean
(range)
a-CEHC 0 15 181 270 676 388 0 1031 3727 1360 477 157 1003 429 1740.3
(118-9450)
a-CMBHC 0 0 71 0 515 23 0 86 302 21 65 18 0 39 42.9
(0-148)
P-CEHC 25 167 254 130 131 975 594 419 512 242 42 13 52 29 208.3
(10-1639)
P-CMBHC 0 0 42 55 24 0 0 163 37 47 50 11 31 18 24.5
(0-126)
6-CEHC 50 15 40 50 108 23 141 913 132 651 477 21 0 318 239.1
(6-892)
6-CMBHC 0 0 0 0 27 0 0 238 0 0 69 9 33 43 29.6
(0-114)
y-CEHC 0 70 163 355 498 118 0 5663 693 2334 2023 175 3106 2675 1320.1
(60-4351)
y-CMBHC 0 0 71 0 97 0 459 6 20 23 12 21 0 18 40.6
(0-178)
Table 5.4; Urinary vitam in E metabolite concentrations in nm ol/m m ol creatinine o f patients w ith peroxisomal 
(P), m itochondrial (M ) or suspected peroxisom al or m itochondrial disorders (S).
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Patients with mitochondrial disorders
Patient M l demonstrated normal urinary concentrations of all vitamin E metabolites 
analysed. For patient M2 urine sample (a) (taken at 12 weeks of age), no a-CEHC or 
y-CEHC were detected, and the concentration of y-CMBHC (459nmol/mmol 
creatinine) was greater than the maximum of the control range (178nmol/mmol 
creatinine). The metabolite concentrations for patient M2 sample (b) (taken at 14 
weeks of age) demonstrated p- and 6-CMBHC and 5- and y-CEHC concentrations 
elevated above the control ranges. For patient M3 the concentration of a-CMBHC 
was higher (302nmol/mmol creatinine) than the maximum of the control range 
(148nmol/mmol creatinine).
Patients with suspected peroxisomal or mitochondrial disorders
The concentrations of urinary metabolites of vitamin E of patients S1-S5 were within 
the normal range except for S4 (refer to table 5.4) where 6-CEHC was not detected.
Metabolite concentrations in patients and controls as a function of age
Figures 5.9 a and b, show the concentrations (nmol/mmol creatinine) of a-CEHC and 
y-CEHC respectively, for each control subject and patient as a function of age 
(weeks). It can be seen that in general the urinary concentrations of a- and y-CEHC of
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difficult to come to a firm conclusion regarding the precise involvement of the 
peroxisome and mitochondrion in vitamin E metabolism.
All the suspected, but unconfirmed cases of mitochondrial and peroxisomal disorders, 
showed concentrations of urinary vitamin E metabolites within the control ranges 
with the exception of undetectable 6-CEHC in patient S4 who had a suspected 
mitochondrial defect. This finding may be a reflection of the mild phenotypes 
exhibited by these patients.
The urinary vitamin E metabolite profiles appeared to be affected in the two patients 
with Zellweger syndrome (PI and P2) which have a reduced number of peroxisomes. 
Patient PI showed an absence of a-CEHC and a-CMBHC and P2 an absence of a- 
CMBHC with a greatly reduced a-CEHC concentration (approximately ten fold lower 
than the lower limit of the control range), suggesting that the peroxisomes may be 
involved in the chain-shortening of a-TH. Although, patient PI also showed an 
absence of y-CEHC and y-CMBHC, patient P2 showed an absence of y-CMBHC with 
normal levels of y-CEHC. This may suggest that p-oxidation of y-TH is also effected 
but possibly to a lesser extent than a-TH. There does not, however, appear to be a 
similar effect on the concentrations of the p and 6 homologues of CEHC detected in 
the urine of these patients. PI and P2 were 0.7 and 5.4 weeks of age respectively and 
were, therefore, younger than all the control subjects, the youngest of which was 10 
weeks old. It is therefore possible that the urinary metabolites of these patients may 
reflect their age and nutritional status. It would, therefore, be relevant to have detailed 
information on how these patients were fed, but unfortunately this information was 
not available.
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Patient P3 was diagnosed with a mild peroxisome biogenesis defect (PBD), with a 
reduced number of peroxisomes. The concentrations of all the urinary vitamin E 
metabolites in these patients fell within the control range.
Patients P4 and P5 were diagnosed with D-BP deficiency which consists of three 
groups of deficiencies; 1- complete D-BP deficiency; 2- isolated enoyl-CoA hydratase 
deficiency; 3- isolated 3-hydroxyacyl-CoA dehydrogenase deficiency. Patient P4 was 
diagnosed with isolated 3-hydroxyacyl-CoA dehydrogenase deficiency, and had 
urinary vitamin E metabolite concentrations which fell within the control ranges. 
Patient P5 was also diagnosed with D-BP deficiency, but the specific defect of the D- 
BP protein has yet to be determined. All urinary vitamin E metabolite concentrations 
fell within the control range, except for the concentration of a-CMBHC which was 
more than three fold greater than the upper limit of the control range.
In the mitochondrial disorder group, two of the patients had defects of the 
mitochondrial respiratory chain enzymes. Patient M l was diagnosed with Pearson’s 
syndrome exhibiting some characteristics of another mtDNA deletion disorder - 
Keam-Sayre syndrome (Morris et al., 1997). The concentrations of the urinary 
vitamin E metabolites in the patients were all within the control ranges.
Patient M2 was diagnosed with a Pearson’s-like syndrome. This syndrome has many 
of the clinical features of Pearson’s syndrome but has normal mitochondrial DNA. 
Two samples were analysed from this patient at 12 and 14 weeks of age. There were 
differences in the concentrations of the urinary vitamin E metabolites between the two 
samples which could be largely explained by treatment during this period. Patients
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with Pearson’s-like syndrome exhibit pancreatic insufficiency and during the period 
in which the two samples were taken, the patient was treated with pancreatic enzyme 
replacement and also received Intralipid intravenously to maintain energy, lipid and 
nutrient balance. Intralipid contains soya oil where the predominant form of vitamin E 
is y-TH, with high 6-TH and low concentrations of a - and (3-TH. In addition the 
patient was also administered Vitlipid in order to increase vitamin E supplementation 
levels. Vitlipid contains synthetic all-rac-a-TH. In response to treatment there was 
significant clinical improvement and plasma vitamin E concentrations were 
normalised. During the treatment period all the vitamin E metabolites became 
detectable and some of them (6-, y-CEHC and (3- and 8-CMBHC) increased above the 
upper end of the control range. Unfortunately plasma vitamin E concentration data 
was not available for all the subjects.
The patient with LCHAD deficiency (M3) had concentrations of vitamin E 
metabolites which fell within the control range except for an increased a-CMBHC 
concentration.
In summary, there was some evidence from the two patients with Zellweger syndrome 
that the peroxisome may be involved in chain shortening of the tocopherols. In 
general, however, the changes in urinary metabolite concentrations observed in these 
patients with mitochondrial and peroxisomal abnormalities were not consistent and 
not as severe as might have been expected. It would appear that sufficient enzyme 
activity was present to preserve peroxisomal and mitochondrial pathways in these 
patients who have survived, as complete elimination of such pathways are likely to be 
incompatible with life.
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6.1 Introduction
The aim of this study was to investigate the role of peroxisomes and mitochondria in 
vitamin E metabolism comparing the metabolism of a-TH and y-TH in cultures of 
human skin fibroblasts and human hepatoblastoma (HepG2) cells supplemented with 
these tocopherols.
Two different approaches were attempted. Firstly, skin fibroblasts from patients with 
specific peroxisomal and mitochondrial defects were investigated and secondly, 
mitochondrial and peroxisomal functions were manipulated in HepG2 cells.
6.1.1 Manipulation of mitochondrial fatty acid oxidation
It was decided to use etomoxir (sodium 2-[6-(4-chlorophenoxy)hexyl]oxirane-2- 
carboxylate) as a mitochondrial p-oxidation inhibitor for the manipulation of 
mitochondrial FA oxidation in this study. Etomoxir is an inhibitor of CPT-I, which is 
the first committed step of mitochondrial FA oxidation, and is the rate-limiting step. 
Many studies employ CPT -I inhibitors as a control of overall FA oxidation (Barnett et 
al., 1992; Suzuki et al., 1991).
Etomoxir was chosen as a mitochondrial inhibitor in this investigation rather than 
other CPT-I inhibitors, due to its ready availability and experience of its use in our 
department.
182
Chapter 6 -  In vitro investigation of the cellular localization of tocopherol metabolism
6.1.2 Manipulation of peroxisomal fatty acid oxidation
Studies involving the regulation of peroxisomal FA |3-oxidation, have mainly 
investigated the effect of peroxisome proliferation, and a number of reliable 
peroxisome proliferators are available. It was decided to use perfluorooctane 
sulphonate (PFOS) as a peroxisome proliferator for the manipulation of peroxisomal 
FA oxidation in this study. PFOS is commercially available and relatively 
inexpensive, and unlike most other peroxisome proliferators does not affect 
mitochondrial bioenergetics and biogenesis.
PFOS belongs to a family of perfluorinated alkyls, which includes the well studied 
perfluooctanoic acid (PFOA). PFOA is a stable and non-oxidisable FA analog that 
causes peroxisome proliferation both in vivo (Ikeda et al., 1985) and in vitro 
(Intrasuksri and Feller, 1991), independent of mitochondrial (3-oxidation. Intrasuksri 
et al (1998) showed that the stimulatory effects of PFOA are due to the stimulation of 
acyl-CoA oxidase (ACO) activity in hepatocytes. It was suggested that the increase in 
ACO activity was due to de novo enzyme synthesis, as cyclohexamide (an inhibitor of 
protein synthesis), caused complete blocking of ACO activity. It appears that PFOA 
like other non-p-oxidisable FAs and xenobiotics, interacts directly to up-regulate 
expression of the peroxisome proliferator response genes through the activation of 
PPAR-a. PPAR-a is a ligand dependent transcription factor, whereby any elevation in 
enzyme activity mediated through this receptor would increase protein synthesis. 
PFOS is also able to induce peroxisomal proliferation (Berge et al., 1989; Sohlenius et 
al., 1993) and in contrast to PFOA, contains a sulphur substitution at the (3-carbon. 
Many studies have reported that compounds that cause peroxisome proliferation in
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rodents also interfere with mitochondrial bioenergetics and biogenesis. This led to the 
suggestion that the proliferation of the peroxisome and the mitochondria may be 
related. However, PFOS unlike PFOA and other peroxisome proliferators, causes 
peroxisome proliferation without affecting the mitochondria, and this therefore 
suggests that peroxisome proliferation can be independent of the effects on 
mitochondrial function (Berthiaume and Wallace, 2002). Berthiaume and Wallace 
(2002), showed that PFOS and PFOA have similar potencies for peroxisome 
proliferation, however, PFOS did not cause the characteristic hepatomegaly observed 
by PFOA, suggesting some differences in their mechanism of action (Berthiaume and 
Wallace, 2002).
6.2 Metabolism of vitamin E in human skin fibroblasts 
and HepG2 cells in culture
6.2.1 Cell culture techniques
A normal fibroblast cell line was obtained as a growing cell culture, which had been 
established from a skin biopsy, from a metabolically normal patient, by the Enzyme 
Laboratory at Great Ormond Street Hospital. Fibroblasts were grown as mono-layers 
in tissue culture flasks, which had a surface area of 25cm2 and contained 5ml Hams 
F10 growth medium. The Hams F10 growth medium contained 25mM HEPES and
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ImM L-glutamine, and was supplemented with 12% fetal bovine serum (FBS) and 
1% penicillin/streptomycin antibiotic solution (lmg/ml). Once prepared, the medium 
was stored for up to one month at 4°C.
The HepG2 cell line was supplied by the European Collection of Cell cultures 
(ECACC-85011430) as a frozen aliquot. Upon reconstitution of the cell line, cultures 
were grown in Dulbecco’s modified eagle medium (D-MEM (MOD)), with 10%FBS 
and 1% penicillin/streptomycin. Cultures were initially left to grow to confluency for 
approximately 6 days.
Cell cultures were incubated at 37°C with 5% (v/v) CO2 in an incubator. The growth 
medium was replaced twice a week and the cells in each flask were sub-cultured, 
harvested or stored in liquid nitrogen as required, depending on their confluency, 
which was validated by phase contrast microscopy.
Materials
All cell culture procedures were carried out under sterile conditions. Disposable 
sterile plastic-ware was obtained from Falcon. Culture medium, FBS (EC approved 
origin), phosphate buffered saline (PBS) and trypsin solution (0.25%) were supplied 
by Gibco-life technologies, and penicillin/streptomycin antibiotic solution (lmg/ml) 
supplied by Sigma Chemicals. Trypsin buffer was made up in distilled water and 
consisted of 0.1M sodium chloride and 10M sodium citrate. All culture solutions were 
sterilised by filtering through a Millex 0.22pm syringe filter before use. Glassware 
was autoclaved at 125°C for 30 mins.
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Trypan blue stain solution (4%) and 4,6-Diamidino-2-phenylindole (DAPI) stain were 
purchased from Sigma Chemicals.
(+)-y-Tocopherol (RRR-y-TH)(T-1782) and (±)-a-tocopherol (all-rac-a-TH)(T-3251) 
were purchased from Sigma Chemicals and made up to 500mM stock solutions in 
acetone. Perflurooctane sulphonic acid (PFOS) was supplied by Fluka Chemicals. 
Etomoxir was a gift from Dr Simon Eaton, Surgery Unit, The Institute of Child 
Health, London. Etomoxir was made up to a ImM solution in ultrapure water.
Cell culture techniques
Cell culture techniques, including 1)- subculturing cell cultures, 2)- harvesting and 
storage of cultures, 3)- harvesting cells for analysis and 4)- reconstituting cells from 
storage in liquid nitrogen, were carried out using standard protocols as detailed by the 
Enzyme Laboratory, Great Ormond Street Hospital. Briefly, cells were released from 
the plastic flasks by trypsinisation using sterile trypsin solution (0.25%) for 5-10 
minutes at 37°C. Cells harvested for storage in liquid nitrogen were suspended in ice- 
cold growth medium containing 10% (v/v) dimethyl sulphoxide (DMSO). Cells 
harvested for analysis were washed then suspended in PBS and stored at -20°C.
Cell Viability and screening for mycoplasma contamination-
The cell viability of the cultures was estimated using the ‘trypan blue viability test’ 
and expressed as a percentage of the viable cells compared to total number of cells. 
Cell lines were screened for mycoplasma contamination by in situ DNA fluorescence, 
using DAPI (4,6-diamidino-2-phenylindole) staining. None of the cultures examined 
exhibited the presence of mycoplasma.
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6.2.2 a-Tocopherol supplementation of cell cultures
6.2.2.1 Supplementation of human skin fibroblast cultures with a-tocopherol
The first experiments involved the supplementation of human skin fibroblasts with 
all-rac-a-TH. Metabolism of the supplemented TH was monitored by the analysis of 
metabolites in the spent culture medium at the end of the incubation period.
Preparation of supplemented growth medium
The supplementation of the growth medium was based on the protocol used by Tran 
and Chan (1992) and Young et al (2001) involving the dispersion of TH in FBS 
before addition to the medium;
1- FBS was allowed to equilibrate at 37°C in a water-bath and 500mM a-TH at 
room temperature for approximately 20 minutes.
2- 80 pi of 500mM all-rac-a-TH (in acetone) was added to 30 ml FBS. N2 was 
briefly blown over the surface of the FBS to remove the acetone. The mixture 
was placed in a 37°C water-bath for 20 mins and then rotated at room 
temperature for 2 hrs. The mixture was then sterilized by passing through a 
0.22p Millex syringe filter.
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3- Determination of a-TH concentration in supplemented FBS samples
Three 50pl aliquots of the filtered FBS were removed and the a-TH extracted 
by solvent extraction and its concentration determined by normal phase high 
performance liquid chromatography (HPLC) with fluorometric detection 
(Metcalfe et al., 1989) by a modification of the method Buttriss and Diplock, 
(1983) as follows;
i) 1ml methanol was added to 50pi of the supplemented FBS, vortexed 
and then 1ml hexane was added. The mixture was vortexed and 
centrifuged at 2,500g for 5 minutes. The upper hexane phase 
containing the extracted TH was removed.
ii) a-TH concentration of the FBS was determined by injecting 20pi of 
the upper hexane phase on to a normal phase HPLC column. The 
HPLC system consisted of a spectra-Physics SP8770 isocratic pump 
(pressure at 28-30kPsi, flow rate of lml/min), Shimadzu Fluorescence 
HPLC monitor RF-535 (excitation wavelength 295nm, and emission 
wavelength 320nm), Shimadzu Chromatopac C-R8A integrator and an 
APEX silica 3p 1070428 chromatography column with a guard 
column.
iii) a-TH concentration was calculated from a standard curve using 
GraphPad Prism and the concentrations of a-TH in FBS calculated 
manually.
4- The amount of TH supplemented FBS to be added to the medium to give the 
required a-TH concentration was calculated.
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5- The remaining required ingredients of the growth medium were made up prior 
to addition of the TH supplemented FBS, as follows; Hams F10 growth 
medium, unsupplemented FBS (to make up total final FBS concentration to 
10%) and antibiotic solution (penicillin/streptomycin, at 1%) were mixed 
together, then sterilized by passing through a 0.22 “Millex” syringe filter.
6- The sterilized (filtered) TH supplemented FBS was added to the sterilized 
medium made in step 5, and was mixed by rotation for 10-15 mins.
7 The final concentration of a-TH in the medium was measured in 100 pi 
aliquots of medium, using normal phase HPLC with fluorimetric detection as 
in step 2.
8- The medium was placed in a 37°C water-bath for 20 minutes, before feeding 
to the cell cultures.
Analysis of spent culture media and cells for a-tocopherol and a-tocopherol 
metabolites
Cell cultures were incubated with the appropriate medium and at the end of the 
incubation period, the medium was removed from each culture flask and stored at 
-20°C until analysis. Cells were harvested by trypsinisation, and stored in trypsin 
buffer solution at -20°C until analysis.
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Extraction o f tocopherol from the spent media and cell suspension
Extraction of a-T H  from both the spent media, and cell suspensions were carried out 
using the solvent extraction method and normal phase HPLC with fluorescence 
detection as described above for supplemented FBS, using 50pl of the cell suspension 
and 100pi of media respectively.
Protein determination o f cell cultures
Protein determination was based on the bicinchoninic acid (BCA) method of Smith et 
al (1985).
Extraction o f tocopherol metabolites from media
Initially vitamin E metabolites were extracted from the spent medium using solid 
phase extraction with a C4 cartridge supplied by Jones Chromatography similar to the 
method developed for the extraction of urinary metabolites (chapter 2). The 
deconjugation and the second solid phase extraction step were not carried out, as 
unlike human urine, TH metabolites secreted by HepG2 cells appear to be 
unconjugated (Parker and Swanson, 2000). This was later confirmed by Dr Mills in 
our laboratory using tandem mass spectrometry. Preparation for GC-MS analysis was 
also performed as described for the urinary metabolites. It was, however, found that 
the extraction from the media was incomplete using this method, since in addition to 
the lack of peaks for the metabolites, no peak was detected for the internal standard 
(d9-a-CEHC), which was added to the sample prior to the extraction.
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Parker and Swanson (2000) studied the metabolism of y-TH in HepG2 cells in culture 
and described a method for the extraction and measurement of TH metabolites from 
the medium. The procedure involved extracting the metabolites into methyl tertiary- 
butyl ether (MTBE). The MTBE phase was then evaporated to dryness and 
derivatised for gas chromatography-mass spectrometry (GC-MS) analysis. Using this 
method, Parker and his group were able to detect both y-CEHC and the longer chain 
metabolite, y-CMBHC, in the growth medium.
Parker and Swanson’s protocol adapted for the present study was as follows.
The samples of growth media, 5ml in volume, were spiked with internal standard, d9- 
a-CEHC, to give a final concentration of lpM  and acidified to pH 1.5. The samples 
were vortexed with 5ml MTBE for 20 seconds and then centrifuged at 4,000g for 10 
minutes. The upper phase, containing the TH was removed, and the extraction step 
was repeated on the remaining lower phase. The upper phases were combined and 
evaporated to dryness. The samples were then derivatised with 150 pi 
acetonitrile/BSTFA (2:1), at 60°C for 1 hour. Derivatised samples were evaporated to 
approximately one third their volume and run on GC-MS using the same parameters 
as for the urinary vitamin E metabolites (see chapter 2).
Results of the preliminary experiment
The solvent extraction method used to extract vitamin E metabolites from the spent 
medium from skin fibroblasts provided good detection of the internal standard, d9-a- 
CEHC and a-TH, but no a-TH metabolites were detected (figure 6.1).
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Figure 6.1; Selected ion chromatogram showing the internal standard, d9-a-CEHC, and 
a-TH in harvested culture medium from skin fibroblasts. No vitamin E metabolites 
were detected.
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6.2.2.2 Preconditioning cultured HepG2 and human skin fibroblast cell lines
with a-tocopherol
A supplementation study, based on the experimental procedure of Birringer et al 
(2001) using both HepG2 cells and human skin fibroblasts was carried out. The 
protocol is outlined in figure 6.2. Both cell lines were “preconditioned” with lOOpM 
all-rac-a-TH for 10 days. The reason for preconditioning cells with a-TH 
supplemented growth medium was to allow uptake of a-TH and activation of its 
metabolic pathway. These a-TH adapted cells were then incubated with 
unsupplemented medium for 3 days. On day thirteen, cells were incubated with 
200pM all-rac-a-TH for 2 days. At the end of the experiment, both the medium and 
the cells were harvested, and frozen at -20°C prior to analysis.
Results of supplementation study with preconditioning of HepG2 cells and 
human skin fibroblast cells
Measurement o f a-TH in harvested cells and media
Triplicate flasks of skin fibroblasts and HepG2 cells were “preconditioned” and 
supplemented with a-TH and compared to blanks without added a-TH. The amounts 
(pmoles) of a-TH recovered in the medium and in the harvested cells were examined 
for all triplicate flasks of both cell lines throughout the course of the feeding protocol, 
and the mean results are shown in figure 6.3. The triplicate flasks of both cell lines
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grown on unsupplemented medium (blanks) did not show any detectable a-TH in the 
medium or the harvested cells.
In the HepG2 cell culture experiment, supplemented medium in the preconditioning 
period initially contained 0.5pmoles a-TH (100pM), which showed a decrease to 
approximately 0.3 to 0.4pmoles during the preconditioning phase. As expected, a-TH 
levels in the medium dropped to less than O.lpmole during the unsupplemented 
period. a-TH levels increased to 0.9pmole when the medium was supplemented with 
200pM a-TH. The lower a-TH levels obtained in the harvested media compared to 
the actual supplemented concentration may reflect a-TH being taken up by the 
HepG2 cells. HepG2 cell cultures were split and half were harvested on days 3, 5, 8 
and 10 of the preconditioning period, at the end of the unsupplemented period (dayl3) 
and at the end of the experiment (day 15). Extraction and analysis of the harvested 
HepG2 cell cultures showed that levels of a-TH remained relatively constant 
throughout the experiment, at approximately 0 .2pmoles in the total cell culture.
Human skin fibroblast cell cultures, contained similar levels of a-TH in the harvested 
media to that of the initial medium. Cells were only harvested at the end of the 
preconditioning period (day 10) and at the end of the experiment (day 15), and 
showed only trace levels of a-TH.
The supplementation of HepG2 cells and skin fibroblasts with all-rac-a-TH in the 
present study, showed that HepG2 cells in contrast to skin fibroblasts were able to 
take up a-TH from the supplemented growth medium.
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Measurement o f a-TH metabolites in spent media
The concentrations of a-TH metabolites were analysed in the growth medium of both 
cell lines and expressed per total protein concentration of the cells in the culture. This 
allowed the results of the present study to be standardised and compared to the results 
obtained by Birringer et al. (2001). It was found that HepG2 cells were able to 
metabolise a-TH to its side-chain shortened products, including a-CEHC, a-CMBHC 
and a-CMHHC, and then secrete into the growth medium. The detection of these 
three chain-shortened metabolites is shown by the chromatogram (figure 6.4). The 
time-course analysis for all three chain-shortened metabolites during the 
preconditioning and supplementation of the HepG2 cells with supplemented all-rac- 
a-TH is shown in figure 6.5. No a-TH metabolites could be detected in the spent 
medium of human skin fibroblasts. The concentration of metabolites remain relatively 
constant throughout the preconditioning period, where at day 8 the mean 
concentrations of, in particular the CMHHC and CMBHC are increased which may be 
due to the fact that at this point cultures had been incubated on the same 
supplemented medium for 3 days without harvesting or splitting of cell cultures 
compared to two days at all other harvest points.
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Figure 6.4; Chromatogram of extracted metabolites from HepG2 cell cultures fed all- 
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6.2.3 y-Tocopherol supplementation of cell culture
6.2.3.1 Y-Tocopherol supplementation of human skin fibroblasts and HepG2 
cells for 48 hours.
Supplementation studies of skin fibroblasts and HepG2 cells were repeated with y-TH 
as there is evidence that y-TH is more readily metabolised than a-TH (Birringer et al., 
1991). Cell cultures were grown as previously described (section 6.2.1), and 
supplemented with y-TH. As this form of TH is readily metabolised there was no need 
for preconditioning as was carried out with a-TH. The concentration of y-TH was 
altered from 200pM which was used in the previous a-TH experiments, to 50pM as 
the higher concentration appeared to stunt cell growth.
Preparation of supplemented growth medium
Preparation of the supplemented growth medium was carried out as described for a- 
TH, in section 6.2.2.1 to give a final concentration of 50pM y-TH in the growth 
medium. Concentrations of y-TH supplemented into the FBS, and the final 
supplemented growth medium were measured using HPLC with fluorometric 
detection as described previously, before supplementing the cultures.
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Feeding cultures supplemented medium
The study protocol was conducted, whereby three flasks of 85-90% confluent human 
skin fibroblast and HepG2 cell cultures were fed 50pM y-TH supplemented medium 
for 48hrs. A fourth flask of each cell line was fed unsupplemented medium to provide 
a control culture. Cell cultures were harvested after 48 hours incubation.
Results following supplementation of human skin fibroblasts and HepG2 cells 
with y-tocopherol
Concentrations of y-TH in the cell suspension are as follows and are quoted in pM as 
cell protein measurements were not available. y-TH concentrations in HepG2 cell 
suspensions had a mean value of 7.367 (n=3, SDEV=1.457) and for human skin 
fibroblast cell suspensions had a mean value of 9.335 (n=3, SDEV=3.508). These 
concentrations showed evidence of uptake of y-TH by both cell lines. Metabolites 
were, however, only detected in the medium of the HepG2 cell cultures (figure 6.6 ). It 
can, therefore, be concluded that human skin fibroblasts are unable to metabolise the 
THs and/or secrete the resulting metabolites to a level that can be detected by the 
analytical method used. In the HepG2 cell culture medium, the three chain-shortened 
metabolites of y-TH (y-CEHC, y-CMBHC and y-CMHHC) were detected at similar 
concentrations (with means of 4.50, 6.25 and 4.20pmol/mg cell protein, respectively).
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Figure 6 .6 ; The concentrations of the y-TH metabolites, y-CEHC, y-CMBHC and y- 
CMHHC, in the harvested media o f triplicate flasks of HepG2 cell cultures fed with 50pM 
y-TH supplemented medium for 48 hours (means are indicated by the lines).
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Discussion of results
In the preliminary experiments, healthy human control skin fibroblasts showed a very 
low uptake of a-TH into cells from the supplemented growth medium, and did not 
show any evidence of a-TH metabolism (see section 6.2.2.1).
In the second set of experiments the uptake and metabolism of a-TH using both 
HepG2 cells and human skin fibroblasts were compared (see section 6.2.2.2). Cultures 
of both cell lines were preconditioned for an extended period of time on growth 
medium containing a-TH. All three side-chain shortened metabolites, a-CEHC, a- 
CMBHC and a-CMHHC were produced by the HepG2 cells but could not be detected 
in media from skin fibroblasts.
The third set of experiments (see section 6.2.3.1) involved the study of the 
metabolism of y-TH using both HepG2 cells and skin fibroblasts. Skin fibroblasts did 
not produce any detectable y-TH metabolites whereas HepG2 cells actively 
metabolised y-TH. y-TH was more readily metabolised than a-TH as it did not require 
the preconditioning stage necessary for the formation of detectable concentrations of 
a-TH metabolites. Supplementation with 50 pM y-TH for only 48hrs with no 
preconditioning yielded similar concentrations of the equivalent metabolites CEHC, 
CMBHC and CMHHC in the spent medium compared with 200pM a-TH and 
“preconditioning”.
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It has been previously reported in the literature that a-TH was not metabolised by 
HepG2 cells, although y-TH was readily metabolised (Parker and Swanson, 2000). 
The findings of Parker and Swanson (2000) were confirmed by Birringer et al (2001) 
who re-examined a-TH metabolism by cultured HepG2 cells. They reported that the 
presence of y-TH and 6-TH in the growth medium resulted in y/6-CEHC and CMBHC 
metabolites as secretory products in the spent medium, whereas a- and (3-TH did not 
appear to be metabolised. Birringer’s group further observed that preconditioning of 
the cultured cells with all-rac-a-TH for 10 days was necessary before any metabolites 
of a-TH could be detected in the growth medium.
The concentration of a-CEHC in the spent medium peaked on day 8 of the 10-day 
preconditioning with lOOpM a-TH with give a mean of lOpmol/mg of protein 
(equivalent to 26ng/mg protein). At the end of the study following 48 hours 
incubation a-CEHC concentration was approximately lpmol/mg protein in the spent 
medium. These values were similar to the a-CEHC concentrations of 20ng/mg 
protein reported by Birringer (2001) in studies involving a 10-day incubation with 
lOOpM a-TH. In our study the longer chain metabolites, a-CMBHC and a-CMHHC, 
were present in higher concentrations with a mean of 39 and 32pmol/mg protein, 
respectively.
It was interpreted that the difference in handling of the different THs (a- and y-TH in 
our study and a-, |3-, 6- and y-TH in Birringer’s study) may result from either 
differences in the uptake of the THs by the HepG2 cells or differences in their 
metabolism. An adequate intracellular concentration of TH is obviously required
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before metabolism can take place and as discussed previously (section 1.5.2) it is well 
recognised that a-TTP is highly selective for a-TH. This results in a-TH being 
specifically selected for transfer back into the circulation, whereas the other THs tend 
to be metabolised and excreted.
The relatively higher concentrations of the longer-chain metabolites, a-CMBHC and 
a-CMHHC may have been due to incomplete oxidation to a-CEHC, as a result of 
more rapid flux of the steps prior to the conversion step to a-CEHC. This metabolism 
of a-TH appeared to be different from y-TH, where the concentrations of y-CEHC, y- 
CMBHC and y-CMHHC were similar. The unsupplemented stage resulted in a 
decrease in metabolite levels detected in the spent medium, showing a rapid response 
in metabolism by the cells to a-TH availability in the growth medium.
The differences in the ability of HepG2 cells and human skin fibroblasts to handle a- 
TH may be explained by the fact that HepG2 cells are metabolically more active and 
specialised compared with skin fibroblasts. The failure of the skin fibroblasts to 
metabolise a-TH was therefore likely to be the result of inactivity of the relevant 
metabolic pathways and/or the low uptake of a-TH by this cell line.
The initial aim of the study was to investigate skin fibroblasts from patients, however, 
the inactivity of this cell line made it necessary to use other approaches. It was, 
therefore, decided to use HepG2 cells to investigate the subcellular organelle(s) 
involved in the metabolism of y-TH.
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6.2.4 Intracellular sites of tocopherol metabolism in HepG2 
cells
HepG2 cells were incubated with y-TH supplemented growth medium and both 
mitochondrial and peroxisomal activity were manipulated separately, in order to try 
and gain a better understanding of the localisation of the metabolism of the 
tocopherols.
As discussed in sections 6.1.1 and 6.1.2 it was decided to use etomoxir as a 
mitochondrial inhibitor, and PFOS as a peroxisomal proliferator.
6.2.4.1 y-Tocopherol supplementation of HepG2 cells for 48 hours with 
manipulation of mitochondrial and peroxisomal function
Cell cultures were grown in four groups of three flasks and supplemented with y-TH. 
One group was supplemented with y-TH only and acted as a control. Addition of a 
mitochondrial inhibitor (20 pM etomoxir) and/or a peroxisome proliferator (100 pM 
PFOS) was made to the other three groups (figure 6.7).
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Figure 6.7; Supplementation of HepG2 cell cultures with y-TH and 
mitochondrial inhibitor and/or peroxisome proliferator
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Preparation of supplemented growth medium
Preparation of y-TH supplemented growth medium was carried out as described 
previously (6.2.2.1). Four groups of media were made up, containing the following 
amount and concentrations of the test agents;
[y-TH/-]: 40pi deionised water 
[y-TH/P]: 20 pi 50 mM PFOS and 20 pi water 
[y-TH/E]: 20 pi ImM Etomoxir and 20 pi water 
[y-TH/P/E]: 20pl 50 mM PFOS and 20pl ImM Etomoxir 
Media were then mixed, and sterilized by passing through a 0.22 p “Millex” filter.
Feeding programme of cultures with y-TH supplemented medium with added 
Etomoxir and/or PFOS
The feeding programme lasted for five days at the end of which culture media and 
cells were harvested (figure 6.8). The treatment of cell cultures during the feeding 
programme is described as follows.
Day 1- Twelve flasks of 85-90% confluent HepG2 cell cultures were grown on 
unsupplemented stock medium.
Three flasks where designated for each treatment group, [y-TH/-], [y-TH/P], [y-TH/E] 
and [y-TH/P/E]. 100pM PFOS was fed to the two appropriate cell culture groups, [y- 
TH/P] and [y-TH/P/E], to enable the action of this agent to be effective on the cell
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DAY 1 DAY 2 DAY 3 DAY 4 DAY 5
GROUPS
[y-TH/P]
and
[y-TH/P/E]
ADD  
lOOpM PFOS
FEED 50 pM y-TH 
SUPPLEMENTED 
MEDIUM
with added
i) 100 pM PFOS for
group
[y-TH/P]
ii) 20pM Etomoxir
for group 
[y-TH/P]
iii) lOOpMPFOS 
and 20pM Etomoxir
for group 
[y-TH/P/E]
HARVEST 
MEDIUM 
AND CELLS
Figure 6 .8 ; Feeding programme for HepG2 cell cultures with y-TH supplemented 
medium with added etomoxir and/or PFOS
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culture and allow time for proliferation of the peroxisomes of the cells before 
supplementing with y-TH on day 3. All other cultures were fed with unsupplemented 
stock growth medium.
Day 3- y-TH supplemented culture growth medium was made freshly as described in 
section 6.2.3.1, with additions of either Etomoxir or PFOS as stated. Cultures were 
fed with the appropriate supplemented growth medium and incubated for 48 hours.
Day 5- The medium of each culture flask was harvested separately. The cells were 
detached from the culture flasks by trypsinisation, resuspended in sterile PBS and 
then harvested separately. Both harvested medium and cells were stored at -20°C 
prior to analysis (see section 6.2.2.1).
Results of y-TH supplementation of HepG2 cell cultures for 48 hours treated 
with Etomoxir and/or PFOS
All cultures were 95-100% confluent upon harvesting on day 5, and each culture flask 
contained a mean of 71mg cell protein.
Cellular uptake o f y-tocopherol by cell cultures
Figure 6.9 shows the concentration of y-TH in the harvested cells and media from 
each individual flask in this study expressed as nmol per mg cell protein. The cellular 
concentrations in the control group gave similar concentrations in the triplicate flasks, 
in the range 1.28-1.45nmol/mg cell protein. The media concentrations of y-TH were
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Figure 6.9; Concentrations of y-TH in cells and media of HepG2 cell cultures fed with 
50[iM y-TH supplemented media for 48hrs and treated with PFOS and/or etomoxir 
(each bar n=3).
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only available for two of the three flasks and gave concentrations of 4.56 and 
3.30nmol/mg cell protein. The y-TH concentrations in the cells and media of the 
treated cultures showed similar concentrations to that of the control group except for 
the cellular concentration in the PFOS/etomoxir group which tended to be increased 
(1.78-2.48nmol/mg cell protein).
y-TH metabolite concentrations in the spent media
Figure 6.10 shows the concentrations of the three side-chain shortened metabolites of 
y-TH (y-CEHC, y-CMBHC and y-CMHHC), in the media from each individual flask 
expressed as pmol per mg cellular protein.
The control group, [y-TH/-], showed concentrations of y-CEHC in the range of 11.4- 
17.3, y-CMBHC in the range of 3.5-6.6 and y-CMHHC in the range 1.77- 
3.13pmol/mg cell protein. The y-TH metabolite concentrations in the spent media of 
the treated cultures are discussed below in relation to the control group.
PFOS treated group - y-CEHC concentrations in the spent medium were similar to 
the control values in the range of 13.8-18.8pmol/mg cell protein. y-CMBHC and y- 
CMHHC concentrations appeared to be lower than that of the control group, in the 
ranges 0.6-1.8 and 0.3-0.6pmol/mg cell protein, respectively. The data set is very 
small and is therefore only insufficient to carry out limited statistical analyses. The 
overall affect of the different treatments on the three individual metabolites was 
statistically analysed using GLM univariate analysis with Bonferonni post test (SPSS 
software). These tests gave the following results; CEHC was not significantly affected
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Figure 6  .10; Concentrations of y-TH metabolites, y-CEHC, y-CMBHC and y-CMHHC, in the harvested media of the four 
groups. Each point represents one flask.
Chapter 6 
- 
In 
vitro 
investigation 
of 
the 
cellular localization 
of 
tocopherol m
etabolism
Chapter 6 -  In vitro investigation of the cellular localization of tocopherol metabolism
according to the Null hypothesis (p=0.104), CMBHC and CMHHC were significantly 
affected (p= 0.038 and p= 0.040 respectively).
Etomoxir treated group -  y-CEHC concentrations appeared to be lower than 
the control range with concentrations between 5.5-llpmol/mg cell protein. y-CMBHC 
and y-CMHHC concentrations were similar to the control ranges, being in the range 
of 2.5-5.8 and 1.4-3.2pmol/mg cell protein, respectively.
PFOS and Etomoxir treated group -The concentration of y-CEHC was 
reduced in two of the three flasks compared to the control range, whereas the 
concentration of the third flask was within the control range. Both y-CMBHC and y- 
CMHHC appeared to be reduced, with concentrations between 0.7-2.2 and 0.4- 
0.9nmol/mg cell protein, respectively.
When the concentrations of each of the metabolites are expressed as a percentage of 
the total of the three metabolites, as shown in figure 6.11, the reproducibility of the 
results and differences between the groups became clearer. The mean of the three 
metabolites in the control group were 66% y-CEHC, 23% y-CMBHC and 11% y- 
CMHHC.
PFOS treated group -  The percentage of y-CEHC was higher than the 
control group with a mean of 91%, and y-CMBHC and y-CMHHC were lower with 
means of 7% and 3%, respectively.
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Etomoxir treated group -  The percentage of y-CEHC appeared to be lower 
than the control group with a mean of 58%, and y-CMBHC and y-CMHHC had means 
of 23% and 15% respectively.
PFOS and Etomoxir treated group -  The percentage of y-CEHC was 83% 
which was higher than the control group and the group treated with etomoxir alone, 
but lower than the group treated with PFOS alone. The mean percentage of y- 
CMBHC and y-CMHHC were 12 and 5% respectively which were lower than the 
control group and the group treated with etomoxir alone and slightly higher than the 
group treated with PFOS alone.
6.2.4.2 Effect of varying concentrations of etomoxir and PFOS on y-TH 
metabolite concentrations
A further study was undertaken using varying concentrations of PFOS and etomoxir, 
to further investigate the effects of these agents on the metabolism of y-TH.
One group of cells was treated with varying concentrations of PFOS, in the range 50 
to 200pM and a second group with a range of etomoxir concentrations from 20 to 
150pM. A third group of cells were supplemented with y-TH only and were used as 
controls. The experiment was carried out on two separate occasions referred to as TC2 
and TC3.
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Experimental protocol
The feeding programme for the HepG2 cell cultures was performed as described in 
section 6.2.4.I. Eleven cell culture flasks at 85-90% confluency were selected, where 
three were used as control flasks, four were treated with PFOS and the remaining four 
were treated with etomoxir.
Results
y-Tocopherol uptake by cells in culture
Figure 6.12 shows the concentration of y-TFI in the harvested cells and in the spent 
media from each flask in both experiments (TC2 and TC3) expressed as nmol per mg 
cell protein. Firstly in TC2, the control group had cellular concentrations, in the range 
1.02-1.90nmol/mg cell protein. The media concentrations of y-TH were in the range 
of 3.05-5.58nmol/mg cell protein. In TC3, the control group had cellular 
concentrations in the range 2.00-2.32nmol/mg cell protein and media concentrations 
of 4.62-4.93nmol/mg cell protein. The y-TH concentrations in the cells and the spent 
media of the treated cultures gave similar concentrations to that of the control group.
Although the concentrations of the etomoxir and PFOS treated groups in TC3 tended 
to be greater than the controls, there were no consistent trends with increasing 
concentrations of the PFOS or etomoxir.
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Figure 6.12; Concentrations of y-TH in cells and media of HepG2 cell cultures fed with 
50pM y-TH and treated with varying concentrations of either PFOS or etomoxir (each 
bar n=l).
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Effect o f PFOS concentrations on y-TH metabolites
Figure 6.13 shows the concentrations of y-CEHC, y-CMBHC and y-CMHHC 
pmol/mg cell protein in the spent culture media of each flask treated with PFOS in 
TC2 and TC3 plotted against the concentration of PFOS used. The results of the two 
experiments showed a similar trend. y-CEHC concentrations tended to decrease with 
50-100pM PFOS compared to the controls but concentrations tended to increase with 
150 and 200pM PFOS and at 200pM were increased compared to the controls, y- 
CMBHC concentrations decreased with increasing concentrations of PFOS which was 
particularly marked in TC2. y-CMHHC concentrations decreased with increasing 
PFOS concentrations in both TC2 and TC3.
Effect o f etomoxir on y-TH metabolism
Figure 6.14 shows the concentrations of y-CEHC, y-CMBHC and y-CMHHC in 
pmol/mg cell protein in the spent media of the cells treated with etomoxir in TC2 and 
TC3 and is plotted against the concentration of etomoxir used. y-CEHC 
concentrations decreased with increasing concentrations of etomoxir. y-CMBHC 
showed a decrease in concentration with increasing etomoxir concentration in TC2, 
however, in TC3 concentrations did not appear to differ from the control value, which 
was also much lower than the control in TC2. Similarly, y-CMHHC concentrations 
showed a decrease in response to increasing etomoxir concentrations in TC2, but no 
significant changes in TC3.
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Discussion of results
This study showed that treatment of HepG2 cells with a fixed concentration (100 pM) 
of the peroxisome proliferator, PFOS, resulted in increased concentrations of y-CEHC 
and reduced concentrations of y-CMBHC and y-CMHHC. This was generally 
confirmed when concentrations were varied from 50 to 200pM PFOS. This may 
suggest that increasing numbers of peroxisomes result in an increased flux of the y- 
TH metabolites through to CEHC. It may be proposed that the peroxisomes have a 
role in y-TH side-chain oxidation, and may be involved in the conversion steps in the 
formation of y-CMBHC and y-CMHHC. The possible involvement of peroxisomes in 
TH side-chain oxidation was also suggested in patients with Zellweger Syndrome as 
discussed in chapter 5, whereby patients have a reduced number of peroxisomes and 
demonstrated an absence or significantly reduced levels of urinary a- and y-TH 
metabolites including a-/y-CEHC and a-/y-CMBHC (refer to section 5.2.3.2).
A fixed concentration (20 pM) of the mitochondrial CPT-I inhibitor, etomoxir, 
resulted in a decreased concentration of the shortest chain metabolite, y-CEHC, 
whereas the concentration of the longer chain metabolites remained relatively 
constant. These results were generally confirmed when the etomoxir concentrations 
were varied (10-150pM) in the growth medium. This suggests that the mitochondria 
may be involved in the final conversion of y-CMBHC to y-CEHC. Etomoxir is 
expected to reduce mitochondrial activity, therefore, the reduced concentration of y- 
CEHC and unchanged concentration of the longer chain metabolites y-CMBHC and y- 
CMHHC may suggest mitochondrial involvement in the conversion of y-CMBHC to
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y-CEHC. This would agree with studies of pristanic acid metabolism where 
mitochondria have been shown to be responsible for the final cycles of side-chain 
oxidation (see section 5.1.4). Higher etomoxir concentrations of 50-100pM 
corresponded with a decrease in y-CMBHC and y-CMHHC, which may be explained 
by a possible toxic effect, however, this only occurred in TC2.
The combined effect of the addition of both PFOS and etomoxir appears to be 
intermediate to that exhibited by either of the treatments alone, whereby y-CEHC is 
elevated and y-CMBHC and y-CMHHC are reduced relative to the controls.
When interpreting these results the specificity of the modulators must be considered. 
Although in the literature, PFOS is thought to act as a specific peroxisome 
proliferator, etomoxir is known to increase the expression of the gene encoding the 
rate-limiting enzyme, acyl-CoA oxidase (ACO), of peroxisomal (3-oxidation. Thus 
studies have shown that coupled with the decrease in mitochondrial FA oxidation 
there is also an observable increase in peroxisomal FA oxidation upon the use of the 
mitochondrial CPT-I inhibitor, etomoxir (Skorin et al., 1992). It is thought that the 
intracellular accumulation of lipids following inhibition of CPT -I activity by etomoxir 
leads to a peroxisome proliferator associated receptor, PPAR-a, mediated increase in 
the expression of genes involved in alternative FA oxidation pathways. An example 
of this is detection of an increase in mRNA expression of acyl-CoA oxidase (ACO), a 
rate limiting enzyme of peroxisomal (3-oxidation (Cabrero et al., 1999). Thus the 
results obtained using such agents should be interpreted with some caution.
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This chapter has dealt with the metabolism of y-TH, by human HepG2 cells. Having 
established that three successive chain shortened metabolites, CMHHC, CMBHC and 
CEHC are produced and excreted in to the culture medium, the manipulation of the 
mitochondria and peroxisomes showed that both these organelles play a role in y-TH 
metabolism. Proliferation of the peroxisomes using the peroxisome proliferator, 
PFOS, resulted in an increase in y-CEHC which supports the results obtained for the 
Zellweger patient’s urine studied in chapter 5. Inhibition of the import of the 
shortened chain metabolites CMBHC and/ or CMHHC into the mitochondria using a 
CPT-I inhibitor, Etomoxir, resulted in a decrease in y-CEHC. It therefore appears that 
y-TH is initially metabolized by the peroxisome and the later stages of metabolism 
leading to the shortest chain metabolite CEHC is carried out by the mitochondrion.
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The aims of my study were to investigate 1) whether a-TL can be used as a potential 
biomarker of in vivo oxidative stress and 2) the cellular localisation of the side-chain 
shortening processes involved in TH conversion to the urinary metabolic products 
(CEHC, CMBHC and CMHHC).
7.1 a-Tocopheronolactone -  a potential biomarker of 
oxidative stress?
a-Tocopheronolactone (a-TL) was first discovered by Simon et al (1956) and initially 
thought to be one of the major metabolites of TH in human urine. Subsequent studies 
have found that chain shortened metabolites with an unoxidised ring, CEHC and 
CMBHC are the major urinary metabolites (Chiku et al., 1984) and that a-TL along 
with the other ‘Simon metabolites” may be products of artefactual oxidation during 
the analytical procedure. The addition of the internal standard, deuterated a-CEHC, 
prior to sample preparation enabled the estimation of artefactual oxidation as shown 
by the conversion of the deuterated a-CEHC standard to deuterated a-TL. Our studies 
also demonstrated that there was a consistently higher concentration of undeuterated 
a-TL than that calculated as a product of artefactual conversion by deuterated a- 
CEHC standard to a-TL. This difference may represent endogenous a-TL and, 
therefore, may offer a potential biomarker of in vivo oxidative stress.
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Methods were established to measure and compare urinary a-TL and 8-isoprostane 
(an independent biomarker of in vivo oxidative stress) from individuals taking part in 
a strenuous exercise regimen. Although good correlations between a-TL and 8- 
isoprostane were demonstrated, the groups chosen for this study, unfortunately, did 
not show any evidence of oxidative stress over a period of. A response could have 
been missed as the study was continued for 48 hours following exercise and Sacheck 
et al (2003) have reported that plasma F2-isoprostane levels were only elevated after 
72 hours post exercise. In retrospect exercise is a complex process and involves a 
number of mechanisms including adaptation by upregulation of antioxidant defences 
and repair systems (Radak et al., 2002; Svensson et al., 2002).
Possible future work might involve a similar urinary analysis of other groups of 
individuals, such as sepsis patients, who have been consistently shown to have 
increased in vivo oxidative stress (Takeda et al., 1984; Goode et al., 1995; Galley et 
al., 1996). An alternative methodology may also be used, whereby, the conjugates of 
vitamin E metabolites are directly analysed by tandem mass spectrometry (MS-MS). 
MS-MS enables the analysis of metabolites without their deconjugation and 
derivatisation to trimethylsilyl derivatives which is required for GC-MS methods. 
Using MS-MS, endogenous urinary conjugates of a-CEHC cannot undergo 
artefactual oxidation to form a-TL. Any a-TL detected must, therefore, be a real 
product formed in vivo from a-TH and excreted in urine. If a-TL is established as an 
authentic metabolite and can be measured accurately, it may be useful as a non- 
invasive marker of oxidative stress and used to monitor disease progression and the 
effects of interventions such as nutritional supplementation or drugs.
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7.2 Localisation of tocopherol metabolism
The detection of vitamin E metabolites has provided an insight into pathways of 
vitamin E metabolism. The principal metabolites in human urine and plasma are the 
chroman ring intact and side-chain oxidised metabolites including 6-, y-, and a-CEHC 
(Chiku et al., 1984; Schultz et al., 1995; Wechter et al., 1996). It was postulated that 
THs undergo sequential side-chain shortening reactions prior to their removal from 
the body. Sequential side-chain shortening by p-oxidation to produce CEHC is 
supported by the presence of precursors, such as CMBHC and CMHHC in human 
urine and in spent culture medium of HepG2 cells grown on y-TH (Sontag and Parker, 
2002; Pope et al., 2002; Birringer et al., 2002).
The sub-cellular localisation of the metabolism of TH has not yet been fully 
characterised. The initial co-oxidation is a prerequisite for p-oxidation, whereby the 
terminal methyl group of the vitamin E side-chain is oxidised to provide a suitable 
substrate for p-oxidation. Studies using inhibitors of various cytochrome P450 (CYP) 
enzymes have indicated that this co-oxidation of a- and y-TH is CYP 3A dependent 
and occurs in the microsomes (Parker et al., 2000; Birringer et al., 2001;Ikeda et al., 
2002). The cellular pathway and location of p-oxidation of the vitamin E side-chain 
have not been fully characterised, but it has been postulated that it occurs in the 
peroxisomes or mitochondria or in both organelles (as is the case for phytanic acid).
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Originally two approaches were used to investigate the cellular localisation of 
tocopherol metabolism in vivo. The first of these approaches involved the use of 
patient material in the form of both skin fibroblasts derived from skin biopsy and 
urine. It was concluded that skin fibroblast studies were not possible due to the 
apparent lack of TH metabolism by this cell line, which may be due to its inherent 
metabolic inactivity. Alternatively, inadequate amount of the free phenolic form of 
tocopherol, which was supplemented to the growth medium, may have been taken up 
by the fibroblasts and transported to the sites of metabolism to enable side-chain 
shortening to proceed. Future work may include the use of acetate esters of TH i.e. a- 
tocopheryl acetate (a-TAc) which is commonly used in oral vitamin E supplements. 
a-TAc is more stable than a-TH and has been shown to be better absorbed by the skin 
than the free phenolic form of TH (Beijersbergen van Henegouwen et al., 1995; 
Mavon et al., 2004). Although supplementing fibroblasts with a-TAc may result in an 
improved uptake, the capability of this cell line to metabolise the side chain of the 
tocopherols remains unknown.
The analysis of urinary vitamin E metabolites from patients with mitochondrial and 
peroxisomal disorders were inconclusive. Although two patients diagnosed with 
Zellweger Syndrome (with a greatly reduced number of peroxisomes), showed an 
absence of a- and y-TH urinary metabolites, concentrations of p- and 6-TH 
metabolites were within normal control ranges. This suggested a possible role of the 
peroxisomes in the metabolism of a- and yTH, and that (3- and 6-TH may be 
metabolised by different pathways. The only other patient that demonstrated a 
metabolite profile that deviated from the control ranges was a patient diagnosed with 
Pearson’s-like syndrome, with a defective mitochondrial respiratory chain. There was
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an absence of a-TH metabolites in the urine, whereas the other metabolites were 
within normal ranges, suggesting the possible involvement of the mitochondria in the 
metabolism of a-TH. The inconclusive nature of these results suggested there was 
sufficient residual activity of the mitochondrial and peroxisomal systems in these 
patients, and that a total absence of activity of either systems may be incompatible 
with life.
An alternative approach to the study of the localisation of TH metabolism was the use 
of HepG2 cells and modulators of mitochondrial and peroxisomal activity. HepG2 
cells grown on y-TH supplemented growth medium and treated with a mitochondrial 
inhibitor (etomoxir) and/or a peroxisome proliferator (PFOS) gave some indication of 
the involvement of these organelles in y-TH metabolism. The inhibition of the 
mitochondrial CPT-I activity by etomoxir resulted in the reduced formation of the end 
product y-CEHC and some accumulation of y-CMBHC and y-CMHHC, suggesting 
involvement in the formation of y-CEHC. This was coupled, however, with a decrease 
in the total concentration of the metabolites detected, a possible result of reduced 
activity of overall metabolism in the cells due to reduced mitochondrial activity. 
Peroxisome proliferation of this cell line appeared to cause an increase in the 
metabolic flux of y-TH demonstrated by a decrease in the longer chain length 
metabolites (CMBHC and CMHHC) and an increase in the shortest chain metabolite 
(CEHC) suggesting a role in the formation of y-CEHC via y-CMBHC and y-CMHHC.
Future work to investigate the subcellular localisation of TH metabolism may include 
mitochondrial or peroxisomal enzyme knock-out studies. In addition further a-/y-TH 
supplementation studies with HepG2 cells may be carried out to investigate whether
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there are any significant changes in the expression of proteins in mitochondrial and/or 
peroxisomal organelle fractions. Such studies may lead to the characterisation of the 
enzymes and other proteins involved in the cellular uptake and metabolism of the 
THs.
231
References Cited
Akeson,AL, C W Woods, L B Mosher, C E Thomas, R L Jackson, (1991), 
Inhibition of IL-1beta expression in THP-1 cells by probucol and tocopherol: 
Atherosclerosis, 86:261-270.
Angel,P, M Imagawa, R Chiu, B Stein, R J Imbra, H J Rahmsdorf, C Jonat, P 
Herrlich, M Karin, (1987), Phorbol ester-inducible genes contain a common 
cis element recognized by a TPA-modulated trans-acting factor: Cell, 49:729- 
739.
Arita,M, K Nomura, H Arai, K Inoue, (1997), alpha-tocopherol transfer protein 
stimulates the secretion of alpha-tocopherol from a cultured liver cell line 
through a brefeldin A-insensitive pathway: Proc.Natl.Acad.Sci.il.S.A, 
94:12437-12441.
Asakawa.T, S Matsushita, (1980), Thiobarbituric acid test for detecting lipid 
peroxides: Lipids, 14:401-406.
Asami,S, T Hirano, R Yamaguchi, H Itoh, H Kasai, (1998), Reduction of 8- 
hydroxyguanine in human leukocyte DNA by physical exercise.: Free Radic 
Res, 29:581-585.
Avigan,J, D Steinberg, A Gutman, C E Mize, G W Milne, (1966), Alpha- 
decarboxylation, an important pathway for degradation of phytanic acid in 
animals: Biochem.Biophys.Res.Commun., 24:838-844.
Azzi,A, R Ricciarelli, J M Zingg, (2002), Non-antioxidant molecular functions 
of alpha-tocopherol (vitamin E): FEBS Lett., 519:8-10.
Baes,M, S Huyghe, P Carmeliet, P E Declercq, D Collen, G P Mannaerts, P P 
Van Veldhoven, (2000), Inactivation of the peroxisomal multifunctional
232
protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty 
acids and bile acid intermediates but also of very long chain fatty acids: J.Biol 
Chem., 275:16329-16336.
Banerjee.AK, A Mandal, D Chanda, S Chakraborti, (2003), Oxidant, 
antioxidant and physical exercise: Mol.Cell Biochem., 253:307-312.
Baynes,JW, (1991), Role of oxidative stress in development of complications 
in diabetes: Diabetes, 40:405-412.
Beal,MF, (1998), Excitotoxicity and nitric oxide in Parkinson's disease 
pathogenesis: Ann.Neurol., 44:S110-S114.
Behrens,WA, R Madere, (1986), Alpha- and gamma tocopherol 
concentrations in human serum: J.Am.Coll.Nutr., 5:91-96.
Beijersbergen van Henegouwen,GM, H E Junginger, H de Vries, (1995), 
Hydrolysis of RRR-alpha-tocopheryl acetate (vitamin E acetate) in the skin 
and its UV protecting activity (an in vivo study with the rat): 
J.Photochem.Photobiol.B, 29:45-51.
Bellizzi,MC, A K Dutta-Roy, W P James, (1997), High D-glucose does not 
affect binding of alpha-tocopherol to human erythrocytes: Mol.Cell Biochem., 
170:187-193.
Ben Hamida,M, S Belal, G Sirugo, C Ben Hamida, K Panayides, P lonannou, 
J Beckmann, J L Mandel, F Hentati, M Koenig,., (1993), Friedreich's ataxia 
phenotype not linked to chromosome 9 and associated with selective 
autosomal recessive vitamin E deficiency in two inbred Tunisian families: 
Neurology, 43:2179-2183.
Benabdeslam,H, H Abidi, I Garcia, G Bellon, R Gilly, A Revol, (1999), Lipid 
peroxidation and antioxidant defenses in cystic fibrosis patients: Clin.Chem 
Lab Med, 37:511-516.
233
Berge,RK, A Aarsland, H Kryvi, J Bremer, N Aarsaether, (1989), 
Alkylthioacetic acid (3-thia fatty acids)--a new group of non-beta-oxidizable, 
peroxisome-inducing fatty acid analogues. I. A study on the structural 
requirements for proliferation of peroxisomes and mitochondria in rat liver: 
Biochim.Biophys.Acta, 1004:345-356.
Berthiaume,J, KB Wallace, (2002), Perfluorooctanoate, 
perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; 
peroxisome proliferation and mitochondrial biogenesis: Toxicol.Lett., 129:23- 
32.
Bessard,J, J L Cracowski, F Stanke-Labesque, G Bessard, (2001), 
Determination of isoprostaglandin F2[alpha] type III in human urine by gas 
chromatography-electronic impact mass spectrometry. Comparison with 
enzyme immunoassay: Journal of Chromatography B: Biomedical Sciences 
and Applications, 754:333-343.
Betarbet,R, T B Sherer, G MacKenzie, M Garcia-Osuna, A V Panov, J T 
Greenamyre, (2000), Chronic systemic pesticide exposure reproduces 
features of Parkinson's disease: Nat.Neurosci., 3:1301-1306.
Bindoli,A, M Valente, L Cavallini, (1985), Inhibition of lipid peroxidation by 
alpha-tocopherolquinone and alpha-tocopherolhydroquinone: Biochem.Int., 
10:753-761.
Birringer M,DDB-FR, (2001), Tocopherols are metabolized in HepG2 cells by 
side chain omega-oxidation and consecutive beta-oxidation.: Free Radic Biol 
Med, 31:226-232.
Birringer,M, P Pfluger, D Kluth, N Landes, R Brigelius-Flohe, (2002), Identities 
and differences in the metabolism of tocotrienols and tocopherols in HepG2 
cells: J.Nutr., 132:3113-3118.
Blatt,DH, S W Leonard, M G Traber, (2001), Vitamin E kinetics and the 
function of tocopherol regulatory proteins: Nutrition, 17:799-805.
234
Boaz,M, S Smetana, T Weinstein, Z Matas, U Gafter, A laina, A Knecht, Y 
Weissgarten, D Brunner, M Fainaru, M S Green, (2000), Secondary 
prevention with antioxidants of cardiovascular disease in endstage renal 
disease (SPACE): randomised placebo-controlled trial: Lancet, 356:1213- 
1218.
Boguth,W, H Niemann, (1971), Electron spin resonance of chromanoxy free 
radicals from alpha, zeta, beta, gamma, delta-tocopherol and tocol:
Biochim.Biophys.Acta, 248:121 -130.
Bonnefont,JP, F Taroni, P Cavadini, C Cepanec, M Brivet, J M Saudubray, J 
P Leroux, F Demaugre, (1996), Molecular analysis of carnitine 
palmitoyltransferase II deficiency with hepatocardiomuscular expression: 
Am.J.Hum.Genet., 58:971-978.
Borg,G. Perceived Exertion (Borg rating of perceived exertion scale). National 
Center for chronic disease prevetion and health promotion, CDC . 1998.
Ref Type: Electronic Citation
Boyd,NF, V McGuire, (1991), The possible role of lipid peroxidation in breast 
cancer risk: Free Radic Biol.Med, 10:185-190.
Burton,GW, D O Foster, B Perly, T F Slater, I C Smith, K U Ingold, (1985), 
Biological antioxidants: Philos.Trans.R.Soc.Lond B Biol.Sci., 311:565-578.
Buttriss.JL, A T Diplock, (1983), High performance liquid chromatography 
methods for vitamin E in tissues: Methods Enzymol., 105:131-138.
Cabrero,A, M Alegret, R Sanchez, T Adzet, J C Laguna, M Vazquez, (1999), 
Etomoxir, sodium 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate, up- 
regulates uncoupling protein-3 mRNA levels in primary culture of rat 
preadipocytes: Biochem.Biophys.Res.Commun., 263:87-93.
Cachia.O, J E Benna, E Pedruzzi, B Descomps, M A Gougerot-Pocidalo, C L 
Leger, (1998), alpha-tocopherol inhibits the respiratory burst in human
235
monocytes. Attenuation of p47(phox) membrane translocation and 
phosphorylation: J.Biol.Chem., 273:32801-32805.
Catignani,GL, (1980), Hepatic alpha-tocopherol-binding protein: Methods 
Enzymol., 67:117-122.
Chan,AC, K Tran, D D Pyke, W S Powell, (1989), Effects of dietary vitamin E 
on the biosynthesis of 5-lipoxygenase products by rat polymorphonuclear 
leukocytes (PMNL): Biochim.Biophys.Acta, 1005:265-269.
Chance,B, H Sies, A Boveris, (1979), Hydroperoxide metabolism in 
mammalian organs: Physiol Rev., 59:527-605.
Chevion,S, D S Moran, Y Heled, Y Shani, G Regev, B Abbou, E Berenshtein, 
E R Stadtman, Y Epstein, (2003), Plasma antioxidant status and cell injury 
after severe physical exercise: Proc.Natl.Acad.Sci.U.S.A, 100:5119-5123.
Chiku,S, K Hamamura, T Nakamura, (1984), Novel urinary metabolite of d- 
delta-tocopherol in rats: J.Lipid Res., 25:40-48.
Cooper,TG, H Beevers, (1969), Mitochondria and glyoxysomes from castor 
bean endosperm. Enzyme constitutents and catalytic capacity: J.Biol Chem., 
244:3507-3513.
Copp,RP, T Wisniewski, F Hentati, A Larnaout, M Ben Hamida, H J Kayden,
(1999), Localization of alpha-tocopherol transfer protein in the brains of 
patients with ataxia with vitamin E deficiency and other oxidative stress 
related neurodegenerative disorders: Brain Res., 822:80-87.
Croes,K, M Casteels, E De Hoffmann, G P Mannaerts, P P Van Veldhoven,
(1996), alpha-Oxidation of 3-methyl-substituted fatty acids in rat liver. 
Production of formic acid instead of C02, cofactor requirements, subcellular 
localization and formation of a 2-hydroxy-3-methylacyl-CoA intermediate: 
Eur.J.Biochem., 240:674-683.
236
Dandona,P, KThusu, S Cook, B Snyder, J Makowski, D Armstrong, T 
Nicotera, (1996), Oxidative damage to DNA in diabetes mellitus: Lancet, 
347:444-445.
Davi,G, G Ciabattoni, A Consoli, A Mezzetti, A Falco, S Santarone, E 
Pennese, E Vitacolonna, T Bucciarelli, F Costantini, F Capani, C Patrono,
(1999), In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation 
in diabetes mellitus: effects of improved metabolic control and vitamin E 
supplementation: Circulation, 99:224-229.
Davies,KJ, A T Quintanilha, G A Brooks, L Packer, (1982), Free radicals and 
tissue damage produced by exercise: Biochem.Biophys.Res.Commun., 
107:1198-1205.
Devaraj,S, S V Hirany, R F Burk, I Jialal, (2001a), Divergence between LDL 
oxidative susceptibility and urinary F(2)- isoprostanes as measures of 
oxidative stress in type 2 diabetes: Clin.Chem., 47:1974-1979.
Devaraj,S, I Hugou, I Jialal, (2001b), Alpha-tocopherol decreases CD36 
expression in human monocyte-derived macrophages: J.Lipid Res., 42:521- 
527.
Devaraj,S, I Jialal, (1999), Alpha-tocopherol decreases interleukin-1 beta 
release from activated human monocytes by inhibition of 5-lipoxygenase: 
Arterioscler.Thromb. Vase. Biol., 19:1125-1133.
Devaraj,S, I Jialal, (2000), Low-density lipoprotein postsecretory modification, 
monocyte function, and circulating adhesion molecules in type 2 diabetic 
patients with and without macrovascular complications: the effect of alpha- 
tocopherol supplementation: Circulation, 102:191-196.
Devaraj,S, D Li, I Jialal, (1996), The effects of alpha tocopherol 
supplementation on monocyte function. Decreased lipid oxidation, interleukin 
1 beta secretion, and monocyte adhesion to endothelium: J.Clin.Invest, 
98:756-763.
237
Douki,T, T Delatour, F Bianchini, J Cadet, (1996), Observation and prevention 
of an artefactual formation of oxidized DNA bases and nucleosides in the GC- 
EIMS method: Carcinogenesis, 17:347-353.
Draper,HH, A S Csallany, M Hadley, (2000), Urinary aldehydes as indicators 
of lipid peroxidation in vivo: Free Radic.Biol.Med., 29:1071-1077.
Droge,W, H P Eck, S Mihm, (1994), Oxidant-antioxidant status in human 
immunodeficiency virus infection: Methods Enzymol., 233:594-601.
Durckheimer,W, LA Cohen, (1964), The chemistry of 9-hydroxy-alpha- 
tocopherone, a quinone hemi-acetal: J.Am.Chem.Soc., 86:4388-4393.
Dutla-Roy,AK, (1994), Insulin mediated processes in platelets, erythrocytes 
and monocytes/macrophages: effects of essential fatty acid metabolism: 
Prostaglandins Leukot.Essent.Fatty Acids, 51:385-399.
Dutta-Roy,AK, D J Leishman, M J Gordon, F M Campbell, G G Duthie,
(1993), Identification of a low molecular mass (14.2 kDa) alpha-tocopherol- 
binding protein in the cytosol of rat liver and heart: Biochem.Biophys.Res 
Commun., 196:1108-1112.
Dworski.R, L J Roberts, J J Murray, J D Morrow, T V Hartert, J R Sheller, 
(2001), Assessment of oxidant stress in allergic asthma by measurement of 
the major urinary metabolite of F2-isoprostane, 15-F2t-lsoP (8-iso- 
PGF2alpha): Clin.Exp.Allergy, 31:387-390.
Ebadi,M, S K Srinivasan, M D Baxi, (1996), Oxidative stress and antioxidant 
therapy in Parkinson's disease: Prog.Neurobiol., 48:1-19.
Eldjarn,L, O Stokke, KTry, (1966), Alpha-oxidation of branched chain fatty 
acids in man and its failure in patients with Refsum's disease showing 
phytanic acid accumulation: Scand.J.CIin.Lab Invest, 18:694-695.
238
Elias,E, D P Muller, J Scott, (1981), Association of spinocerebellar disorders 
with cystic fibrosis or chronic childhood cholestasis and very low serum 
vitamin E: Lancet, 2:1319-1321.
Esterbauer,H, J Lang, S Zadravec, T F Slater, (1984), Detection of 
malonaldehyde by high-performance liquid chromatography: Methods 
Enzymol., 105:319-328.
Evans,HM, K S Bishop, (1922), On the Existence of a hitherto unrecognised 
dietary factor essential for reproduction: Science, 56:650-651.
Ferdinandusse,S, S Denis, P T Clayton, A Graham, J E Rees, J T Allen, B N 
McLean, A Y Brown, P Vreken, H R Waterham, R J Wanders, (2000a), 
Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase 
cause adult-onset sensory motor neuropathy: Nat.Genet., 24:188-191.
Ferdinandusse,S, S Denis, E van Berkel, G Dacremont, R J Wanders, 
(2000b), Peroxisomal fatty acid oxidation disorders and 58 kDa sterol carrier 
protein X (SCPx). Activity measurements in liver and fibroblasts using a newly 
developed method: J.Lipid Res., 41:336-342.
Ferdinandusse.S, J Mulders, L Ijlst, S Denis, G Dacremont, H R Waterham, R 
J Wanders, (1999), Molecular cloning and expression of human carnitine 
octanoyltransferase: evidence for its role in the peroxisomal beta-oxidation of 
branched-chain fatty acids: Biochem.Biophys.Res.Commun., 263:213-218.
Ferdinandusse,S, H Overmars, S Denis, H R Waterham, R J Wanders, P 
Vreken, (2001), Plasma analysis of di- and trihydroxycholestanoic acid 
diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency: 
J.Lipid Res., 42:137-141.
Fraga,CG, M K Shigenaga, J W Park, P Degan, B N Ames, (1990), Oxidative 
damage to DNA during aging: 8-hydroxy-2'-deoxyguanosine in rat organ DNA 
and urine: Proc.Natl.Acad.Sci.U.S.A, 87:4533-4537.
239
Freedman, JE, J H Farhat, J Loscalzo, J F Keaney, Jr., (1996), alpha- 
tocopherol inhibits aggregation of human platelets by a protein kinase C- 
dependent mechanism: Circulation, 94:2434-2440.
Galley,HF, M J Davies, N R Webster, (1996), Ascorbyl radical formation in 
patients with sepsis: effect of ascorbate loading: Free Radic Biol.Med, 20:139-
143.
Gazis,A, D J White, S R Page, J R Cockcroft, (1999), Effect of oral vitamin E 
(alpha-tocopherol) supplementation on vascular endothelial function in Type 2 
diabetes mellitus: Diabet.Med, 16:304-311.
Gilligan,DM, M N Sack, V Guetta, P R Casino, A A Quyyumi, D J Rader, J A 
Panza, R O Cannon, III, (1994), Effect of antioxidant vitamins on low density 
lipoprotein oxidation and impaired endothelium-dependent vasodilation in 
patients with hypercholesterolemia: J.Am.Coll.Cardiol., 24:1611-1617.
Goettsch,M, A M Pappenheimer, (1931), Nutritional muscular dystrophy in the 
guinea pig and rabbit: J.Exp.Med, 54:145-166.
Goh,SH, N F Hew, A S H  Ong, Y M Choo, S Brumby, (1990), Tocotrienols 
from palm oil: electron spin resonance spectra of tocotrienoxyl radicals: 
J.Am.Oil Chem.Soc, 67:250-254.
Goldfischer,S, C L Moore, A B Johnson, A J Spiro, M P Valsamis, H K 
Wisniewski, R H Ritch, W T Norton, I Rapin, L M Gartner, (1973), Peroxisomal 
and mitochondrial defects in the cerebro-hepato-renal syndrome: Science, 
182:62-64.
Goode,HF, H C Cowley, B E Walker, P D Howdle, N R Webster, (1995), 
Decreased antioxidant status and increased lipid peroxidation in patients with 
septic shock and secondary organ dysfunction: Crit Care Med, 23:646-651.
Gottstein.T, W Gosch, (1990), Model study of different antioxidant properties 
of alpha- and gamma-tocopherol in rats: Fat Science Technology, 92:139-
144.
240
Hale.D.E.; Batshaw,M.L.; Coates,P.M.; Frerman,F.E.; Goodman,S.I.; Singh,!.; 
Stanley,C.A. Long-chain acyl coenzyme A dehydrogenase deficiency: an 
inherited cause of nonketotic hypoglycemia.:Pediatr.Res:19(7):666-671.
Halliwell,B, (2000), Why and how should we measure oxidative DNA damage 
in nutritional studies? How far have we come?: Am.J.CIin.Nutr., 72:1082- 
1087.
Halliwell,B, M Dizdaroglu, (1992), The measurement of oxidative damage to 
DNA by HPLC and GC/MS techniques: Free Radic Res.Commun., 16:75-87.
Halliwell,B, J M Gutteridge, (1985), The importance of free radicals and 
catalytic metal ions in human diseases: Mol.Aspects Med, 8:89-193.
Halliwell,B, J M Gutteridge, C E Cross, (1992), Free radicals, antioxidants, 
and human disease: where are we now?: J.Lab Clin.Med., 119:598-620.
Halliwell,B, J M C Gutteridge, 1999, Free radicals in biology and medicine, 
Oxford Science Publications, Oxford University Press.
Hansra,G, F Bornancin, R Whelan, B A Hemmings, P J Parker, (1996), 12-0- 
Tetradecanoylphorbol-13-acetate-induced dephosphorylation of protein 
kinase Calpha correlates with the presence of a membrane-associated protein 
phosphatase 2A heterotrimer: J.Biol.Chem., 271:32785-32788.
Harman,D, (1993), Free radical involvement in aging. Pathophysiology and 
therapeutic implications: Drugs Aging, 3:60-80.
Harries,JT, D P Muller, (1971), Absorption of vitamin E in children with biliary 
obstruction: Gut, 12:579-584.
Hartmann,A, A M Niess, M Grunert-Fuchs, B Poch, G Speit, (1995), Vitamin E 
prevents exercise-induced DNA damage: Mutat.Res., 346:195-202.
241
Hehenberger.K, A Hansson, (1997), High glucose-induced growth factor 
resistance in human fibroblasts can be reversed by antioxidants and protein 
kinase C-inhibitors: Cell Biochem.Funct., 15:197-201.
Heymans,HS, J W Oorthuys, G Nelck, R J Wanders, R B Schutgens, (1985), 
Rhizomelic chondrodysplasia punctata: another peroxisomal disorder: 
N.Engl.J.Med, 313:187-188.
Hofius,D, U Sonnewald, (2003), Vitamin E biosynthesis: biochemistry meets 
cell biology: Trends Plant Sci., 8:6-8.
Hollander,D, E Rim, K S Muralidhara, (1975), Mechanism and site of small 
intestinal absorption of alpha-tocopherol in the rat: Gastroenterology, 
68:1492-1499.
Holvoet.P, D Collen, (1994), Oxidized lipoproteins in atherosclerosis and 
thrombosis: FASEB J., 8:1279-1284.
Hoppel,CL, J Kerner, P Turkaly, J Turkaly, B Tandler, (1998), The malonyl- 
CoA-sensitive form of carnitine palmitoyltransferase is not localized 
exclusively in the outer membrane of rat liver mitochondria: J.Biol.Chem., 
273:23495-23503.
Hosomi,A, M Arita, Y Sato, C Kiyose, T Ueda, O Igarashi, H Arai, K Inoue,
(1997), Affintity for alpha-tocopherol transfer protein as a determinant of the 
biological activities of vitamin E analogs: FEBS Lett., 409:105-108.
Huiiing,M, V lacobazzi, L Ijlst, P Savelkoul, W Ruitenbeek, H L van den, C 
Indiveri, J Smeitink, FTrijbels, R Wanders, F Palmieri, (1997), Cloning of the 
human carnitine-acylcarnitine carrier cDNA and identification of the molecular 
defect in a patient: Am.J.Hum.Genet., 61:1239-1245.
Huizing,M, U Wendel, W Ruitenbeek, V lacobazzi, L Ijlst, P Veenhuizen, P 
Savelkoul, L P van den Heuvel, J A Smeitink, R J Wanders, J M Trijbels, F 
Palmieri, (1998), Carnitine-acylcarnitine carrier deficiency: identification of the 
molecular defect in a patient: J.Inherit.Metab Dis., 21:262-267.
242
Hultqvist,M, J Hegbrant, C Nilsson-Thorell, T Lindholm, P Nilsson, T Linden,
U Hultqvist-Bengtsson, (1997), Plasma concentrations of vitamin C, vitamin E 
and/or malondialdehyde as markers of oxygen free radical production during 
hemodialysis: Clin.Nephrol., 47:37-46.
lkeda,S, T Tohyama, K Yamashita, (2002), Dietary sesame seed and its 
lignans inhibit 2,7,8-trimethyl- 2(2'-carboxyethyl)-6-hydroxychroman excretion 
into urine of rats fed gamma-tocopherol: J.Nutr., 132:961 -966.
lkeda,T, K Aiba, K Fukuda, M Tanaka, (1985), The induction of peroxisome 
proliferation in rat liver by perfluorinated fatty acids, metabolically inert 
derivatives of fatty acids: J.Biochem.(Tokyo), 98:475-482.
Ingold,KU, G W Burton, D O Foster, L Hughes, D A Lindsay, A Webb, (1987), 
Biokinetics of and discrimination between dietary RRR- and SRR-alpha- 
tocopherols in the male rat: Lipids, 22:163-172.
lntrasuksri,U, D R Feller, (1991), Comparison of the effects of selected 
monocarboxylic, dicarboxylic and perfluorinated fatty acids on peroxisome 
proliferation in primary cultured rat hepatocytes: Biochem.Pharmacol., 42:184- 
188.
lntrasuksri,U, S M Rangwala, M O'Brien, D J Noonan, D R Feller, (1998), 
Mechanisms of peroxisome proliferation by perfluorooctanoic acid and 
endogenous fatty acids: Gen.Pharmacol., 31:187-197.
Islam,KN, S Devaraj, I Jialal, (1998), alpha-Tocopherol enrichment of 
monocytes decreases agonist-induced adhesion to human endothelial cells: 
Circulation, 98:2255-2261.
Jansen,GA, S J Mihalik, P A Watkins, H W Moser, C Jakobs, S Denis, R J 
Wanders, (1996), Phytanoyl-CoA hydroxylase is present in human liver, 
located in peroxisomes, and deficient in Zellweger syndrome: direct, 
unequivocal evidence for the new, revised pathway of phytanic acid alpha- 
oxidation in humans: Biochem.Biophys.Res.Commun., 229:205-210.
243
Jansen,GA, R Ofman, S Ferdinandusse, L Ijlst, A O Muijsers, O H Skjeldal, O 
Stokke, C Jakobs, G T Besley, J E Wraith, R J Wanders, (1997), Refsum 
disease is caused by mutations in the phytanoyl-CoA hydroxylase gene: 
Nat.Genet., 17:190-193.
Jenkins,RR, (1988), Free radical chemistry. Relationship to exercise: Sports 
Med, 5:156-170.
Jovanovic,SV, D Clements, K MacLeod, (1998), Biomarkers of oxidative 
stress are significantly elevated in Down syndrome: Free Radic Biol.Med, 
25:1044-1048.
Kamal-Eldin,A, L A Appelqvist, (1996), The chemistry and antioxidant 
properties of tocopherols and tocotrienols: Lipids, 31:671 -701.
Kaneko,K, C Kiyose, T Ueda, H Ichikawa, O Igarashi, (2000), Studies of the 
metabolism of alpha-tocopherol stereoisomers in rats using [5-methyl- 
(14)C]SRR- and RRR-alpha-tocopherol: J.Lipid Res., 41:357-367.
Kanno,T, T Utsumi, H Kobuchi, Y Takehara, J Akiyama, T Yoshioka, A A 
Horton, K Utsumi, (1995), Inhibition of stimulus-specific neutrophil superoxide 
generation by alpha-tocopherol: Free Radic.Res., 22:431-440.
Kanno,T, T Utsumi, Y Takehara, A Ide, J Akiyama, T Yoshioka, A A Horton, K 
Utsumi, (1996), Inhibition of neutrophil-superoxide generation by alpha- 
tocopherol and coenzyme Q: Free Radic.Res., 24:281-289.
Kasai,H, Y Okada, S Nishimura, M S Rao, J K Reddy, (1989), Formation of 8- 
hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a 
peroxisome proliferator: Cancer Res., 49:2603-2605.
Kedziora.J, G Bartosz, (1988), Down's syndrome: a pathology involving the 
lack of balance of reactive oxygen species: Free Radic.Biol.Med., 4:317-330.
Keller,W, (1842),On the conversion of benzoic acid into hippuric acid:
Ann.Chem.Pharm, 43:108
244
Kempna,P, J M Zingg, R Ricciarelli, M Hierl, S Saxena, A Azzi, (2003),
Cloning of novel human SEC14p-like proteins: ligand binding and functional 
properties: Free Radio Biol.Med, 34:1458-1472.
Kitabchi,AE, J Wimalasena, J Barker, (1980), Specific receptor sites for alpha- 
tocopherol in purified isolated adrenocortical cell membrane:
Biochem.Biophys.Res Commun., 96:1739-1746.
Kivits.GA, M A Ganguli-Swarttouw, E J Christ, (1981), The composition of 
alkanes in exhaled air of rats as a result of lipid peroxidation in vivo. Effects of 
dietary fatty acids, vitamin E and selenium: Biochim.Biophys.Acta, 665:559- 
570.
Kohar.l, M Baca, C Suarna, R Stocker, P T Southwell-Keely, (1995), Is alpha- 
tocopherol a reservoir for alpha-tocopheryl hydroquinone?: Free 
Radic. Biol. Med., 19:197-207.
Konturek.PC, S J Konturek, J Majka, M Zembala, E G Hahn, (1997),
Melatonin affords protection against gastric lesions induced by ischemia- 
reperfusion possibly due to its antioxidant and mucosal microcirculatory 
effects: Eur.J.Pharmacol., 322:73-77.
Korzeniewski,B, J A Zoladz, (2003), Training-induced adaptation of oxidative 
phosphorylation in skeletal muscles: Biochem.J., 374:37-40.
Koyama,K, M Kaya, T Ishigaki, J Tsujita, S Hori, T Seino, A Kasugai, (1999), 
Role of xanthine oxidase in delayed lipid peroxidation in rat liver induced by 
acute exhausting exercise: Eur.J.Appl.Physiol Occup.Physiol, 80:28-33.
Landes,N, P Pfluger, D Kluth, M Birringer, R Ruhl, G Bol, H Glatt, R Brigelius- 
Flohe, (2003), Vitamin E activates gene expression via the pregnane X 
receptor: Biochem.Pharmacol., 65:269-273.
Lawson,JA, H Li, J Rokach, M Adiyaman, S W Hwang, S P Khanapure, G A 
FitzGerald, (1998), Identification of two major F2 isoprostanes, 8,12-iso- and
245
5-epi-8,12-iso-isoprostane F2alpha-VI, in human urine: J.Biol.Chem., 
273:29295-29301.
Liebler,DC, J A Burr, (1992), Oxidation of vitamin E during iron-catalyzed lipid 
peroxidation: evidence for electron-transfer reactions of the tocopheroxyl 
radical: Biochemistry, 31:8278-8284.
Liebler,DC, J A Burr, (2000), Antioxidant reactions of alpha- 
tocopherolhydroquinone: Lipids, 35:1045-1047.
Liebler,DC, K L Kaysen, T A Kennedy, (1989), Redox cycles of vitamin E: 
hydrolysis and ascorbic acid dependent reduction of 8a- 
(alkyldioxy)tocopherones: Biochemistry, 28:9772-9777.
Liska,DJ, (1998), The detoxification enzyme systems: Altern.Med.Rev., 3:187- 
198.
Liu,J, H C Yeo, E Overvik-Douki, T Hagen, S J Doniger, D W Chu, G A 
Brooks, B N Ames, (2000), Chronically and acutely exercised rats: biomarkers 
of oxidative stress and endogenous antioxidants: J.Appl.Physiol, 89:21-28.
Lovlin,R, W Cottle, I Pyke, M Kavanagh, A N Belcastro, (1987), Are indices of 
free radical damage related to exercise intensity: Eur.J.Appl.Physiol 
Occup.Physiol, 56:313-316.
Manor,D, J Atkinson, (2003), Is tocopherol associated protein a misnomer?: 
J.Nutr.Biochem., 14:421-422.
Marchioli,R, (1999), Antioxidant vitamins and prevention of cardiovascular 
disease: laboratory, epidemiological and clinical trial data: Pharmacol.Res., 
40:227-238.
Margaritis.l, F Tessier, M J Richard, P Marconnet, (1997), No evidence of 
oxidative stress after a triathlon race in highly trained competitors: Int.J.Sports 
Med., 18:186-190.
246
MastaloudisA; Leonard,S.W.; Traber,M.G. (2001), Oxidative stress in 
athletes during extreme endurance exercise: Free Radic Biol Med., 31:911- 
922.
Mattson,MP, (1995), Free radicals and disruption of neuronal ion homeostasis 
in AD: a role for amyloid beta-peptide?: Neurobiol.Aging, 16:679-682.
Mavon,A, V Raufast, D Redoules, (2004), Skin absorption and metabolism of 
a new vitamin E prodrug, delta-tocopherol-glucoside: in vitro evaluation in 
human skin models: J.Control Release, 100:221-231.
McCord,JM, I Fridovich, (1968), The reduction of cytochrome c by milk 
xanthine oxidase: J.Biol.Chem., 243:5753-5760.
McCord,JM, R S Roy, S W Schaffer, (1985), Free radicals and myocardial 
ischemia. The role of xanthine oxidase: Adv.Myocardiol., 5:183-189.
McGarry.JD, D W Foster, (1980), Regulation of hepatic fatty acid oxidation 
and ketone body production: Annu.Rev.Biochem., 49:395-420.
Meier,R, TTomizaki, C Schulze-Briese, U Baumann, A Stocker, (2003), The 
molecular basis of vitamin E retention: structure of human alpha-tocopherol 
transfer protein: J.Mol.Biol., 331:725-734.
Metcalfe,T, D M Bowen, D P Muller, (1989), Vitamin E concentrations in 
human brain of patients with Alzheimer's disease, fetuses with Down's 
syndrome, centenarians, and controls: Neurochem.Res., 14:1209-1212.
Miyazawa.S, S Furuta, T Osumi, T Hashimoto, N Ui, (1981), Properties of 
peroxisomal 3-ketoacyl-coA thiolase from rat liver: J.Biochem.(Tokyo), 
90:511-519.
Montine,TJ, M F Beal, M E Cudkowicz, H O'Donnell, R A Margolin, L 
McFarland, A F Bachrach, W E Zackert, L J Roberts, J D Morrow, (1999),
247
Increased CSF F2-isoprostane concentration in probable AD: Neurology, 
52:562-565.
Morley,S, C Panagabko, D Shineman, B Mani, A Stocker, J Atkinson, D 
Manor, (2004), Molecular determinants of heritable vitamin E deficiency: 
Biochemistry, 43:4143-4149.
Morris,AA, P J Lamont, P T Clayton, (1997), Pearson's syndrome without 
marrow involvement: Arch.Dis.Child, 77:56-57.
Morrow,JD, K E Hill, R F Burk, T M Nammour, K F Badr, L J Roberts, (1990), 
A series of prostaglandin F2-like compounds are produced in vivo in humans 
by a non-cyclooxygenase, free radical-catalyzed mechanism: 
Proc.Natl.Acad.Sci.il.S.A, 87:9383-9387.
Mosser.J, Y Lutz, M E Stoeckel, C O Sarde, C Kretz, A M Douar, J Lopez, P 
Aubourg, J L Mandel, (1994), The gene responsible for adrenoleukodystrophy 
encodes a peroxisomal membrane protein: Hum.Mol.Genet., 3:265-271.
Motley,A, E Hettema, B Distel, H Tabak, (1994), Differential protein import 
deficiencies in human peroxisome assembly disorders: J.Cell Biol., 125:755- 
767.
Mukai,K, N Tsuzuki, S Ouchi, K Fukuzawa, (1982), Electron spin resonance 
studies of chromanoxyl radicals derived from tocopherols: Chem.Phys.Lipids, 
30:337-345.
Muller,DP, J T Harries, J K Lloyd, (1974), The relative importance of the 
factors involved in the absorption of vitamin E in children: Gut, 15:966-971.
Muller,DP, J K Lloyd, A C Bird, (1977), Long-term management of 
abetalipoproteinaemia. Possible role for vitamin E: Arch.Dis.Child, 52:209- 
214.
248
Muller,DP, J K Lloyd, O H Wolff, (1983), Vitamin E and neurological function: 
abetalipoproteinaemia and other disorders of fat absorption: Ciba 
Found.Symp., 101:106-121.
Muralidhara,KS, D Hollander, (1977), Intestinal absorption of alpha-tocopherol 
in the unanesthetized rat. The influence of luminal constituents on the 
absorptive process: J.Lab Clin.Med, 90:85-91.
Nebert,DW, F J Gonzalez, (1987), P450 genes: structure, evolution, and 
regulation: Annu.Rev.Biochem., 56:945-993.
Neunteufl,T, K Kostner, R Katzenschlager, M Zehetgruber, G Maurer, F 
Weidinger, (1998), Additional benefit of vitamin E supplementation to 
simvastatin therapy on vasoreactivity of the brachial artery of 
hypercholesterolemic men: J.Am.Coll.Cardiol., 32:711-716.
Niki,E, J Tsuchiya, R Tanimura, Y Kamiya, (1982), Regeneration of vitamin E 
from alpha-chromanoxyl radical by glutathione and vitamin C: Chem. Lett.,789- 
792.
Obata,T, K Tomaru, T Nagakura, Y Izumi, T Kawamoto, (2000), Smoking and 
oxidant stress: assay of isoprostane in human urine by gas chromatography- 
mass spectrometry: J.Chromatogr.B Biomed.Sci.Appl., 746:11-15.
Ogawa,A, S Yamamoto, M Kanazawa, M Takayanagi, S Hasegawa, Y Kohno,
(2000), Identification of two novel mutations of the carnitine/acylcarnitine 
translocase (CACT) gene in a patient with CACT deficiency: J.Hum.Genet., 
45:52-55.
Olpin,SE, J Allen, J R Bonham, S Clark, P T Clayton, J Calvin, M Downing, K 
Ives, S Jones, N J Manning, R J Pollitt, S J Standing, M S Tanner, (2001), 
Features of carnitine palmitoyltransferase type I deficiency: J.Inherit.Metab 
Dis., 24:35-42.
Ouahchi.K, M Arita, H Kayden, F Hentati, M Ben Hamida, R Sokol, H Arai, K 
Inoue, J L Mandel, M Koenig, (1995), Ataxia with isolated vitamin E deficiency
249
is caused by mutations in the alpha-tocopherol transfer protein: Nat.Genet., 
9:141-145.
Packer,JE, T F Slater, R L Willson, (1979), Direct observation of a free radical 
interaction between vitamin E and vitamin C: Nature, 278:737-738.
Pahan,K, I Singh, (1995), Phytanic acid oxidation: topographical localization 
of phytanoyl-CoA ligase and transport of phytanic acid into human 
peroxisomes: J.Lipid Res., 36:986-997.
Panagabko,C, S Morley, S Neely, H Lei, D Manor, J Atkinson, (2002), 
Expression and refolding of recombinant human alpha-tocopherol transfer 
protein capable of specific alpha-tocopherol binding: Protein Expr.Purif., 
24:395-403.
Parker,RS, T J Sontag, J E Swanson, (2000), Cytochrome P4503A- 
dependent metabolism of tocopherols and inhibition by sesamin: 
Biochem.Biophys.Res.Commun., 277:531 -534.
Parker,RS, J E Swanson, (2000), A novel 5'-carboxychroman metabolite of 
gamma-tocopherol secreted by HepG2 cells and excreted in human urine: 
Biochem.Biophys.Res.Commun., 269:580-583.
Pastor,MC, C Sierra, M Dolade, E Navarro, N Brandi, E Cabre, A Mira, A 
Seres, (1998), Antioxidant enzymes and fatty acid status in erythrocytes of 
Down's syndrome patients: Clin.Chem, 44:924-929.
Pearson,HA, J S Lobel, S A Kocoshis, J L Naiman, J Windmiller, A T Lammi, 
R Hoffman, J C Marsh, (1979), A new syndrome of refractory sideroblastic 
anemia with vacuolization of marrow precursors and exocrine pancreatic 
dysfunction: J.Pediatr., 95:976-984.
Petruzzelli.S, L M Tavanti, N Pulera, E Fornai, R Puntoni, A Celi, C Giuntini,
(2000), Effects of nicotine replacement therapy on markers of oxidative stress 
in cigarette smokers enrolled in a smoking cessation program: 
Nicotine.Tob.Res., 2:345-350.
250
